[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3318
1. Kanno N, Lesage G, Phinizy JL, Glaser S, Francis H, Alpini G: Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology; 2002 Jun;35(6):1329-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities.
  • Growth factor signaling, mediated by the mitogen-activated protein kinase (MAPK) cascade, induces cell mitosis.
  • Adenosine 3',5'-monophosphate (cAMP) may inhibit or stimulate mitosis (depending on the cell type) through the activation of MAPK and Raf proteins.
  • Among Raf proteins, Raf-1 and B-Raf differentially regulate mitosis.
  • Our aims were to evaluate the role and mechanisms of action of the alpha(2)-adrenergic agonist UK14,304 in the regulation of growth of the human cholangiocarcinoma cell line Mz-ChA-1.
  • Immunocytochemistry and immunoblotting for alpha(2A)-, alpha(2B)-, or alpha(2C)-adrenergic receptor subtypes showed positive reaction in Mz-ChA-1 cells.
  • We found that physiological concentrations of UK14,304 increased cAMP levels and inhibited proliferation and MAPK activity in Mz-ChA-1 cells.
  • Mz-ChA-1 cells expressed Raf-1 and B-Raf.
  • In Mz-ChA-1 cells, alpha(2)-adrenoreceptor stimulation causes up-regulation of cAMP, which inhibits EGF-induced MAPK activity through an acute increase of Raf-1 and sustained activation of B-Raf.
  • In conclusion, because alpha(2)-AR inhibition of growth occurred downstream of Ras, adrenergic stimulation or other stimulants of cAMP may overcome the Ras mutations and offer a new therapeutic approach for patients with cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms. Bile Ducts, Intrahepatic. Cholangiocarcinoma. Proto-Oncogene Proteins c-raf / metabolism. Receptors, Adrenergic, alpha-2 / metabolism
  • [MeSH-minor] Adrenergic alpha-Agonists / pharmacology. Blotting, Western. Brimonidine Tartrate. Cell Division / drug effects. Cell Division / physiology. Cyclic AMP / metabolism. Humans. Inositol 1,4,5-Trisphosphate / metabolism. MAP Kinase Signaling System / physiology. Proto-Oncogene Proteins B-raf. Quinoxalines / pharmacology. Tumor Cells, Cultured. ras Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12029618.001).
  • [ISSN] 0270-9139
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK54208; United States / NIDDK NIH HHS / DK / DK58411
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-Agonists; 0 / Quinoxalines; 0 / Receptors, Adrenergic, alpha-2; 4S9CL2DY2H / Brimonidine Tartrate; 85166-31-0 / Inositol 1,4,5-Trisphosphate; E0399OZS9N / Cyclic AMP; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


2. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R: Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes; 2002 Mar;51(3):638-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sirolimus is an immunosuppressant that inhibits interleukin (IL)-2 signaling of T-cell proliferation but not IL-2-induced T-cell apoptosis.
  • Therefore, we hypothesized that administration of IL-2, together with sirolimus, might shift T-cell proliferation to apoptosis and prevent autoimmune destruction of islet beta-cells.
  • Similarly, sirolimus and IL-2 were synergistic in protecting syngeneic islet grafts from recurrent autoimmune destruction after transplantation in diabetic NOD mice, and diabetes did not recur after stopping sirolimus and IL-2 combination therapy.
  • Immunocytochemical examination of islet grafts revealed significantly decreased numbers of leukocytes together with increased apoptosis of these cells in mice treated with sirolimus and IL-2, whereas beta-cells were more numerous, and significantly fewer were apoptotic.
  • In addition, Th1-type cells (gamma-interferon-positive and IL-2(+)) were decreased the most, and Th2-type cells (IL-4(+) and IL-10(+)) and Th3-type cells (transforming growth factor-beta1(+)) were increased the most in islet grafts of sirolimus and IL-2-treated mice.
  • We conclude that 1) combination therapy with sirolimus and IL-2 is synergistic in protecting islet beta-cells from autoimmune destruction;.
  • 2) diabetes prevention continues after withdrawal of therapy; and 3) the mechanism of protection involves a shift from Th1- to Th2- and Th3-type cytokine-producing cells, possibly due to deletion of autoreactive Th1 cells.
  • [MeSH-major] Autoimmune Diseases / prevention & control. Diabetes Mellitus, Type 1 / prevention & control. Immunosuppressive Agents / therapeutic use. Interleukin-2 / therapeutic use. Sirolimus / therapeutic use
  • [MeSH-minor] Animals. Apoptosis. Drug Synergism. Drug Therapy, Combination. Female. Immunohistochemistry. Interferon-gamma / analysis. Islets of Langerhans / immunology. Islets of Langerhans / metabolism. Islets of Langerhans Transplantation. Mice. Mice, Inbred NOD. Tumor Necrosis Factor-alpha / analysis

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11872661.001).
  • [ISSN] 0012-1797
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Interleukin-2; 0 / Tumor Necrosis Factor-alpha; 82115-62-6 / Interferon-gamma; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


3. Choi S, Park CG, Kim MY, Lim GH, Kim JH, Yeum CH, Yoon PJ, So I, Kim KW, Jun JY: Action of imipramine on activated ATP-sensitive K(+) channels in interstitial cells of Cajal from murine small intestine. Life Sci; 2006 Apr 11;78(20):2322-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Action of imipramine on activated ATP-sensitive K(+) channels in interstitial cells of Cajal from murine small intestine.
  • Tricyclic antidepressants have been widely used for the treatment of depression and as a therapeutic agent for the altered gastrointestinal (GI) motility of irritable bowel syndrome (IBS).
  • The aim of this study was to clarify whether antidepressants directly modulate pacemaker currents in cultured interstitial cells of Cajal (ICC).
  • We used the whole-cell patch-clamp techniques at 30 degrees C in cultured ICC from the mouse small intestine.
  • Treatment of pinacidil, an ATP-sensitive K(+) channel opener, in the ICC using the current clamping mode, produced hyperpolarization of the membrane potential and decreased the amplitude of the pacemaker potentials.
  • Observations of the voltage clamp mode with imipramine, desipramine and amitryptyline suppressed the action of pinacidil in the ICC.
  • We used chelerythrine, a potent PKC inhibitor and GDPbetaS, a nonhydrolyzable guanosine 5-diphosphate (GDP) analogue that permanently inactivates GTP-binding proteins.
  • We conclude that imipramine inhibited the activated ATP-sensitive K(+) channels in ICC.
  • [MeSH-major] ATP-Binding Cassette Transporters / drug effects. Antidepressive Agents, Tricyclic / pharmacology. Imipramine / pharmacology. Intestine, Small / metabolism. Potassium Channels, Inwardly Rectifying / drug effects
  • [MeSH-minor] Animals. Cells, Cultured. Enzyme Inhibitors / pharmacology. Female. GTP-Binding Proteins / antagonists & inhibitors. GTP-Binding Proteins / metabolism. Gastrointestinal Motility / drug effects. KATP Channels. Male. Mice. Mice, Inbred BALB C. Patch-Clamp Techniques. Pinacidil / pharmacology. Protein Kinase C / antagonists & inhibitors. Protein Kinase C / metabolism. Vasodilator Agents / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMIPRAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16266721.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / Antidepressive Agents, Tricyclic; 0 / Enzyme Inhibitors; 0 / KATP Channels; 0 / Potassium Channels, Inwardly Rectifying; 0 / Vasodilator Agents; 0 / uK-ATP-1 potassium channel; 7B0ZZH8P2W / Pinacidil; EC 2.7.11.13 / Protein Kinase C; EC 3.6.1.- / GTP-Binding Proteins; OGG85SX4E4 / Imipramine
  •  go-up   go-down


Advertisement
4. Chang PY, Cheng MF, Lee HS, Hsieh CB, Yao NS: Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer. Onkologie; 2010;33(1-2):45-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
  • BACKGROUND: Cetuximab has been proved to be effective alone or in combination with other chemotherapeutic agents in the treatment of various malignancies.
  • The aim of this report was to describe our experience of using cetuximab with chemotherapeutics agents to treat advanced-stage biliary tract cancer.
  • CASE REPORTS: We retrospectively analyzed the outcomes of 5 biliary tract cancer patients receiving cetuximab-containing therapy.
  • Four of them had stage IV disease, and 1 patient had incomplete resection at the time of diagnosis.
  • Only 1 surgical specimen was adequate for K-ras mutation test, and the wild type was confirmed.
  • Complete response was found in the patient who had wild type K-ras.
  • CONCLUSIONS: Cetuximab-containing therapy might be an effective treatment for advanced biliary tract cancer.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Gallbladder Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Camptothecin / administration & dosage. Camptothecin / adverse effects. Camptothecin / analogs & derivatives. Cetuximab. Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Disease Progression. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CETUXIMAB .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2010;33(1-2):10-1 [20164655.001]
  • (PMID = 20164661.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; PQX0D8J21J / Cetuximab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Tsai HF, Tsai HJ, Hsieh M: Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells. Biochem Biophys Res Commun; 2004 Nov 26;324(4):1274-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
  • An unstable CAG trinucleotide repeat expansion in MJD gene on long arm of chromosome 14 has been identified as the pathologic mutation of MJD and apoptosis was previously shown to be responsible for the neuronal cell death of the disease.
  • In this study, we utilized human neuronal SK-N-SH cells stably transfected with HA-tagged full-length MJD with 78 polyglutamine repeats to examine the effects of polyglutamine expansion on neuronal cell survival in the early stage of disease.
  • Various pro-apoptotic agents were used to assess the tolerance of the mutant cells and to compare the differences between cells with and without mutant ataxin-3.
  • Concentration- and time-dependent experiments showed that the increase in staurosporine-induced cell death was more pronounced and accelerated in cells containing expanded ataxin-3 via MTS assays.
  • Interestingly, under basal conditions, Western blot and immunocytochemical analyses showed a significant decrease of Bcl-2 protein expression and an increase of cytochrome c in cells containing expanded ataxin-3 when compared with those of the parental cells.
  • The same reduction of Bcl-2 was further confirmed in fibroblast cells with mutant ataxin-3.
  • In addition, exogenous expression of Bcl-2 desensitized SK-N-SH-MJD78 cells to poly-Q toxicity.
  • These results indicated that mitochondrial-mediated cell death plays a role in the pathogenesis of MJD.
  • In our cellular model, full-length expanded ataxin-3 that leads to neurodegenerative disorders significantly impaired the expression of Bcl-2 protein, which may be, at least in part, responsible for the weak tolerance to polyglutamine toxicity at the early stage of disease and ultimately resulted in an increase of stress-induced cell death upon apoptotic stress.
  • [MeSH-major] Apoptosis. Machado-Joseph Disease / genetics. Mitochondria / metabolism. Nerve Tissue Proteins / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Trinucleotide Repeat Expansion
  • [MeSH-minor] Ataxin-3. Cell Line, Tumor. Cytochromes c / metabolism. Fibroblasts / metabolism. Humans. Neuroblastoma. Neurons / metabolism. Neurons / pathology. Nuclear Proteins. Repressor Proteins. Staurosporine / toxicity

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 2.
  • Genetic Alliance. consumer health - Neuroblastoma 3.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15504352.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ataxin-3; 0 / Nerve Tissue Proteins; 0 / Nuclear Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Repressor Proteins; 9007-43-6 / Cytochromes c; EC 3.4.22.- / ATXN3 protein, human; H88EPA0A3N / Staurosporine
  •  go-up   go-down


6. Baron F, Storb R: Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review. Springer Semin Immunopathol; 2004 Nov;26(1-2):71-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic cell transplantation as treatment for hematological malignancies: a review.
  • Allogeneic hematopoietic cell transplantation (HCT) was originally developed as a form of rescue from high-dose chemoradiotherapy, which is given both to eradicate malignancy and provide sufficient immunosuppression for allogeneic engraftment.
  • However, a better understanding of the complexities of the human leukocyte antigen (HLA) system has allowed selecting compatible sibling donors, and the development of postgrafting immunosuppressive regimens has helped prevent serious graft-versus-host disease, thereby changing the role of allogeneic HCT from a desperate therapeutic maneuver to a curative treatment modality for many patients with malignant hematological diseases.
  • Important advances have also been made in the prevention and treatment of infectious complications and in other areas of supportive care.
  • Since the late seventies, it has been recognized that allogeneic immunocompetent cells transplanted with the stem cells, or arising from them, mediated therapeutic anti-tumor effects independent of the action of the high-dose therapy, termed graft-versus-tumor (GVT) effects.
  • Also, progress in adoptive transfer of T cells with relative tumor specificity and disease-targeted therapy with agents such as Imatinib, Rituximab or radiolabeled monoclonal antibodies would make allogeneic HCT even more effective.
  • [MeSH-major] Hematologic Neoplasms / therapy. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Animals. Clinical Trials as Topic. Dogs. Graft vs Host Disease / etiology. Graft vs Tumor Effect. HLA Antigens. History, 20th Century. History, 21st Century. Humans. Transplantation Conditioning. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1998 May;21(10):995-1003 [9632272.001]
  • [Cites] N Engl J Med. 1979 May 10;300(19):1068-73 [34792.001]
  • [Cites] Blood. 2003 Jul 15;102(2):756-62 [12663454.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):231-8 [11990860.001]
  • [Cites] Blood. 2002 Feb 1;99(3):1071-8 [11807015.001]
  • [Cites] Blood. 1977 Apr;49(4):511-33 [14751.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]
  • [Cites] N Engl J Med. 1979 Sep 13;301(11):597-9 [381925.001]
  • [Cites] Blood. 1995 Sep 1;86(5):2041-50 [7655033.001]
  • [Cites] Blood. 1997 Apr 15;89(8):3048-54 [9108426.001]
  • [Cites] N Engl J Med. 1975 Apr 24;292(17):895-902 [235092.001]
  • [Cites] Blood. 1988 Oct;72(4):1300-4 [3048439.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3595-9 [11739162.001]
  • [Cites] Blood. 1997 Apr 15;89(8):3055-60 [9108427.001]
  • [Cites] Exp Hematol. 2003 Oct;31(10):941-52 [14550810.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2777-85 [12855568.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4531-6 [9192777.001]
  • [Cites] Blood. 2004 Aug 15;104(4):961-8 [15113759.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3584-8 [11739160.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:372-97 [14633791.001]
  • [Cites] Tissue Antigens. 2003 Jun;61(6):415-24 [12823765.001]
  • [Cites] Exp Hematol. 1995 Dec;23(14):1553-62 [8542946.001]
  • [Cites] Blood. 2004 Feb 1;103(3):767-76 [12958064.001]
  • [Cites] N Engl J Med. 1997 Aug 7;337(6):373-81 [9241126.001]
  • [Cites] Br Med J. 1956 Sep 15;2(4993):626-7 [13356034.001]
  • [Cites] Blood. 2004 Jan 1;103(1):347-52 [12969970.001]
  • [Cites] Lancet. 2000 Apr 8;355(9211):1231-7 [10770306.001]
  • [Cites] Blood. 2003 Aug 1;102(3):827-33 [12689933.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2303-14 [9746768.001]
  • [Cites] Science. 1951 May 4;113(2940):510-11 [14828383.001]
  • [Cites] Blood. 2002 Mar 15;99(6):2107-13 [11877286.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2021-30 [12791654.001]
  • [Cites] Transplant Proc. 1973 Mar;5(1):923-6 [4572153.001]
  • [Cites] Br J Haematol. 2003 Jan;120(2):281-8 [12542488.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4376-81 [7492799.001]
  • [Cites] Blood. 2001 Dec 15;98(13):3569-74 [11739158.001]
  • [Cites] Transplant Proc. 1971 Mar;3(1):400-4 [4398496.001]
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):537-46 [10653869.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3121-7 [12384408.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(7):351-9 [12171481.001]
  • [Cites] Transplantation. 1968 Jul;6(4):587-93 [4876499.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] N Engl J Med. 1998 Oct 22;339(17):1186-93 [9780338.001]
  • [Cites] Blood. 2000 Sep 15;96(6):2062-8 [10979948.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3447-54 [12855572.001]
  • [Cites] Blood. 1991 Oct 15;78(8):2120-30 [1912589.001]
  • [Cites] N Engl J Med. 2000 Sep 14;343(11):750-8 [10984562.001]
  • [Cites] N Engl J Med. 1981 Jun 18;304(25):1529-33 [7015133.001]
  • [Cites] Blood. 1999 Jul 15;94(2):434-41 [10397710.001]
  • [Cites] N Engl J Med. 1983 Dec 1;309(22):1347-53 [6355849.001]
  • [Cites] Transplantation. 1970 Jun;9(6):571-87 [4911417.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2419-25 [11001893.001]
  • [Cites] Blood. 1979 Aug;54(2):468-76 [378292.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Oct;9(10):610-5 [14569557.001]
  • [Cites] N Engl J Med. 1986 Jan 23;314(4):202-7 [3510388.001]
  • [Cites] Blood. 1999 Nov 1;94(9):3234-41 [10556212.001]
  • [Cites] Blood. 2000 Jan 1;95(1):67-71 [10607686.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1620-9 [12393457.001]
  • [Cites] Blood. 1999 Dec 1;94(11):3960-2 [10627126.001]
  • [Cites] Blood. 2001 Feb 1;97(3):631-7 [11157478.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1611-8 [12176879.001]
  • [Cites] Blood. 2004 Jan 1;103(1):78-84 [12969980.001]
  • [Cites] J Natl Cancer Inst. 1951 Aug;12(1):197-201 [14874130.001]
  • [Cites] Ann Intern Med. 1994 Apr 15;120(8):646-52 [8135448.001]
  • [Cites] Ann Intern Med. 1986 Feb;104(2):155-63 [3511810.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1525-31 [12176866.001]
  • [Cites] N Engl J Med. 1957 Sep 12;257(11):491-6 [13464965.001]
  • [Cites] Transplantation. 1970 Mar;9(3):240-6 [4392379.001]
  • [Cites] Transplantation. 1968 Jan;6(1):45-58 [4866738.001]
  • [Cites] N Engl J Med. 2001 Jan 18;344(3):175-81 [11172139.001]
  • [Cites] Blood. 2003 Jan 15;101(2):441-5 [12393604.001]
  • [Cites] Biol Blood Marrow Transplant. 2000;6(3A):309-20 [10905768.001]
  • [Cites] Blood. 1986 Jul;68(1):119-25 [3521761.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • [Cites] Blood. 1998 Feb 1;91(3):756-63 [9446633.001]
  • [Cites] Biol Blood Marrow Transplant. 2002;8(9):512-20 [12374456.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33 [12720215.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2581-7 [9516160.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3390-400 [11369628.001]
  • (PMID = 15549304.001).
  • [ISSN] 0344-4325
  • [Journal-full-title] Springer seminars in immunopathology
  • [ISO-abbreviation] Springer Semin. Immunopathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA18029; United States / NHLBI NIH HHS / HL / HL36444; United States / NCI NIH HHS / CA / CA78902; United States / NCI NIH HHS / CA / CA15704; United States / NIDDK NIH HHS / DK / DK42716; United States / NCI NIH HHS / CA / P01 CA078902
  • [Publication-type] Historical Article; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HLA Antigens
  • [Number-of-references] 89
  •  go-up   go-down


7. Scism JL, Powers KM, Artru AA, Lewis L, Shen DD: Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. Brain Res; 2000 Nov 24;884(1--2):77-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study.
  • Previous pharmacokinetic studies suggested that the unfavorable brain-to-plasma gradient is maintained by coupled efflux transport processes at both the brain parenchymal cells and blood-brain barrier (BBB); one or both of the efflux transporters are inhibitable by probenecid.
  • The present study in rabbits utilized microdialysis to measure drug concentration in the brain extracellular fluid (ECF) of the cerebral cortex during steady-state i.v. infusion with VPA alone or with VPA plus probenecid.
  • Brain intracellular compartment (ICC) concentration was estimated.
  • In control rabbits, the ICC concentration was 2.8+/-0.28 times higher than the ECF concentration.
  • Probenecid co-infusion elevated the ICC-to-ECF concentration ratio to 4.2+/-0.44, which confirms the existence of an efflux transport system in brain parenchymal cells.
  • Co-infusion of probenecid did not have a significant effect on VPA efflux at the BBB as evidenced by a minimal change in the ECF-to-unbound plasma concentration ratio.
  • This study suggests the presence of distinctly different organic anion transporters for the efflux of VPA at the parenchymal cells and capillary endothelium in the brain.
  • [MeSH-major] Biological Transport, Active / drug effects. Blood-Brain Barrier / drug effects. Brain / drug effects. Drug Interactions / physiology. Extracellular Space / drug effects. Probenecid / pharmacology. Valproic Acid / pharmacokinetics
  • [MeSH-minor] Animals. Carrier Proteins / drug effects. Carrier Proteins / metabolism. Cell Membrane / drug effects. Cell Membrane / metabolism. Epilepsy / drug therapy. Intracellular Fluid / drug effects. Intracellular Fluid / metabolism. Ion Pumps / drug effects. Ion Pumps / metabolism. Male. Microdialysis / statistics & numerical data. Neuroglia / cytology. Neuroglia / drug effects. Neuroglia / metabolism. Neurons / cytology. Neurons / drug effects. Neurons / metabolism. Rabbits

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PROBENECID .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11082489.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS-30738
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] NETHERLANDS
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Ion Pumps; 614OI1Z5WI / Valproic Acid; PO572Z7917 / Probenecid
  •  go-up   go-down


8. Imayasu M, Shimada S: Phosphorylation of MAP kinase in corneal epithelial cells during wound healing. Curr Eye Res; 2003 Sep;27(3):133-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation of MAP kinase in corneal epithelial cells during wound healing.
  • PURPOSE: To investigate the role of mitogen-activated protein kinase (MAPK), such as p44/42 MAPK, p38 MAPK and stress-activated protein kinase (SAPK), in corneal epithelial cells during the wound healing process.
  • Then the corneal wound healing process was observed with an immunocytochemical technique using specific antibodies reacting only with phosphorylated p44/42 MAPK, p38 MAPK or SAPK.
  • Cell lysates of corneal epithelial cells in rabbits stimulated with keratinocyte growth factor (KGF) and hepatocyte growth factor (HGF) were processed for Western blot using antibodies to phosphorylated p44/42 MAPK.
  • RESULTS: Maximum activation of p44/42 MAPK was observed in wing and basal cells at wounded regions in rat cornea at 1 hour after the incision.
  • Activation of p44/42 MAPK was still detected in all basal and wing cells at wounded regions at up to 24 hours when the incisions were completely closed, and then receded to normal intensity after 7 days.
  • Western blot analysis of cultured corneal epithelial cells in rabbits showed phosphorylation of p44/42 MAPK after 30 minutes in response to KGF and HGF, whereas non-activated p44/42 MAPK was ordinarily detected even at the absence of KGF or HGF.
  • CONCLUSIONS: These results demonstrate that p44/42 MAPK is activated during the corneal wound healing process and suggest that KGF and HGF play an important role in initiation of cell migration and proliferation in the initial wound healing process by activating p44/42 MAPK.
  • [MeSH-minor] Animals. Blotting, Western. Cell Division / drug effects. Cell Line. Enzyme Activation. Fibroblast Growth Factor 7. Fibroblast Growth Factors / pharmacology. Hepatocyte Growth Factor / pharmacology. Immunohistochemistry. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3. Mitogen-Activated Protein Kinase 9. Phosphorylation. Rabbits. Rats. Rats, Wistar. p38 Mitogen-Activated Protein Kinases

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14562178.001).
  • [ISSN] 0271-3683
  • [Journal-full-title] Current eye research
  • [ISO-abbreviation] Curr. Eye Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fgf7 protein, rat; 126469-10-1 / Fibroblast Growth Factor 7; 62031-54-3 / Fibroblast Growth Factors; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.1.24 / Mitogen-Activated Protein Kinase 9; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


9. Meuser T, Pietruck C, Gabriel A, Xie GX, Lim KJ, Pierce Palmer P: 5-HT7 receptors are involved in mediating 5-HT-induced activation of rat primary afferent neurons. Life Sci; 2002 Sep 27;71(19):2279-89
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to determine whether the 5-hydroxytryptamine7 (5-HT7) receptor is expressed by nociceptor-like neurons in the rat PNS and whether 5-HT activates these nociceptors via the 5-HT7 receptor subtype.
  • Using a polyclonal antibody and the method of immunofluorescence staining, we demonstrated that the 5-HT7 receptor appears predominately on "nociceptor-like" neurons of the rat lumbar dorsal root ganglia.
  • Using immunocytochemical methods, we showed that the immunoreactivity of the 5-HT7 receptor antibody complex is localized in the superficial layers of the spinal cord dorsal horn, which corresponds with laminae I, IIouter and IIinner.
  • [MeSH-major] Posterior Horn Cells / drug effects. Posterior Horn Cells / metabolism. Receptors, Serotonin / metabolism. Serotonin / pharmacology
  • [MeSH-minor] 8-Hydroxy-2-(di-n-propylamino)tetralin / pharmacology. Animals. Dose-Response Relationship, Drug. Fluorescent Antibody Technique, Indirect. Injections, Intra-Articular. Knee Joint. Lumbosacral Region. Male. Methiothepin / pharmacology. Microscopy, Fluorescence. Proto-Oncogene Proteins c-fos / metabolism. Rats. Rats, Sprague-Dawley. Serotonin Antagonists / pharmacology. Serotonin Receptor Agonists / pharmacology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215375.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / 1R29NS37224-01
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-fos; 0 / Receptors, Serotonin; 0 / Serotonin Antagonists; 0 / Serotonin Receptor Agonists; 0 / serotonin 7 receptor; 333DO1RDJY / Serotonin; 55D94103HL / Methiothepin; 78950-78-4 / 8-Hydroxy-2-(di-n-propylamino)tetralin
  •  go-up   go-down


10. Lynch JW: Native glycine receptor subtypes and their physiological roles. Neuropharmacology; 2009 Jan;56(1):303-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Numerous lines of biochemical, biophysical, pharmacological and genetic evidence suggest the majority of glycinergic neurotransmission in adults is mediated by heteromeric alpha1beta GlyRs.
  • Immunocytochemical co-localisation experiments suggest the presence of alpha2beta, alpha3beta and alpha4beta GlyRs at synapses in the adult mouse retina.
  • Immunocytochemical and electrophysiological evidence also implicates alpha3beta GlyRs as important mediators of glycinergic inhibitory neurotransmission in nociceptive sensory neuronal circuits in peripheral laminae of the spinal cord dorsal horn.
  • The development of pharmacological agents that can discriminate strongly between different beta subunit-containing GlyR isoforms will help to address this issue, and thereby provide important insights into a variety of central nervous system functions including retinal signal processing and spinal pain mechanisms.
  • Finally, agents that selectively potentiate different GlyR isoforms may be useful as therapeutic lead compounds for peripheral inflammatory pain and movement disorders such as spasticity.
  • [MeSH-minor] Animals. Humans


11. Mikelsaar AV, Sünter A, Toomik P, Mikelsaar R, Kalev I, Kõiveer A, Piirsoo A, Karpson K, Juronen E: Titin A-band-specific monoclonal antibody Tit1 5H1.1. Cellular Titin as a centriolar protein in non-muscle cells. Hybridoma (Larchmt); 2010 Oct;29(5):391-401
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Titin A-band-specific monoclonal antibody Tit1 5H1.1. Cellular Titin as a centriolar protein in non-muscle cells.
  • The antibody reacts with titin also in non-muscle cells, producing a punctate pattern in cytoplasm and the nucleus.
  • The most striking finding was a clear reaction of MAb Tit1 5H1.1 with centrioles in all cell types investigated so far.
  • Immunocytochemical co-localization study with ninein-specific antibodies confirmed that the target antigen of MAb Tit1 5H1.1 is a centriole-associated protein.
  • Experiments of the inhibition of synthesis of titin using titin siRNA duplex for the destruction of titin mRNA have shown a decreased staining of centrioles by MAb Tit1 5H1.1 in non-muscle cells and support the proposal that the target antigen of MAb is indeed titin.
  • We suggest this anti-titin monoclonal antibody could be a valuable tool in the study of titin function and its subcellular location, both in muscle and non-muscle cells.
  • [MeSH-major] Antibodies, Monoclonal / biosynthesis. Cells / metabolism. Centrioles / metabolism. Muscle Proteins / immunology. Muscle Proteins / metabolism. Protein Kinases / immunology. Protein Kinases / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Antibody Specificity. Cells, Cultured. Connectin. Epitopes. Female. Humans. Immunoblotting. Mice. Mice, Inbred BALB C. Muscle Cells / drug effects. Muscle Cells / metabolism. RNA, Small Interfering / pharmacology. Spectrometry, Mass, Electrospray Ionization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21050039.001).
  • [ISSN] 1557-8348
  • [Journal-full-title] Hybridoma (2005)
  • [ISO-abbreviation] Hybridoma (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Connectin; 0 / Epitopes; 0 / Muscle Proteins; 0 / RNA, Small Interfering; 0 / TTN protein, human; EC 2.7.- / Protein Kinases
  •  go-up   go-down


12. Hurd WW, Fomin VP, Natarajan V, Brown HL, Bigsby RM, Singh DM: Expression of protein kinase C isozymes in nonpregnant and pregnant human myometrium. Am J Obstet Gynecol; 2000 Dec;183(6):1525-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this study was to compare the distributions of protein kinase C isozymes in human nonpregnant and pregnant myometrial tissues and primary cell cultures.
  • Western immunoblot analysis was performed on homogenates of myometrial tissues and primary cell cultures with monoclonal antibodies specific for protein kinase C isozymes.
  • Redistribution and translocation of protein kinase C were examined by means of immunocytochemical methods.
  • The protein kinase C isozyme distribution in primary myometrial cell cultures was identical to that in the myometrial tissues.
  • Protein kinase C redistribution and translocation were demonstrated in these cultured myometrial cells.
  • CONCLUSION: Both human myometrial tissues and primary cell cultures expressed a broad range of protein kinase C isozymes.
  • [MeSH-minor] Biological Transport / drug effects. Cells, Cultured. Female. Humans. Immunohistochemistry. Labor, Obstetric / metabolism. Oxytocin / pharmacology. Reference Values. Tetradecanoylphorbol Acetate / pharmacology. Tissue Distribution / drug effects

  • MedlinePlus Health Information. consumer health - Pregnancy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. Oxytocin .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2001 Sep;185(3):778-9 [11568819.001]
  • (PMID = 11120522.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / HD36692
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Isoenzymes; 50-56-6 / Oxytocin; EC 2.7.11.13 / Protein Kinase C; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


13. Ahn YH, Koh JY, Hong SH: Protein synthesis-dependent but Bcl-2-independent cytochrome C release in zinc depletion-induced neuronal apoptosis. J Neurosci Res; 2000 Sep 1;61(5):508-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluorescence immunocytochemical staining as well as immunoblots of cell extracts revealed the release of cytochrome C into the cytosol 18-20 hr after the exposure onset.
  • Because Bcl-2 has been shown to block cytochrome C release potently, we exposed human neuroblastoma cells (SH-SY5Y) to TPEN.
  • [MeSH-major] Apoptosis / physiology. Cytochrome c Group / secretion. Neurons / metabolism. Protein Biosynthesis. Proto-Oncogene Proteins c-bcl-2 / metabolism. Zinc / metabolism
  • [MeSH-minor] Animals. Cells, Cultured. Cerebral Cortex / cytology. Cerebral Cortex / drug effects. Cerebral Cortex / metabolism. Cholinesterase Inhibitors / pharmacology. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Ethylenediamines / pharmacology. Excitatory Amino Acid Agonists / pharmacology. Humans. Mice. Mitochondria / metabolism. N-Methylaspartate / pharmacology. Neuroblastoma / metabolism. Neuroblastoma / pathology. Protein Synthesis Inhibitors / pharmacology. Transfection

  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10956420.001).
  • [ISSN] 0360-4012
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Cholinesterase Inhibitors; 0 / Cytochrome c Group; 0 / Enzyme Inhibitors; 0 / Ethylenediamines; 0 / Excitatory Amino Acid Agonists; 0 / Protein Synthesis Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 16858-02-9 / N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine; 6384-92-5 / N-Methylaspartate; J41CSQ7QDS / Zinc
  •  go-up   go-down


14. Jung T, Engels M, Kaiser B, Poppek D, Grune T: Intracellular distribution of oxidized proteins and proteasome in HT22 cells during oxidative stress. Free Radic Biol Med; 2006 Apr 15;40(8):1303-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracellular distribution of oxidized proteins and proteasome in HT22 cells during oxidative stress.
  • The production of free radicals and the resulting oxidative damage of cellular structures are always connected with the formation of oxidized proteins.
  • The 20S proteasome is responsible for recognition and degradation of oxidatively damaged proteins.
  • No detailed studies on the intracellular distribution of oxidized proteins during oxidative stress and on the distribution of the proteasome have been performed until now.
  • Therefore, we used immunocytochemical methods to measure protein carbonyls, a form of protein oxidation products, and proteasome distribution within cells.
  • Both immunocytochemical methods of measurement are semiquantitative and the load of oxidized proteins is increased after various oxidative stresses explored, with the highest increase in the perinuclear region of the cell.
  • Distribution of the proteasome and the total protein content revealed the highest concentration of both in the nucleus.
  • The normalized ratio of protein carbonyls to protein content was formed, indicating the highest concentration of oxidized proteins in the cytosolic region near the cell membrane.
  • By forming the protein oxidation-to-proteasome ratio it was concluded that the highest load of oxidized proteins to the proteasome takes place in the cytosol, independent of the oxidant explored.
  • [MeSH-major] Oxidative Stress. Proteasome Endopeptidase Complex / metabolism. Proteins / metabolism
  • [MeSH-minor] Animals. Cell Line. Hydrogen Peroxide / pharmacology. Mice. Oxidants / pharmacology. Oxidation-Reduction / drug effects

  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631520.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oxidants; 0 / Proteins; BBX060AN9V / Hydrogen Peroxide; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


15. Sun JY, Yang H, Miao S, Li JP, Wang SW, Zhu MZ, Xie YH, Wang JB, Liu Z, Yang Q: Suppressive effects of swainsonine on C6 glioma cell in vitro and in vivo. Phytomedicine; 2009 Nov;16(11):1070-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressive effects of swainsonine on C6 glioma cell in vitro and in vivo.
  • Swainsonine, an extract from Astragalus membranaceus, is known for its anti-cancer effects and could prevent metastases.
  • In order to investigate the effects and mechanisms of swainsonine in C6 glioma cells, we carry out correlated experiments in vitro and in vivo.
  • After treatment with swainsonine, the effective dose and IC(50) value of swainsonine in the C6 glioma cell were examined using the MTT assay.
  • Cell cycle distribution and apoptotic rates were analyzed using FCM and [Ca(2+)](i) was measured by LSCM.
  • Expressions of p16 and p53 protein were evaluated by immunocytochemical methods.
  • The results indicated that the growth of C6 glioma cells is inhibited by swainsonine in vitro, with an IC(50) value within 24h of 0.05 microg/ml.
  • Swainsonine could inhibit the proliferation of C6 glioma cells in vitro and the growth of C6 glioma in vivo.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Glioma / drug therapy. Phytotherapy. Swainsonine / pharmacology
  • [MeSH-minor] Animals. Astragalus Plant. Calcium / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Genes, p16 / drug effects. Genes, p53 / drug effects. Male. Plant Extracts / pharmacology. Plant Extracts / therapeutic use. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19427771.001).
  • [ISSN] 1618-095X
  • [Journal-full-title] Phytomedicine : international journal of phytotherapy and phytopharmacology
  • [ISO-abbreviation] Phytomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; RSY4RK37KQ / Swainsonine; SY7Q814VUP / Calcium
  •  go-up   go-down


16. He S, McEuen AR, Blewett SA, Li P, Buckley MG, Leufkens P, Walls AF: The inhibition of mast cell activation by neutrophil lactoferrin: uptake by mast cells and interaction with tryptase, chymase and cathepsin G. Biochem Pharmacol; 2003 Mar 15;65(6):1007-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inhibition of mast cell activation by neutrophil lactoferrin: uptake by mast cells and interaction with tryptase, chymase and cathepsin G.
  • Inhibitors of mast cell tryptase and chymase can be effective as mast cell stabilising compounds.
  • Lactoferrin has been reported to inhibit tryptase activity, but its actions on other serine proteases of mast cells and its potential to alter mast cell function are not known.
  • We have examined the ability of lactoferrin to inhibit mast cell tryptase, chymase and cathepsin G, and investigated its potential to modulate the activation of human mast cells.
  • Enzymatically dispersed cells from human skin, lung and tonsil were challenged with anti-IgE or calcium ionophore A23187, following incubation with recombinant human lactoferrin, and histamine release determined.
  • IgE-dependent histamine release from skin mast cells was inhibited by up to 50% following incubation with lactoferrin (50 or 500 nM).
  • Tonsil mast cells were also stabilised by lactoferrin, but not those from lung.
  • A double-labelling immunocytochemical procedure revealed the presence of lactoferrin in 4-6% of mast cells, and this proportion increased to 40% following incubation with lactoferrin.
  • The ability of lactoferrin to inhibit IgE-dependent activation of human mast cells and modulate protease activity suggests that the release of this neutrophil product may have a role in the downregulation of allergic inflammation.
  • [MeSH-major] Cathepsins / metabolism. Lactoferrin / pharmacology. Mast Cells / drug effects. Serine Endopeptidases / metabolism
  • [MeSH-minor] Cathepsin G. Chymases. Enzyme Stability / drug effects. Heparin / pharmacology. Histamine / metabolism. Humans. Immunohistochemistry. Neutrophils / chemistry. Tryptases

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. HEPARIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12623133.001).
  • [ISSN] 0006-2952
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 820484N8I3 / Histamine; 9005-49-6 / Heparin; EC 3.4.- / Cathepsins; EC 3.4.21.- / Lactoferrin; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.20 / CTSG protein, human; EC 3.4.21.20 / Cathepsin G; EC 3.4.21.39 / Chymases; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


17. Bacon CL, Gallagher HC, Haughey JC, Regan CM: Antiproliferative action of valproate is associated with aberrant expression and nuclear translocation of cyclin D3 during the C6 glioma G1 phase. J Neurochem; 2002 Oct;83(1):12-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell cycle progression is tightly regulated by cyclins, cyclin-dependent kinases (cdks) and related inhibitory phophatases.
  • Here, we employed mitotic selection to synchronize the C6 glioma cell cycle at the start of the G1 phase and mapped the temporal regulation of selected cyclins, cdks and inhibitory proteins throughout the 12 h of G1 by immunoblot analysis.
  • The D-type cyclins, D3 and D1, were differentially expressed during the C6 glioma G1 phase.
  • The influence of the anticonvulsant agent valproic acid (VPA) on expression of cyclins and related proteins was determined, since its teratogenic potency has been linked to cell cycle arrest in the mid-G1 phase.
  • Exposure of C6 glioma to VPA induced a marked up-regulation of cyclin D3 and decreased expression of the proliferating cell nuclear antigen.
  • In synchronized cell populations, increased expression of cyclin D3 by VPA was detected in the mid-G1 phase (3-5 h).
  • Immunocytochemical localization demonstrated rapid intracellular translocation of cyclin D3 to the nucleus following VPA exposure, suggesting that VPA-induced cell cycle arrest may be mediated by precocious activation of cyclin D3 in the G1 phase.
  • [MeSH-major] Cell Cycle / drug effects. Cyclins / metabolism. Glioma / drug therapy. Glioma / metabolism. Proto-Oncogene Proteins. Valproic Acid / pharmacology
  • [MeSH-minor] Active Transport, Cell Nucleus / drug effects. Animals. Anticonvulsants / pharmacology. Cell Cycle Proteins / metabolism. Cell Division / drug effects. Cell Line. Cell Nucleus / metabolism. Cyclin D1 / metabolism. Cyclin D3. Cyclin-Dependent Kinase 4. Cyclin-Dependent Kinase Inhibitor p27. Cyclin-Dependent Kinases / metabolism. Dose-Response Relationship, Drug. G1 Phase / drug effects. Immunoblotting. Immunohistochemistry. Proliferating Cell Nuclear Antigen / metabolism. Rats. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12358724.001).
  • [ISSN] 0022-3042
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Ccnd3 protein, rat; 0 / Cdkn1b protein, rat; 0 / Cell Cycle Proteins; 0 / Cyclin D3; 0 / Cyclins; 0 / Proliferating Cell Nuclear Antigen; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; 614OI1Z5WI / Valproic Acid; EC 2.7.11.22 / Cdk4 protein, rat; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


18. Bose A, Chakraborty T, Chakraborty K, Pal S, Baral R: Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun; 2008;8:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.
  • We assessed the immunological status of stage III and IV head and neck squamous cell carcinoma (HNSCC) patients and age-matched healthy individuals.
  • These cells showed lower expression of the early activation marker CD69.
  • Within this PBMC population, the proportion of CD4+, CD8+ T cells, CD3- CD56+, CD16+ NK cells and CD3+ CD56+ NK-T cells was seriously downregulated.
  • However, the proportion of CD4+ CD25+ Foxp3+ regulatory T cells having suppressor function was upregulated.
  • Other immune cells, like CD14+ monocytes/macrophages and CD20+ B cells, were also fewer in number, although this difference was not statistically significant.
  • Dysregulation in the profile of immunocompetent cells and cytokine secretion was reflected in the suppressed cytotoxic function of HNSCC PBMCs, as tested on KB (oral cancer), MCF7 (breast cancer), COLO205 (colon cancer), Jurkat (T cell leukemia), K562 (erythroleukemia) and U937 (monocytic lymphoma) cell lines.
  • Assessment of the extent of immune dysfunction might help design immunotherapeutic protocols by incorporating any agent having immunomodulatory function.
  • [MeSH-major] Carcinoma, Squamous Cell / immunology. Head and Neck Neoplasms / immunology. Leukocytes, Mononuclear / immunology
  • [MeSH-minor] Cytokines / immunology. Cytotoxicity, Immunologic. Down-Regulation. Fas Ligand Protein / biosynthesis. Fas Ligand Protein / immunology. Granzymes / biosynthesis. Granzymes / immunology. Humans. Lymphocyte Activation. Neoplasm Staging. Perforin / biosynthesis. Perforin / immunology. Th1 Cells / immunology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1994 May 15;57(4):612-9 [8181865.001]
  • [Cites] Curr Opin Immunol. 1992 Jun;4(3):314-20 [1418711.001]
  • [Cites] Annu Rev Immunol. 1998;16:359-93 [9597134.001]
  • [Cites] Cancer Res. 1998 Jul 15;58(14):3132-41 [9679981.001]
  • [Cites] Clin Cancer Res. 1999 Jun;5(6):1369-79 [10389921.001]
  • [Cites] Int Immunol. 2005 Feb;17(2):193-205 [15642955.001]
  • [Cites] Oral Oncol. 2006 Feb;42(2):161-71 [16249117.001]
  • [Cites] Nat Rev Immunol. 2006 Apr;6(4):295-307 [16557261.001]
  • [Cites] Hum Immunol. 2007 Oct;68(10):823-31 [17961770.001]
  • [Cites] Mol Ther. 2001 Dec;4(6):551-8 [11735339.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):287-98 [11880205.001]
  • [Cites] Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34 [11900988.001]
  • [Cites] Blood. 2002 Dec 1;100(12):4049-58 [12393627.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1870-84 [14603040.001]
  • [Cites] Hum Immunol. 2003 Dec;64(12):1160-6 [14630398.001]
  • [Cites] Annu Rev Immunol. 2004;22:405-29 [15032583.001]
  • [Cites] Int Immunopharmacol. 2004 Mar;4(3):355-66 [15037213.001]
  • [Cites] Strahlenther Onkol. 2004 Apr;180(4):187-93 [15057428.001]
  • [Cites] J Immunol. 1987 Apr 15;138(8):2711-7 [3031163.001]
  • [Cites] Int J Cancer. 1990 Aug 15;46(2):245-50 [2143498.001]
  • [Cites] J Clin Lab Immunol. 1989 Sep;30(1):21-5 [2641790.001]
  • [Cites] Annu Rev Immunol. 1997;15:749-95 [9143706.001]
  • (PMID = 18547033.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 126465-35-8 / Perforin; EC 3.4.21.- / Granzymes
  • [Other-IDs] NLM/ PMC2935775
  •  go-up   go-down


19. Ieta K, Tanaka F, Utsunomiya T, Kuwano H, Mori M: CEACAM6 gene expression in intrahepatic cholangiocarcinoma. Br J Cancer; 2006 Aug 21;95(4):532-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CEACAM6 gene expression in intrahepatic cholangiocarcinoma.
  • The purpose of this study was to investigate the clinicopathological and biological significance of human carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) gene expression in human intrahepatic cholangiocarcinoma.
  • However, in cholangiocarcinoma expression of CEACAM6 and its clinicopathological significance have not been investigated.
  • CEACAM6 expression status was determined and analysed with respect to various clinicopathological parameters in 23 intrahepatic cholangiocarcinomas.
  • Additionally, we investigated effects of CEACAM6 gene in the cholangiocarcinoma cell lines.
  • CEACAM6 gene expression in cancer tissues was higher than in noncancerous tissues in 16 of the 23 cases; however, it was not statistically significant.
  • We demonstrated that CEACAM6-transfected cells were more proliferative, more invasive and more chemoresistant to gemcitabine compared to mock-transfected cells.
  • CEACAM6 is a potential prognostic indicator and potential chemoresistant marker to gemcitabine for patients with intrahepatic cholangiocarcinoma.
  • [MeSH-major] Antigens, CD / metabolism. Bile Duct Neoplasms / metabolism. Bile Ducts, Intrahepatic. Cell Adhesion Molecules / metabolism. Cholangiocarcinoma / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Division. Cell Line, Tumor. Drug Screening Assays, Antitumor. Humans. Prognosis. Transfection

  • Genetic Alliance. consumer health - Intrahepatic cholangiocarcinoma.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncology. 2004;66(3):167-79 [15218306.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):667-74; discussion 675-6 [15383794.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1384-90 [15316565.001]
  • [Cites] Am Surg. 2004 Sep;70(9):743-8; discussion 748-9 [15481288.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] Br J Cancer. 1993 Jan;67(1):58-65 [7678982.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):130-6 [8318403.001]
  • [Cites] Oncogene. 1998 May;16(20):2681-6 [9632144.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1096-101 [10070968.001]
  • [Cites] Ann Surg. 2005 Mar;241(3):491-6 [15729073.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2889-93 [15837738.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1655-67 [15887157.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii93-6 [15958484.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8809-17 [16204051.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] Stem Cells. 2006 Mar;24(3):506-13 [16239320.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):595-605 [10666389.001]
  • [Cites] Pathol Int. 2000 Apr;50(4):273-9 [10849312.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3419-24 [10910050.001]
  • [Cites] Surgery. 2002 Jan;131(1 Suppl):S39-47 [11821786.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):151-63 [11896570.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3638-46 [14512395.001]
  • [Cites] Oncogene. 2004 Jan 15;23(2):465-73 [14724575.001]
  • [Cites] Cancer Sci. 2004 May;95(5):385-92 [15132764.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3987-93 [15173012.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5834-42 [15208677.001]
  • (PMID = 16868542.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD66 antigens; 0 / Cell Adhesion Molecules
  • [Other-IDs] NLM/ PMC2360665
  •  go-up   go-down


20. Ambăruş V, Rezuş C, Ghiuru R, Ionescu S, Manea P, Leuciuc E, Artenie R, Sandru V, Cosovanu A: [The implications of thromboembolism in chronic heart failure]. Rev Med Chir Soc Med Nat Iasi; 2002 Jan-Mar;106(1):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The implications of thromboembolism in chronic heart failure].
  • [Transliterated title] Implicaţiile tromboembolismului în insuficienţa cardiacă cronică (ICC).
  • The method consisted in the calculation of the annual death rate of the patients with CHF class III-IV NYHA: group A (controls)--who did not receive anticoagulant or antiplatelet therapy; group B--treated with Acenocumarol or Aspirin.
  • [MeSH-minor] Acenocoumarol / therapeutic use. Anticoagulants / therapeutic use. Aspirin / therapeutic use. Computer Graphics. Drug Therapy, Combination. Humans. Platelet Aggregation Inhibitors / therapeutic use. Prospective Studies. Romania / epidemiology. Survival Rate

  • MedlinePlus Health Information. consumer health - Heart Failure.
  • Hazardous Substances Data Bank. ACENOCOUMAROL .
  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12635370.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Platelet Aggregation Inhibitors; I6WP63U32H / Acenocoumarol; R16CO5Y76E / Aspirin
  •  go-up   go-down


21. Hirata Y, Shimokawa N, Oh-hashi K, Yu ZX, Kiuchi K: Acidification of the Golgi apparatus is indispensable for maturation but not for cell surface delivery of Ret. J Neurochem; 2010 Nov;115(3):606-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acidification of the Golgi apparatus is indispensable for maturation but not for cell surface delivery of Ret.
  • We examined the effect of concanamycin A and bafilomycin A1, inhibitors of the vacuolar proton-ATPase, on maturation and expression of Ret, a tyrosine kinase receptor for glial cell line-derived neurotrophic factor.
  • Western and immunocytochemical analyses revealed that the 150-kDa immature form of Ret accumulated in the Golgi apparatus upon treatment with vacuolar proton-ATPase inhibitors, whereas, the 170-kDa mature form of Ret was dramatically decreased.
  • The immature form of Ret was present in the plasma membrane when the cells were treated with the vacuolar proton-ATPase inhibitors.
  • [MeSH-major] Golgi Apparatus / physiology. Proto-Oncogene Proteins c-ret / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Animals. Biotinylation. Blotting, Western. Cell Membrane / metabolism. Electrophoresis, Polyacrylamide Gel. Enzyme Inhibitors / pharmacology. Immunohistochemistry. Macrolides / pharmacology. PC12 Cells. Rats. Receptor, Epidermal Growth Factor / metabolism. Receptor, trkA / biosynthesis. Receptor, trkA / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. Journal of Neurochemistry © 2010 International Society for Neurochemistry.
  • [Cites] J Biol Chem. 1998 Jan 23;273(4):2044-51 [9442042.001]
  • [Cites] J Cell Biol. 1997 Nov 17;139(4):929-40 [9362511.001]
  • [Cites] J Neurochem. 2007 Mar;100(5):1169-76 [17241133.001]
  • [Cites] J Neurochem. 2007 Sep;102(5):1606-13 [17555550.001]
  • [Cites] Curr Opin Cell Biol. 2008 Aug;20(4):415-26 [18511251.001]
  • [Cites] J Exp Biol. 2009 Jun;212(Pt 11):1604-10 [19448070.001]
  • [Cites] J Biochem. 2002 May;131(5):647-51 [11983070.001]
  • [Cites] Eur J Biochem. 2000 Sep;267(17):5646-54 [10951226.001]
  • [Cites] J Membr Biol. 2001 Aug 1;182(3):159-69 [11547339.001]
  • [Cites] Nat Rev Neurosci. 2002 May;3(5):383-94 [11988777.001]
  • [Cites] Int Rev Cytol. 2003;226:259-319 [12921239.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Nov 14;55(11):1405-19 [14597138.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):197-211 [15013219.001]
  • [Cites] J Biol Chem. 1984 Oct 25;259(20):12586-94 [6092339.001]
  • [Cites] Cell. 1985 Sep;42(2):581-8 [2992805.001]
  • [Cites] Biochim Biophys Acta. 1985 Dec 19;821(3):393-403 [2934093.001]
  • [Cites] J Biol Chem. 1986 Nov 15;261(32):15233-41 [3490480.001]
  • [Cites] J Biochem. 1988 Sep;104(3):388-96 [3149275.001]
  • [Cites] Trends Biochem Sci. 1989 Mar;14(3):113-6 [2524915.001]
  • [Cites] Oncogene. 1991 Feb;6(2):297-301 [2000222.001]
  • [Cites] J Cell Biol. 1992 Mar;116(5):1071-80 [1740466.001]
  • [Cites] Oncogene. 1993 Nov;8(11):2925-9 [8414495.001]
  • [Cites] Development. 1993 Dec;119(4):1005-17 [8306871.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):375-6 [7906866.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):377-8 [8114938.001]
  • [Cites] Nature. 1994 Jan 27;367(6461):378-80 [8114939.001]
  • [Cites] Cell Growth Differ. 1994 Mar;5(3):305-11 [8018563.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):4967-70 [7890600.001]
  • [Cites] J Exp Biol. 1997 Jan;200(Pt 1):1-8 [9023991.001]
  • [Cites] Cell. 1999 Apr 16;97(2):153-5 [10219235.001]
  • (PMID = 20796177.001).
  • [ISSN] 1471-4159
  • [Journal-full-title] Journal of neurochemistry
  • [ISO-abbreviation] J. Neurochem.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 HL999999
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Macrolides; 0 / Receptors, Cell Surface; 80890-47-7 / concanamycin A; 88899-55-2 / bafilomycin A1; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, trkA
  • [Other-IDs] NLM/ NIHMS389978; NLM/ PMC3415695
  •  go-up   go-down


22. Tsuchiya K, Tajima H, Yamada M, Takahashi H, Kuwae T, Sunaga K, Katsube N, Ishitani R: Disclosure of a pro-apoptotic glyceraldehyde-3-phosphate dehydrogenase promoter: anti-dementia drugs depress its activation in apoptosis. Life Sci; 2004 May 14;74(26):3245-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disclosure of a pro-apoptotic glyceraldehyde-3-phosphate dehydrogenase promoter: anti-dementia drugs depress its activation in apoptosis.
  • However, these agents do not affect the basal, constitutive mRNA contents.
  • Furthermore, anti-dementia drugs (such as Cognex and Aricept) markedly depress the expression of this pro-apoptotic GAPDH promoter activity.
  • Interestingly, immunocytochemical examination of human post-mortem materials from patients with Alzheimer's disease revealed nuclear aggregated GAPDH in neurons of the affected brain regions, implying an association with apoptotic cell death.
  • The current findings indicate that induction of the pro-apoptotic protein GAPDH is genetically regulated at the level of promoter activation, and this protein may be an important molecular target for developing anti-apoptotic therapeutic agents in certain neurological illnesses.
  • [MeSH-major] Apoptosis / genetics. Gene Expression Regulation, Enzymologic / drug effects. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Nootropic Agents / pharmacology. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Alzheimer Disease / enzymology. Animals. Cell Nucleus / enzymology. Cells, Cultured. Cerebellum / cytology. Cerebellum / enzymology. Cloning, Molecular. Cytarabine / pharmacology. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Molecular Sequence Data. Prefrontal Cortex / cytology. Prefrontal Cortex / enzymology. Rats. Transfection

  • Hazardous Substances Data Bank. CYTARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15094325.001).
  • [ISSN] 0024-3205
  • [Journal-full-title] Life sciences
  • [ISO-abbreviation] Life Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nootropic Agents; 04079A1RDZ / Cytarabine; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


23. Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T, Fujita Y, Takahashi D, Kawana I, Suzuki S, Umemura S: Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis; 2009 Mar;15(3):328-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: At colonoscopy, biopsies were taken from inflamed and non-inflamed mucosa of patients with steroid-naive UC (n = 15), non-IBD inflammatory colitis controls (ICC, n = 6), and non-colitis controls (NCC, n = 14).
  • The presence of extensive mononuclear cells and neutrophils infiltrate in the lamina propria, cryptitis, and epithelial damage defined an inflammatory lesion in the mucosa.
  • Both TNF-alpha mRNA (P = 0.03) and IL-6 mRNA (P = 0.04) were higher in UC compared with ICC.
  • [MeSH-major] Colitis, Ulcerative / genetics. Colon / metabolism. Cytokines / genetics. Drug Resistance / genetics. Gene Expression Regulation. Mesalamine / therapeutic use. RNA, Messenger / genetics
  • [MeSH-minor] Administration, Oral. Adult. Anti-Inflammatory Agents, Non-Steroidal / administration & dosage. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Biopsy. Colonoscopy. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Granulocytes. Humans. Interleukin-6 / biosynthesis. Interleukin-6 / genetics. Interleukin-8 / biosynthesis. Interleukin-8 / genetics. Intestinal Mucosa / metabolism. Intestinal Mucosa / pathology. Leukapheresis / methods. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Remission Induction / methods. Retrospective Studies. Tumor Necrosis Factor-alpha / biosynthesis. Tumor Necrosis Factor-alpha / genetics. Young Adult

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • Hazardous Substances Data Bank. MESALAMINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Inflamm Bowel Dis. 2010 May;16(5):734 [19653287.001]
  • (PMID = 18942752.001).
  • [ISSN] 1536-4844
  • [Journal-full-title] Inflammatory bowel diseases
  • [ISO-abbreviation] Inflamm. Bowel Dis.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cytokines; 0 / Interleukin-6; 0 / Interleukin-8; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor-alpha; 4Q81I59GXC / Mesalamine
  •  go-up   go-down


24. Liao D, Scannevin RH, Huganir R: Activation of silent synapses by rapid activity-dependent synaptic recruitment of AMPA receptors. J Neurosci; 2001 Aug 15;21(16):6008-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our recent immunocytochemical studies that used cultured hippocampal neurons have provided evidence for "morphological silent synapses" that physically contain NMDA receptors but no AMPA receptors.
  • [MeSH-minor] Action Potentials / drug effects. Animals. Calcium-Calmodulin-Dependent Protein Kinase Type 2. Calcium-Calmodulin-Dependent Protein Kinases / metabolism. Cell Count. Cells, Cultured. Cerebral Cortex / cytology. Cerebral Cortex / metabolism. Dendrites / metabolism. Excitatory Amino Acid Agonists / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. Excitatory Postsynaptic Potentials / physiology. Hippocampus / cytology. Hippocampus / metabolism. Immunohistochemistry. Long-Term Potentiation / drug effects. Long-Term Potentiation / physiology. Patch-Clamp Techniques. Phosphorylation. Rats. Receptors, N-Methyl-D-Aspartate / agonists. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Receptors, N-Methyl-D-Aspartate / metabolism. Synaptic Transmission / physiology. Synaptophysin / biosynthesis. Tetrodotoxin / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TETRODOTOXIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11487624.001).
  • [ISSN] 1529-2401
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Receptors, AMPA; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Synaptophysin; 4368-28-9 / Tetrodotoxin; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinase Type 2; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


25. Sarafian VS, Uzunova Y, Hayrabedyan S, Ganchevska P, Filipova M, Filipov I, Lukanov L, Vladimirov S: Histo-blood group antigen expression and proliferative activity of fibroblasts treated with dental monomers. Cell Biol Toxicol; 2008 Jan;24(1):27-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The fibroblast cell line McCoy-Plovdiv was cultivated in a serum-free medium and was treated with both monomers.
  • Cell vitality was measured by the crystal violet test.
  • Mitotic index and cell morphology were assessed.
  • An immunocytochemical technique was applied to follow the expression of proliferative antigens PCNA and Ki-67 and of HBGA.
  • The higher concentrations of the dental monomers reduced cell vitality and mitotic indices and altered proliferative antigen expression.
  • We present novel evidence for altered expression of proliferative antigens and enhanced expression of HBGA B in fibroblasts treated with dental monomers bis-GA and bis-GMA suggesting that these substances affect cell morphology, proliferative activity, and antigenic profile.
  • [MeSH-major] Acrylates / pharmacology. Bisphenol A-Glycidyl Methacrylate / pharmacology. Blood Group Antigens / metabolism. Fibroblasts / cytology. Fibroblasts / drug effects
  • [MeSH-minor] Animals. Cell Line. Cell Proliferation / drug effects. Cell Shape / drug effects. Cell Survival / drug effects. Chromatography, High Pressure Liquid. Dose-Response Relationship, Drug. Ki-67 Antigen / metabolism. Mice. Proliferating Cell Nuclear Antigen / metabolism. Serum

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497083.001).
  • [ISSN] 1573-6822
  • [Journal-full-title] Cell biology and toxicology
  • [ISO-abbreviation] Cell Biol. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / 2,2-bis(4-(2-hydroxy-3-acryloxypropoxy)phenyl)propane; 0 / Acrylates; 0 / Blood Group Antigens; 0 / Ki-67 Antigen; 0 / Proliferating Cell Nuclear Antigen; 454I75YXY0 / Bisphenol A-Glycidyl Methacrylate
  •  go-up   go-down


26. Buch SK, Khurdayan VK, Lutz SE, Knapp PE, El-Hage N, Hauser KF: Glial-restricted precursors: patterns of expression of opioid receptors and relationship to human immunodeficiency virus-1 Tat and morphine susceptibility in vitro. Neuroscience; 2007 Jun 8;146(4):1546-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To assess whether opioids and HIV proteins are directly toxic to glial-restricted precursors (GRPs), we isolated neural stem cells from the incipient spinal cord of embryonic day 10.5 ICR mice.
  • GRPs were characterized immunocytochemically and by reverse transcriptase-polymerase chain reaction (RT-PCR).
  • The effects of morphine (500 nM) and/or Tat (100 nM) on GRP viability were assessed in GRPs at 5 DIV by examining the apoptotic effector caspase-3 and cell viability (ethidium monoazide exclusion) at 96 h following continuous exposure.
  • Tat or morphine alone or in combination caused significant increases in GRP cell death at 96 h, but not at 24 h, following exposure.
  • Although morphine or Tat caused increases in caspase-3 activity at 4 h, this was not accompanied with increased cleaved caspase-3 immunoreactive or ethidium monoazide-positive dying cells at 24 h.
  • Should similar patterns occur in vivo then we predict that immature astroglia and oligodendroglia may be preferentially vulnerable to HIV-1 infection or chronic opiate exposure.

  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MORPHINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478053.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / P01 DA019398; United States / NIDA NIH HHS / DA / R01 DA13287; United States / NIDA NIH HHS / DA / T32 DA016176; United States / NIDA NIH HHS / DA / P01 DA19398; United States / NIDA NIH HHS / DA / R01 DA013728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Gene Products, tat; 0 / Homeodomain Proteins; 0 / Narcotics; 0 / Nkx-2.2 homedomain protein; 0 / RNA, Messenger; 0 / Receptors, Opioid; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Sox2 protein, mouse; 0 / Trans-Activators; 0 / Transcription Factors; 0 / tat Gene Products, Human Immunodeficiency Virus; 0 / tat peptide (1-72), Human immunodeficiency virus 1; 76I7G6D29C / Morphine; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ NIHMS656994; NLM/ PMC4308314
  •  go-up   go-down


27. Rabeneck L, Wristers K, Goldstein JL, Eisen G, Dedhiya SD, Burke TA: Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am J Gastroenterol; 2002 Jan;97(1):32-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: We aimed to assess the Severity of Dyspepsia Assessment (SODA) scales as measures of change in dyspepsia-related health in a blinded, randomized, controlled trial in arthritis patients treated with nonsteroidal anti-inflammatory drugs.
  • Using baseline and 4-wk data, reliability was evaluated with Cronbach's a and the intraclass correlation coefficient (ICC).
  • The ability of SODA to measure change in dyspepsia-related health was evaluated by comparing SODA change scores by dyspepsia adverse event severity level and withdrawal status.
  • Reproducibility was fair to good: Pain Intensity ICC = 0.49, Non Pain Symptoms ICC = 0.61, and Satisfaction ICC = 0.45.
  • SODA change scores (4-wk score - baseline score) increased, or worsened, with increasing dyspepsia severity and differentiated between adjacent levels of dyspepsia severity for eight of nine adjacent comparisons (p < 0.05).
  • SODA change scores also differentiated between those who did and did not withdraw (p < 0.001).
  • CONCLUSIONS: SODA is a reliable, valid instrument for use as a measure of dyspepsia tolerability in future clinical trials involving cyclo-oxygenase-2-specific and/or traditional nonsteroidal anti-inflammatory drugs.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / adverse effects. Cyclooxygenase Inhibitors / adverse effects. Dyspepsia / chemically induced
  • [MeSH-minor] Adult. Aged. Arthritis, Rheumatoid / diagnosis. Arthritis, Rheumatoid / drug therapy. Double-Blind Method. Female. Humans. Incidence. Long-Term Care. Male. Middle Aged. Osteoarthritis / diagnosis. Osteoarthritis / drug therapy. Prognosis. Prospective Studies. ROC Curve. Reproducibility of Results. Risk Factors. Severity of Illness Index

  • Genetic Alliance. consumer health - Dyspepsia.
  • MedlinePlus Health Information. consumer health - Indigestion.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11808967.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / K24 DK59318-01
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Cyclooxygenase Inhibitors
  •  go-up   go-down


28. Yang LJ, Sui YF, Chen ZN: Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A. World J Gastroenterol; 2001 Apr;7(2):216-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A.
  • AIM: To prepare the conjugate of staphylococcal enterotoxin A (SEA) protein which is a bacterial SAg and the F(ab')(2) fragment of mAb HAb18 against human hepatocellular carcinoma (HCC), and identify its activity in order to use SAg in the targeting therapy of HCC.
  • The F(ab')(2) fragment of mAb HAb18 was prepared by papainic digestion method.
  • The conjugate of mAb HAb18 F(ab')(2) fragment and SEA was prepared with chemical conjugating reagent N succinimidyl 3 (2-pyridyldithio) propionate (SPDP) and purified through chromatography column Superose 12 with FPLC system.
  • The antibody activity of HAb18 F(ab')(2) against HCC in the conjugate was identified by indirect immunocytochemical ABC method, and the activity of SEA in the conjugate to activate peripheral blood mononuclear cells (PBMC) was identified with MTT assay.
  • Immunocytochemical staining demonstrated that it reacted with most of HHCC cells of human HCC cell line.
  • SDS-PAGE assay demonstrated that the molecular mass of the first peak was about 130 ku, and the second peak was the mixture of about 45 ku and a little 100 ku proteins.
  • The immunocytochemical staining was similar in HAb18 F(ab') (2) SEA conjugate and HAb18 F(ab') (2), i.e.the cytoplasm and/or cell membranes of most HHCC cells were positively stained.
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Immunoconjugates. Liver Neoplasms / immunology. Superantigens
  • [MeSH-minor] Animals. Antibodies, Monoclonal / chemistry. Enterotoxins / chemistry. Humans. Immunoglobulin Fab Fragments / chemistry. Leukocytes, Mononuclear / immunology. Mice. Mice, Inbred BALB C

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11819763.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Enterotoxins; 0 / Immunoconjugates; 0 / Immunoglobulin Fab Fragments; 0 / Superantigens; 37337-57-8 / enterotoxin A, Staphylococcal
  • [Other-IDs] NLM/ PMC4723525
  •  go-up   go-down


29. Dunn SL, Young EA, Hall MD, McNulty S: Activation of astrocyte intracellular signaling pathways by interleukin-1 in rat primary striatal cultures. Glia; 2002 Jan;37(1):31-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, primary cultures of rat striatal cells were used as a model for the study of IL-1 signaling pathways in the striatum.
  • Immunocytochemical analyses revealed that these cultures consisted of a mixture of neurones and astrocytes and demonstrated expression of the IL-1 type I receptor (IL-1RI) on both cell types.
  • Treatment with IL-1 (3 units/ml) for 10 min increased phosphorylation of p38 MAP kinase in striatal cells.
  • [MeSH-minor] Animals. Glial Fibrillary Acidic Protein / metabolism. Immunohistochemistry. Neurons / cytology. Neurons / drug effects. Neurons / metabolism. Phenotype. Rats. Rats, Sprague-Dawley. p38 Mitogen-Activated Protein Kinases

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 11746781.001).
  • [ISSN] 0894-1491
  • [Journal-full-title] Glia
  • [ISO-abbreviation] Glia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Interleukin-1; 0 / NF-kappa B; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


30. Jeffrey PL, Balcar VJ, Tolhurst O, Weinberger RP, Meany JA: Avian Purkinje neuronal cultures: extrinsic control of morphology by cell type and glutamate. Methods Cell Biol; 2003;71:89-109
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Avian Purkinje neuronal cultures: extrinsic control of morphology by cell type and glutamate.
  • An in vitro coculture system is described to study the avian Purkinje neuron and the interactions occurring with astrocytes and granule cells during development in the cerebellum.
  • Astrocytes initially and granule cells later regulate Purkinje neuron morphology.
  • The coculture system presented here provides an excellent system for investigating the morphological, immunocytochemical, and electrophysiological differentiation of Purkinje neurons under controlled conditions and for studying cell-cell interactions and extrinsic factors, e.g., glutamate in normal and neuropathological conditions.
  • [MeSH-major] Astrocytes / cytology. Cells, Cultured / cytology. Glutamic Acid / pharmacology. Purkinje Cells / cytology. Purkinje Cells / drug effects
  • [MeSH-minor] Animals. Cell Communication / drug effects. Cell Communication / physiology. Cell Differentiation / drug effects. Cell Differentiation / physiology. Chick Embryo. Coculture Techniques / instrumentation. Coculture Techniques / methods. Excitatory Amino Acid Transporter 2 / antagonists & inhibitors. Excitatory Amino Acid Transporter 2 / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12884688.001).
  • [ISSN] 0091-679X
  • [Journal-full-title] Methods in cell biology
  • [ISO-abbreviation] Methods Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Transporter 2; 3KX376GY7L / Glutamic Acid
  •  go-up   go-down


31. Brandt SL, Coudron TA, Habibi J, Brown GR, Ilagan OM, Wagner RM, Wright MK, Backus EA, Huesing JE: Interaction of two Bacillus thuringiensis delta-endotoxins with the digestive system of Lygus hesperus. Curr Microbiol; 2004 Jan;48(1):1-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biochemical and immunocytochemical methods were used to determine the distribution of ingested toxin.
  • Immunocytochemical in vivo localization studies showed negligible association of CrylAc with L. hesperus tissues.
  • [MeSH-major] Bacillus thuringiensis / metabolism. Bacterial Proteins / pharmacokinetics. Bacterial Toxins. Endotoxins / pharmacokinetics. Lepidoptera / metabolism
  • [MeSH-minor] Animals. Blotting, Western. Digestive System / drug effects. Digestive System / metabolism. Electrophoresis, Polyacrylamide Gel. Female. Hemolymph / metabolism. Hemolysin Proteins. Immunohistochemistry. Microscopy, Fluorescence. Pest Control, Biological. Tissue Distribution

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15018095.001).
  • [ISSN] 0343-8651
  • [Journal-full-title] Current microbiology
  • [ISO-abbreviation] Curr. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Bacterial Toxins; 0 / Endotoxins; 0 / Hemolysin Proteins; 0 / insecticidal crystal protein, Bacillus Thuringiensis
  •  go-up   go-down


32. Ichimura T, Kawamura M, Mitani A: Co-localized expression of FasL, Fas, Caspase-3 and apoptotic DNA fragmentation in mouse testis after oral exposure to di(2-ethylhexyl)phthalate. Toxicology; 2003 Dec 15;194(1-2):35-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of apoptosis-related proteins FasL, Fas and Caspase-3, as well as DNA fragmentation were examined in mouse testis 12 h after exposure to 4-0.004 mg/g di(2-ethylhexyl)phthalate (DEHP).
  • Immunocytochemical examination of the highest dose (4 mg/g DEHP) mouse revealed a distribution of FasL in Sertoli cell and Fas in nearby spermatocyte, and Fas and Caspase-3 in the same spermatocyte.
  • Fas-positive spermatocytes had a DNA-fragmented nucleus detectable by terminal deoxynucleotidyl transferase-mediated fluorescein-dUTP nick end labeling (TUNEL) method.
  • After exposure to 4, 0.4, 0.04 or 0.004 mg/g DEHP, the maximum number of nuclei with fragmented DNA per 0.5 microm testis section was 22, 7, 5 and 3, respectively.
  • [MeSH-major] Antigens, CD95 / biosynthesis. Caspases / biosynthesis. DNA Fragmentation / drug effects. Diethylhexyl Phthalate / toxicity. Membrane Glycoproteins / biosynthesis. Testis / drug effects
  • [MeSH-minor] Administration, Oral. Animals. Caspase 3. Fas Ligand Protein. Immunohistochemistry. In Situ Nick-End Labeling. Male. Mice. Mice, Inbred Strains. Seminiferous Epithelium / drug effects. Seminiferous Epithelium / metabolism

  • Hazardous Substances Data Bank. BIS(2-ETHYLHEXYL) PHTHALATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14636694.001).
  • [ISSN] 0300-483X
  • [Journal-full-title] Toxicology
  • [ISO-abbreviation] Toxicology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Fasl protein, mouse; 0 / Membrane Glycoproteins; C42K0PH13C / Diethylhexyl Phthalate; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


33. Levkutová M, Levkut M, Hipíková V, Tomková I, Conková E, Laciaková A: Immune response of E. cuniculi infected mice to aflatoxin B1. Immunopharmacol Immunotoxicol; 2003 Aug;25(3):431-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Application of AFB1 to mice demonstrated a decrease of immunocompetent cells.
  • On the other hand, the mice infected with E. cuniculi and given AFB1 showed significant increased number of both monocytes and CD8+ T cells, and tendency to a decrease in CD4+ T cells.
  • [MeSH-major] Aflatoxin B1 / toxicity. Encephalitozoon cuniculi / pathogenicity. Encephalitozoonosis / immunology. Immunologic Factors / toxicity. Leukocytes / drug effects
  • [MeSH-minor] Administration, Oral. Animals. Body Weight / drug effects. Female. Leukocyte Count. Liver / drug effects. Liver / metabolism. Liver / microbiology. Mice. Mice, Inbred ICR. Time Factors

  • Hazardous Substances Data Bank. AFLATOXIN B1 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19180805.001).
  • [ISSN] 0892-3973
  • [Journal-full-title] Immunopharmacology and immunotoxicology
  • [ISO-abbreviation] Immunopharmacol Immunotoxicol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunologic Factors; 9N2N2Y55MH / Aflatoxin B1
  •  go-up   go-down


34. Akhmadeev AV: [Localization of CART-positive neurons in the amygdala and dependence of their immunoreactivity on the concentration of sex steroids]. Morfologiia; 2009;135(2):12-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunocytochemical reaction was performed on frontal slices of adult rat brain (7 female rats in estrus stage, 7 female rats in metestrus stage and 7 male rats).
  • The portion of immunopositive neurons in animals in estrus and metestrus was counted in relation to their numbers in adjoining slices (stained using Nissl's method).
  • The relative number of immunoreactive neurons in dorsomedial, posterior cortical nuclei and latero-capsular subnucleus of the central nucleus was found to be significantly greater in estrus than in metestrus.
  • The data obtained show that olfactory and integrative centers of amygdala may be involved in the pathogenesis of drug addiction and indicate the possibility of development of new effective methods of gene therapy with the application of an intranasal route of drug delivery.
  • [MeSH-major] Amygdala / metabolism. Gonadal Steroid Hormones / metabolism. Nerve Tissue Proteins / biosynthesis. Neurons / metabolism
  • [MeSH-minor] Animals. Cell Count. Estrus / metabolism. Female. Immunohistochemistry. Male. Metestrus / metabolism. Rats. Rats, Wistar

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19563167.001).
  • [ISSN] 1026-3543
  • [Journal-full-title] Morfologii︠a︡ (Saint Petersburg, Russia)
  • [ISO-abbreviation] Morfologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones; 0 / Nerve Tissue Proteins; 0 / cocaine- and amphetamine-regulated transcript protein
  •  go-up   go-down


35. D'Antoni AV, Zipp GP, Olson VG: Interrater reliability of the mind map assessment rubric in a cohort of medical students. BMC Med Educ; 2009;9:19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, there is no valid and reliable rubric to grade mind maps and this may contribute to their underutilization in medicine.
  • The MMAR can assess mind map depth based upon concept-links, cross-links, hierarchies, examples, pictures, and colors.
  • Interrater reliability was measured using the intraclass correlation coefficient (ICC) statistic.
  • RESULTS: Analysis of the mind maps revealed the following: concept-links ICC = .05 (95% CI, -.42 to .38), cross-links ICC = .58 (95% CI, .37 to .73), hierarchies ICC = .23 (95% CI, -.15 to .50), examples ICC = .53 (95% CI, .29 to .69), pictures ICC = .86 (95% CI, .79 to .91), colors ICC = .73 (95% CI, .59 to .82), and total score ICC = .86 (95% CI, .79 to .91).
  • CONCLUSION: The high ICC value for total mind map score indicates strong MMAR interrater reliability.
  • We conclude that the MMAR may be a valid and reliable tool to assess mind maps in medicine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nurs Educ. 1999 Jan;38(1):42-7 [9921788.001]
  • [Cites] Med Educ. 2005 Jul;39(7):732-41 [15960794.001]
  • [Cites] Med Educ. 2006 Sep;40(9):867-76 [16925637.001]
  • [Cites] Neuroradiology. 2006 Sep;48(9):640-6 [16819653.001]
  • [Cites] Psychol Bull. 1979 Mar;86(2):420-8 [18839484.001]
  • [Cites] Acad Med. 2008 Dec;83(12):1196-203 [19202500.001]
  • [Cites] J Adv Nurs. 1995 Jun;21(6):1175-9 [7665784.001]
  • [Cites] Med Educ. 2002 May;36(5):426-31 [12028392.001]
  • [Cites] Med Educ. 2002 Sep;36(9):820-6 [12354244.001]
  • [Cites] Med Teach. 2002 Nov;24(6):648-9 [12623462.001]
  • [Cites] Med Educ. 1980 Jan;14(1):4-7 [7366494.001]
  • [Cites] Mem Cognit. 1983 May;11(3):251-7 [6621340.001]
  • [Cites] Med Educ. 1993 Nov;27(6):470-3 [8208152.001]
  • [Cites] JAMA. 2000 Sep 6;284(9):1105-10 [10974689.001]
  • (PMID = 19400964.001).
  • [ISSN] 1472-6920
  • [Journal-full-title] BMC medical education
  • [ISO-abbreviation] BMC Med Educ
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2683832
  •  go-up   go-down


36. Aerbajinai W, Giattina M, Lee YT, Raffeld M, Miller JL: The proapoptotic factor Nix is coexpressed with Bcl-xL during terminal erythroid differentiation. Blood; 2003 Jul 15;102(2):712-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcriptional profiles of cultured primary human erythroid cells were examined to identify those genes involved in the control of erythroid growth during the terminal phase of maturation.
  • We next performed Northern blot analyses and determined that the 1.4-kb Nix transcript is expressed at lower levels in erythroleukemia cells than reticulocytes.
  • The expression of Nix and Bcl-xL proteins decreased relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control on the removal of erythropoietin (EPO) from the culture medium.
  • Immunocytochemical analyses demonstrated a similar perinuclear mitochondrial expression pattern for both proteins in hemoglobinized precursors.
  • [MeSH-major] Erythroid Precursor Cells / metabolism. Erythropoiesis / genetics. Membrane Proteins / biosynthesis. Proto-Oncogene Proteins. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Suppressor Proteins
  • [MeSH-minor] Apoptosis / genetics. Blotting, Western. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cysteine Endopeptidases / metabolism. Erythropoietin / pharmacology. Gene Expression Regulation / drug effects. Glycophorin / biosynthesis. Glycophorin / genetics. Humans. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Erythroblastic, Acute / metabolism. Leukemia, Erythroblastic, Acute / pathology. Multienzyme Complexes / metabolism. Polymerase Chain Reaction. Proteasome Endopeptidase Complex. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reticulocytes / drug effects. Reticulocytes / metabolism. Transcription, Genetic / drug effects. Tumor Cells, Cultured / metabolism. bcl-X Protein

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12663450.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCL2L1 protein, human; 0 / BNIP3L protein, human; 0 / Glycophorin; 0 / Membrane Proteins; 0 / Multienzyme Complexes; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 0 / bcl-X Protein; 11096-26-7 / Erythropoietin; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


37. Puri V, Puri S, Svojanovsky SR, Mathur S, Macgregor RR, Klein RM, Welch KM, Berman NE: Effects of oestrogen on trigeminal ganglia in culture: implications for hormonal effects on migraine. Cephalalgia; 2006 Jan;26(1):33-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although migraine is more common in women than men and often linked to the menstrual cycle, few studies have investigated the biological basis of hormonal influences on the trigeminovascular system.
  • Immunocytochemical analysis demonstrated the presence of oestrogen receptor-alpha in a predominantly cytoplasmic location and in neurites.
  • The genes that were upregulated included synapsin-2, endothelin receptor type B, activity and neurotransmitter-induced early gene 7 (ania-7), phosphoserine aminotransferase, MHC-1b, and ERK-1.
  • Immunocytochemistry demonstrated that activated ERK was present in neurons containing peripherin, a marker of nociceptive neurons.
  • [MeSH-major] Estrogens / pharmacology. Migraine Disorders / physiopathology. Trigeminal Ganglion / drug effects. Trigeminal Ganglion / physiology
  • [MeSH-minor] Animals. Cells, Cultured. Estrogen Receptor alpha / genetics. Extracellular Signal-Regulated MAP Kinases / genetics. Extracellular Signal-Regulated MAP Kinases / metabolism. Female. Gene Expression / drug effects. In Vitro Techniques. MAP Kinase Signaling System / drug effects. Neurons, Afferent / cytology. Neurons, Afferent / drug effects. Neurons, Afferent / physiology. Nociceptors / drug effects. Nociceptors / physiology. Oligonucleotide Array Sequence Analysis. Phosphorylation / drug effects. Rats


38. Saleh SN, Albert AP, Peppiatt CM, Large WA: Angiotensin II activates two cation conductances with distinct TRPC1 and TRPC6 channel properties in rabbit mesenteric artery myocytes. J Physiol; 2006 Dec 1;577(Pt 2):479-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cell-attached patches, bath application of low concentrations of Ang II (1 nM) activated cation channel currents (Icat1) with conductances states of about 15, 30 and 45 pS.
  • Moreover in cell-attached patches pretreated with chelerythrine, application of 100 nM Ang II activated Icat1.
  • Agents that deplete intracellular Ca2+ stores also activated cation channel currents with similar properties to Icat2.
  • Immunocytochemical studies showed TRPC6 and TRPC1 expression with TRPC6 preferentially distributed in the plasma membrane and TRPC1 expression located throughout the myocyte.
  • It is proposed that TRPC6 and TRPC1 channel proteins are important components of Ang II-induced Icat1 and Icat2, respectively.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2002 Jul;283(1):L144-55 [12060571.001]
  • [Cites] J Cardiovasc Electrophysiol. 2002 May;13(5):493-501 [12030534.001]
  • [Cites] J Physiol. 2003 May 15;549(Pt 1):143-56 [12679370.001]
  • [Cites] Cell Calcium. 2003 May-Jun;33(5-6):451-61 [12765690.001]
  • [Cites] J Physiol. 2003 Nov 1;552(Pt 3):789-95 [12972630.001]
  • [Cites] Nature. 2003 Dec 4;426(6966):517-24 [14654832.001]
  • [Cites] Br J Pharmacol. 2004 Jan;141(1):23-36 [14662735.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):20941-9 [15016832.001]
  • [Cites] J Biol Chem. 2004 May 21;279(21):22047-56 [15023993.001]
  • [Cites] J Physiol. 2004 Oct 1;560(Pt 1):169-80 [15297579.001]
  • [Cites] Pflugers Arch. 1981 Aug;391(2):85-100 [6270629.001]
  • [Cites] J Biol Chem. 1986 May 5;261(13):5901-6 [3084474.001]
  • [Cites] Biochem J. 1989 Apr 15;259(2):477-83 [2655581.001]
  • [Cites] Br J Pharmacol. 1995 Oct;116(3):2148-54 [8640358.001]
  • [Cites] J Physiol. 1997 Mar 1;499 ( Pt 2):417-28 [9080371.001]
  • [Cites] J Physiol. 2004 Dec 1;561(Pt 2):415-32 [15579537.001]
  • [Cites] J Physiol. 2005 Jan 15;562(Pt 2):395-406 [15528235.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2055-61 [15604128.001]
  • [Cites] J Physiol. 2005 Aug 1;566(Pt 3):769-80 [15919706.001]
  • [Cites] J Physiol. 2006 Jan 1;570(Pt 1):45-51 [16195316.001]
  • [Cites] J Physiol. 2006 Mar 1;571(Pt 2):361-9 [16396924.001]
  • [Cites] J Pharmacol Exp Ther. 2006 May;317(2):488-99 [16415091.001]
  • [Cites] Cell Calcium. 2006 Jul;40(1):29-40 [16697039.001]
  • [Cites] J Physiol. 2004 Sep 15;559(Pt 3):685-706 [15272031.001]
  • [Cites] J Physiol. 2000 Feb 15;523 Pt 1:131-8 [10673549.001]
  • [Cites] J Biol Chem. 2000 Sep 8;275(36):27799-805 [10882720.001]
  • [Cites] Pharmacol Rev. 2000 Dec;52(4):639-72 [11121512.001]
  • [Cites] Circ Res. 2001 Jan 19;88(1):84-7 [11139478.001]
  • [Cites] J Physiol. 2001 Feb 1;530(Pt 3):457-68 [11158276.001]
  • [Cites] Circ Res. 2001 Feb 16;88(3):325-32 [11179201.001]
  • [Cites] J Physiol. 2001 Oct 15;536(Pt 2):409-20 [11600676.001]
  • [Cites] J Physiol. 2002 Feb 1;538(Pt 3):717-28 [11826160.001]
  • [Cites] J Physiol. 2002 Oct 1;544(Pt 1):113-25 [12356885.001]
  • (PMID = 16973707.001).
  • [ISSN] 0022-3751
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] ENG
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Antibodies; 0 / Benzophenanthridines; 0 / Diglycerides; 0 / Enzyme Activators; 0 / Enzyme Inhibitors; 0 / Estrenes; 0 / Pyrrolidinones; 0 / Receptor, Angiotensin, Type 1; 0 / TRPC Cation Channels; 0 / Vasoconstrictor Agents; 0 / transient receptor potential cation channel, subfamily C, member 1; 11128-99-7 / Angiotensin II; 112648-68-7 / 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; 37558-16-0 / Phorbol 12,13-Dibutyrate; 60GCX7Y6BH / Flufenamic Acid; 86390-77-4 / 1-oleoyl-2-acetylglycerol; E3B045W6X0 / chelerythrine; EC 2.7.11.13 / Protein Kinase C; EC 3.1.4.- / Type C Phospholipases; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC1890440
  •  go-up   go-down


39. Sakhaee E, Derakhshanfar A: Polioencephalomalacia associated with closantel overdosage in a goat. J S Afr Vet Assoc; 2010 Jun;81(2):116-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No gross lesions were noted in tissue or organs at necropsy, but microscopic lesions were seen in nervous tissue and hepatic cells.
  • Bilaterally symmetrical status spongiosus of the white matter of the brain, bilateral laminar necrosis, microcavitations, ischaemic cell change and severe degeneration of the cerebellum were seen in nervous tissue.
  • Fatty change and hydropic degeneration in the liver and hepato-cellular degeneration were observed histologically.
  • [MeSH-major] Anthelmintics / administration & dosage. Anthelmintics / adverse effects. Encephalomalacia / veterinary. Goat Diseases / chemically induced. Salicylanilides / administration & dosage. Salicylanilides / adverse effects
  • [MeSH-minor] Animals. Brain / pathology. Drug Overdose. Goats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21247019.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] South Africa
  • [Chemical-registry-number] 0 / Anthelmintics; 0 / Salicylanilides; EUL532EI54 / closantel
  •  go-up   go-down


40. Gil CD, Gullo CE, Oliani SM: Effect of exogenous galectin-1 on leukocyte migration: modulation of cytokine levels and adhesion molecules. Int J Clin Exp Pathol; 2010;4(1):74-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These changes subsided after 24 h.
  • Ultrastructural immunocytochemical analysis of PMNs showed significant Gal-1 expression and co-localization with L-selectin and β2-integrin in the plasma membrane and cytoplasm.
  • Pharmacological treatment with hrGal-1 at 4 h produced an inhibition of PMN migration, associated with diminished expression of adhesion molecules, particularly β2-integrin, and TNF-α and IL-1β release by peritoneal cells.
  • At 24 h, Gal-1 induced an increase in mononuclear phagocytic cell recruitment.
  • [MeSH-major] Cell Adhesion Molecules / metabolism. Cytokines / metabolism. Galectin 1 / pharmacology. Leukocytes / drug effects
  • [MeSH-minor] Animals. Antigens, CD18 / metabolism. Cell Migration Assays, Leukocyte. Cell Movement / drug effects. Disease Models, Animal. Exudates and Transudates / chemistry. Exudates and Transudates / metabolism. Humans. Intercellular Adhesion Molecule-1. L-Selectin / metabolism. Male. Mesentery / drug effects. Mesentery / metabolism. Mesentery / pathology. Mice. Mice, Inbred C57BL. Monocytes / drug effects. Monocytes / metabolism. Monocytes / pathology. Neutrophils / drug effects. Neutrophils / metabolism. Neutrophils / pathology. Peritonitis / immunology. Peritonitis / metabolism. Peritonitis / pathology. Recombinant Proteins

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2000 Feb;31(2):399-406 [10655263.001]
  • [Cites] J Cell Sci. 1994 Jan;107 ( Pt 1):175-81 [8175907.001]
  • [Cites] J Immunol. 1998 May 15;160(10):4831-40 [9590230.001]
  • [Cites] J Immunol. 1998 Jun 15;160(12):6151-8 [9637533.001]
  • [Cites] Br J Haematol. 1998 Jun;101(4):666-9 [9674739.001]
  • [Cites] Eur J Immunol. 1998 Aug;28(8):2311-9 [9710209.001]
  • [Cites] J Immunol. 1999 Feb 1;162(3):1685-91 [9973430.001]
  • [Cites] J Vasc Res. 1999 Jan-Feb;36(1):47-58 [10050073.001]
  • [Cites] J Exp Med. 1999 Aug 2;190(3):385-98 [10430627.001]
  • [Cites] Am J Pathol. 2005 Jun;166(6):1607-17 [15920146.001]
  • [Cites] J Leukoc Biol. 2005 Sep;78(3):639-46 [16000391.001]
  • [Cites] J Immunol. 2006 Apr 1;176(7):4410-8 [16547279.001]
  • [Cites] Cell Biol Int. 2006 Apr;30(4):338-44 [16530434.001]
  • [Cites] Inflamm Res. 2006 Mar;55(3):99-107 [16673152.001]
  • [Cites] J Immunol. 2006 Jul 1;177(1):216-26 [16785517.001]
  • [Cites] Biochemistry (Mosc). 2008 Apr;73(4):393-405 [18457568.001]
  • [Cites] J Leukoc Biol. 2008 Jun;83(6):1459-66 [18372340.001]
  • [Cites] Immunol Rev. 2009 Jul;230(1):144-59 [19594634.001]
  • [Cites] Glycobiology. 2009 Dec;19(12):1402-7 [19561030.001]
  • [Cites] Ann N Y Acad Sci. 2010 Jan;1183:158-82 [20146714.001]
  • [Cites] Nat Rev Mol Cell Biol. 2010 May;11(5):366-78 [20414258.001]
  • [Cites] Lab Invest. 2011 Jan;91(1):33-42 [20714326.001]
  • [Cites] Eur J Immunol. 2000 May;30(5):1331-9 [10820379.001]
  • [Cites] J Leukoc Biol. 2001 Jul;70(1):73-9 [11435488.001]
  • [Cites] J Mol Med (Berl). 2003 Jan;81(1):4-19 [12545245.001]
  • [Cites] J Dairy Sci. 2003 Jul;86(7):2334-42 [12906050.001]
  • [Cites] Am J Pathol. 2003 Oct;163(4):1505-15 [14507657.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):1010-6 [14550305.001]
  • [Cites] Clin Immunol. 2003 Dec;109(3):295-307 [14697744.001]
  • [Cites] Glycoconj J. 2004;19(7-9):433-40 [14758066.001]
  • [Cites] Agents Actions. 1992 Jan;35(1-2):71-8 [1509980.001]
  • [Cites] Br J Pharmacol. 1997 Mar;120(6):1075-82 [9134220.001]
  • (PMID = 21228929.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD18; 0 / Cell Adhesion Molecules; 0 / Cytokines; 0 / Galectin 1; 0 / LGALS1 protein, human; 0 / Recombinant Proteins; 126547-89-5 / Intercellular Adhesion Molecule-1; 126880-86-2 / L-Selectin
  • [Other-IDs] NLM/ PMC3016105
  • [Keywords] NOTNLM ; CD11b / CD62L / immunocytochemistry / monocyte / neutrophil / zymosan peritonitis
  •  go-up   go-down


41. Lieven CJ, Millet LE, Hoegger MJ, Levin LA: Induction of axon and dendrite formation during early RGC-5 cell differentiation. Exp Eye Res; 2007 Nov;85(5):678-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of axon and dendrite formation during early RGC-5 cell differentiation.
  • The retinal ganglion cell (RGC)-like RGC-5 line can be differentiated with staurosporine to stop dividing, extend neurites, and increase levels of several ganglion cell markers.
  • This allows study of regulation of neurite development on a single cell basis.
  • To address this question, RGC-5 cells were differentiated with staurosporine and then immunoblotted for microtubule-associated protein 2 (MAP2) and actin, or stained immunocytochemically for different MAP2 isoforms, tau, growth-associated protein 43 (GAP-43), or the neuronal marker beta-III-tubulin.
  • The presence of MAP2c in differentiated RGC-5 cells is indicative of RGC-like neurite development, and the pattern of staining for the different MAP2 isoforms, as well as positivity for tau and GAP-43, indicates that differentiation induces axon-like and dendrite-like neurites.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Neurosci. 2000 Aug;16(2):141-56 [10924257.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2006 Jan;47(1):427-38 [16384993.001]
  • [Cites] Eur J Cell Biol. 2001 Mar;80(3):245-55 [11322389.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1930-8 [11431463.001]
  • [Cites] Neuron. 2002 Feb 28;33(5):689-702 [11879647.001]
  • [Cites] Science. 2002 Jun 7;296(5574):1860-4 [12052959.001]
  • [Cites] J Neurosci. 2002 Sep 1;22(17):7639-49 [12196587.001]
  • [Cites] Brain Res Dev Brain Res. 2003 Oct 10;145(1):1-8 [14519488.001]
  • [Cites] J Neurosci. 2003 Oct 22;23(29):9479-90 [14573527.001]
  • [Cites] Semin Cell Dev Biol. 2004 Feb;15(1):125-36 [15036215.001]
  • [Cites] J Neurocytol. 2003 Nov;32(9):1077-89 [15044840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 May;78(5):3010-4 [7019915.001]
  • [Cites] J Comp Neurol. 1984 Jun 20;226(2):203-21 [6736300.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] J Cell Biol. 1985 Oct;101(4):1371-8 [3930508.001]
  • [Cites] J Neurosci. 1986 Mar;6(3):714-22 [3514816.001]
  • [Cites] Dev Biol. 1988 Dec;130(2):423-34 [3058539.001]
  • [Cites] Nature. 1988 Dec 15;336(6200):672-4 [3059197.001]
  • [Cites] Brain Res. 1989 Apr 3;483(2):335-46 [2706525.001]
  • [Cites] J Neurosci. 1990 Feb;10(2):588-602 [2137532.001]
  • [Cites] Cell. 1991 Feb 22;64(4):817-26 [1997209.001]
  • [Cites] Dev Biol. 1993 Feb;155(2):533-44 [8432404.001]
  • [Cites] Neuroscience. 1993 Jun;54(4):873-80 [8341422.001]
  • [Cites] Cell. 1995 Feb 10;80(3):445-52 [7859286.001]
  • [Cites] J Cell Biol. 1995 Dec;131(5):1327-40 [8522593.001]
  • [Cites] J Neurosci. 1996 Sep 15;16(18):5583-92 [8795614.001]
  • [Cites] Mol Neurobiol. 1996 Apr;12(2):133-44 [8818147.001]
  • [Cites] Vis Neurosci. 1996 Jul-Aug;13(4):721-33 [8870228.001]
  • [Cites] Exp Neurol. 1999 Feb;155(2):228-42 [10072298.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Jan 31;86(1-2):1-12 [11165366.001]
  • (PMID = 17904550.001).
  • [ISSN] 0014-4835
  • [Journal-full-title] Experimental eye research
  • [ISO-abbreviation] Exp. Eye Res.
  • [Language] ENG
  • [Grant] United States / NEI NIH HHS / EY / R01 EY012492; United States / NEI NIH HHS / EY / P30 EY016665; United States / PHS HHS / / R0112492; United States / NEI NIH HHS / EY / P30EY016665; United States / NEI NIH HHS / EY / R21 EY017970-01; United States / NEI NIH HHS / EY / R21 EY017970; United States / NEI NIH HHS / EY / P30 EY016665-03; United States / NEI NIH HHS / EY / EY012492-04; United States / NEI NIH HHS / EY / R01 EY012492-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Eye Proteins; 0 / GAP-43 Protein; 0 / Isoenzymes; 0 / Mapt protein, rat; 0 / Microtubule-Associated Proteins; 0 / tau Proteins; H88EPA0A3N / Staurosporine
  • [Other-IDs] NLM/ NIHMS34439; NLM/ PMC2194805
  •  go-up   go-down


42. Meyer DK, Olenik C, Hofmann F, Barth H, Leemhuis J, Brünig I, Aktories K, Nörenberg W: Regulation of somatodendritic GABAA receptor channels in rat hippocampal neurons: evidence for a role of the small GTPase Rac1. J Neurosci; 2000 Sep 15;20(18):6743-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Receptor currents were measured with the whole-cell patch-clamp technique during repetitive stimulation with 1 microm muscimol.
  • Immunocytochemical labeling of the receptors showed that the disappearance of receptor clusters in the somatic membrane as induced by muscimol stimulation was enhanced by Rac1 inactivation.
  • [MeSH-minor] Actin Cytoskeleton / drug effects. Actin Cytoskeleton / metabolism. Actins / antagonists & inhibitors. Actins / metabolism. Adenosine Triphosphate / metabolism. Adenosine Triphosphate / pharmacology. Animals. Animals, Newborn. Bacterial Toxins / pharmacology. Cell Membrane / metabolism. Cells, Cultured. Cytoskeleton / metabolism. Dose-Response Relationship, Drug. GABA Agonists / pharmacology. GABA-A Receptor Agonists. Membrane Potentials / drug effects. Microtubules / drug effects. Microtubules / metabolism. Nocodazole / pharmacology. Patch-Clamp Techniques. Rats. Rats, Wistar. Receptor Aggregation / drug effects

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10995817.001).
  • [ISSN] 0270-6474
  • [Journal-full-title] The Journal of neuroscience : the official journal of the Society for Neuroscience
  • [ISO-abbreviation] J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Actins; 0 / Bacterial Toxins; 0 / GABA Agonists; 0 / GABA-A Receptor Agonists; 0 / Receptors, GABA-A; 0 / lethal toxin LT, Clostridium sordellii; 8L70Q75FXE / Adenosine Triphosphate; EC 3.6.5.2 / rac1 GTP-Binding Protein; SH1WY3R615 / Nocodazole
  •  go-up   go-down


43. Kizuki K, Iwadate H, Ookubo R: Growth-stimulating effect of kallikrein on rat neural stem cells--II. Immunocytochemical analysis and specificity of the enzyme for neural stem cells. Yakugaku Zasshi; 2007 May;127(5):919-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth-stimulating effect of kallikrein on rat neural stem cells--II. Immunocytochemical analysis and specificity of the enzyme for neural stem cells.
  • In a previous paper we reported a new function of tissue kallikrein: rat urinary kallikrein (RUK) has a marked growth-stimulatory effect on neural stem cells prepared from brains of prenatal rats.
  • We here report that conspicuous differentiation of neural stem cells to neurons and/or glial cells did not occur during stimulation by kallikrein, and this growth-stimulating effect of kallikrein is considerably specific for neural stem cells, i.e., RUK showed no detectable stimulatory effect on rat glial, PC12, GH(3), and HeLa cells.
  • In addition, this effect of kallikrein for neural stem cells may have value in the treatment of cerebral ischemic stroke-induced injuries etc., i.e., kallikrein administered into the body stimulates neural stem cell proliferation and new neurons may be generated from them.
  • [MeSH-major] Cell Proliferation / drug effects. Embryonic Stem Cells / cytology. Kallikreins / pharmacology
  • [MeSH-minor] Animals. Brain / cytology. Brain / embryology. Cells, Cultured. Dose-Response Relationship, Drug. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Neurons / cytology. Pregnancy. Rats. Rats, Wistar. Stimulation, Chemical. Stroke / therapy. Tubulin / analysis

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17473535.001).
  • [ISSN] 0031-6903
  • [Journal-full-title] Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
  • [ISO-abbreviation] Yakugaku Zasshi
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Tubulin; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


44. Volokh OA, Shepelev IA, Firsova VV, Khramkova EM, Avdeeva NG, Samokhvalova IuI, Eremin SA, Diatlov IA, Zhemchugov VE: [Evaluation of immunobiological activity of Francisella tularensis C-complex preparations as promising component of subunit vaccines]. Zh Mikrobiol Epidemiol Immunobiol; 2007 May-Jun;(3):16-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of immunobiological activity of Francisella tularensis C-complex preparations as promising component of subunit vaccines].
  • Data on influence of Francisella tularensis C-complex preparations on formation of immunity against tularemia are presented.
  • Absence of toxicity, pyrogenicity, and negative effects on immunocompetent cells in combination with protective activity points to possibility of use the C-complex as a component of a subunit vaccine.
  • [MeSH-major] Bacterial Vaccines / immunology. Francisella tularensis / immunology. Tularemia / immunology. Tularemia / prevention & control. Vaccination
  • [MeSH-minor] Animals. Antibodies, Bacterial / blood. Apoptosis. Bacterial Proteins / immunology. Cells, Cultured. Drug Evaluation, Preclinical. Guinea Pigs. Lymphocyte Activation. Membrane Proteins / immunology. Mice. Spleen / physiology. Thymus Gland / physiology. Vaccines, Synthetic / administration & dosage. Vaccines, Synthetic / immunology. Vaccines, Synthetic / toxicity

  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672125.001).
  • [ISSN] 0372-9311
  • [Journal-full-title] Zhurnal mikrobiologii, epidemiologii, i immunobiologii
  • [ISO-abbreviation] Zh. Mikrobiol. Epidemiol. Immunobiol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Bacterial Proteins; 0 / Bacterial Vaccines; 0 / Membrane Proteins; 0 / Vaccines, Synthetic
  •  go-up   go-down


45. O'Malley D, Shanley LJ, Harvey J: Insulin inhibits rat hippocampal neurones via activation of ATP-sensitive K+ and large conductance Ca2+-activated K+ channels. Neuropharmacology; 2003 Jun;44(7):855-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we have used a combination of immunocytochemical and Ca(2+) imaging techniques to determine the functional localisation of insulin receptors as well as the potential role for insulin in modulating hippocampal synaptic activity.
  • Furthermore, application of the K(ATP) channel blocker glybenclamide or the BK channel inhibitors iberiotoxin or charybdotoxin attenuated the actions of insulin, whereas prior incubation with a combination of glybenclamide and iberiotoxin completely blocked insulin action.
  • [MeSH-major] Hippocampus / cytology. Hippocampus / drug effects. Hypoglycemic Agents / pharmacology. Insulin / pharmacology. Neurons / drug effects. Potassium Channels / agonists. Potassium Channels, Calcium-Activated / agonists
  • [MeSH-minor] ATP-Binding Cassette Transporters. Animals. Calcium / metabolism. Calcium Signaling / drug effects. Cells, Cultured. Diagnostic Imaging. Enzyme Inhibitors / pharmacology. Immunohistochemistry. KATP Channels. Large-Conductance Calcium-Activated Potassium Channels. Mitogen-Activated Protein Kinases / metabolism. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Potassium Channels, Inwardly Rectifying. Rats. Receptor, Insulin / drug effects. Receptor, Insulin / immunology

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12726817.001).
  • [ISSN] 0028-3908
  • [Journal-full-title] Neuropharmacology
  • [ISO-abbreviation] Neuropharmacology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ATP-Binding Cassette Transporters; 0 / Enzyme Inhibitors; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / KATP Channels; 0 / Large-Conductance Calcium-Activated Potassium Channels; 0 / Potassium Channels; 0 / Potassium Channels, Calcium-Activated; 0 / Potassium Channels, Inwardly Rectifying; 0 / uK-ATP-1 potassium channel; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, Insulin; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; SY7Q814VUP / Calcium
  •  go-up   go-down


46. Kim MJ, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ: Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study. BMC Cancer; 2008;8:374
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
  • BACKGROUND: There is no standard palliative chemotherapy regimen in biliary tract cancers (BTC).
  • We conducted this study to clarify the efficacy of palliative chemotherapy in BTC.
  • METHODS: Patients with unresectable BTC treated with palliative chemotherapy between Oct 2001 and Aug 2006 at Seoul National University Hospital were reviewed retrospectively.
  • Histologically confirmed cases of intrahepatic cholangiocarcinoma, gallbladder cancer, extrahepatic bile duct cancer, and ampulla of Vater carcinoma were enrolled.
  • Intrahepatic cholangiocarcinoma, gallbladder cancer, extrahepatic bile duct cancer, and ampulla of Vater carcinoma were 92, 72, 58, and 21 cases, respectively.
  • Ninety-nine patients received G-based chemotherapy (94 GP, 5 G alone), and 144 patients received F-based chemotherapy (83 FP, 61 F alone).
  • The response rate (RR), disease control rate (DCR), PFS and OS of G-based chemotherapy versus F-based chemotherapy were 16.7% vs. 19.5% (P=0.591), 52.8% vs. 58.9% (P=0.372), 4.0 months vs. 4.3 months (P=0.816), and 7.8 months vs. 9.1 months (P=0.848), respectively.
  • Sixty-six patients received F or G without P, and 177 patients received F or G with P.
  • The RR, DCR, PFS and OS of chemotherapy without P versus chemotherapy including P were 12.7% vs. 20.6% (P=0.169), 46.0% vs. 60.6% (P=0.049), 3.3 months vs. 4.4 months (P=0.887), and 10.6 months vs. 8.1 months (P=0.257), respectively.
  • CONCLUSION: In unresectable BTC, F-based and G-based chemotherapy showed similar efficacy in terms of RR, DCR, PFS and OS.
  • The benefit of adding P to F or G was not significant except for DCR.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biliary Tract Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives. Pyrimidinones / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Capecitabine. Cisplatin / administration & dosage. Drug Combinations. Female. Fluorouracil / administration & dosage. Fluorouracil / analogs & derivatives. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Organoplatinum Compounds / administration & dosage. Oxonic Acid / administration & dosage. Oxonic Acid / therapeutic use. Palliative Care / methods. Retrospective Studies. Tegafur / administration & dosage. Tegafur / therapeutic use. Treatment Outcome. Uracil / administration & dosage. Uracil / therapeutic use

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2008 Jan;19(1):99-103 [17846018.001]
  • [Cites] Eur J Cancer. 2005 Feb;41(3):398-403 [15691639.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 20):40-5 [12577232.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):193-8 [14739669.001]
  • [Cites] Ann Oncol. 2004 May;15(5):770-4 [15111345.001]
  • [Cites] Biometrics. 1982 Jun;38(2):407-16 [7115871.001]
  • [Cites] Cancer. 1984 Sep 15;54(6):965-9 [6235908.001]
  • [Cites] Expert Opin Pharmacother. 2005 Feb;6(2):211-23 [15757418.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2332-8 [15800324.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):361-5 [16342166.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):647-53 [16142487.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] Ann Oncol. 2006 Jun;17 Suppl 7:vii73-7 [16760299.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] Jpn J Clin Oncol. 2006 Sep;36(9):552-6 [16887837.001]
  • [Cites] Oncology. 2006;70(4):280-4 [17047399.001]
  • [Cites] Oncology. 2006;70(5):358-65 [17179730.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Mar;61(3):230-42 [17157524.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8 [17143602.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jan;61(1):47-52 [17364190.001]
  • [Cites] Jpn J Clin Oncol. 2007 Nov;37(11):843-51 [17942578.001]
  • [Cites] Oncology. 2007;72(1-2):105-10 [18025804.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1245-8 [6092556.001]
  • [Cites] Cancer Chemother Pharmacol. 1993;32(3):167-72 [8500219.001]
  • [Cites] Semin Liver Dis. 1994 May;14(2):109-14 [8047893.001]
  • [Cites] Oncology. 1994 Nov-Dec;51(6):515-7 [7970496.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):521-30 [9816199.001]
  • [Cites] Br J Cancer. 2004 Nov 15;91(10):1769-74 [15505626.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):279-81 [15668284.001]
  • [Cites] Oncology. 2007;73(5-6):311-5 [18493158.001]
  • (PMID = 19091129.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Organoplatinum Compounds; 0 / Pyrimidinones; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 5VT6420TIG / Oxonic Acid; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; 1-UFT protocol
  • [Other-IDs] NLM/ PMC2615782
  •  go-up   go-down


47. Murphy JA, Jensen ON, Walikonis RS: BRAG1, a Sec7 domain-containing protein, is a component of the postsynaptic density of excitatory synapses. Brain Res; 2006 Nov 20;1120(1):35-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BRAG1, a Sec7 domain-containing protein, is a component of the postsynaptic density of excitatory synapses.
  • The postsynaptic density (PSD) at excitatory synapses is a dynamic complex of glutamatergic receptors and associated proteins that governs synaptic structure and coordinates signal transduction.
  • In this study, we report that BRAG1, a putative guanine nucleotide exchange factor for the Arf family of GTP-binding proteins, is a major component of the PSD.
  • Immunocytochemical localization of BRAG1 in dissociated hippocampal neurons shows that it forms discrete clusters that colocalize with the postsynaptic marker PSD-95 at sites along dendrites.
  • BRAG1 contains a Sec7 domain, a domain that catalyzes exchange of GDP for GTP on the Arf family of small GTP-binding proteins.
  • [MeSH-major] Guanine Nucleotide Exchange Factors / metabolism. Nerve Tissue Proteins / metabolism. Synapses / metabolism
  • [MeSH-minor] ADP-Ribosylation Factor 1 / pharmacology. Animals. Blotting, Western / methods. Cells, Cultured. Drug Interactions. Embryo, Mammalian. Guanosine 5'-O-(3-Thiotriphosphate) / pharmacokinetics. Hippocampus / cytology. Immunohistochemistry / methods. Molecular Weight. Neurons / drug effects. Neurons / metabolism. Prosencephalon / cytology. Protein Binding / drug effects. Rats. Sequence Analysis, Protein. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Subcellular Fractions / metabolism. Sulfur Isotopes / pharmacokinetics. Time Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17045249.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Guanine Nucleotide Exchange Factors; 0 / Iqsec2 protein, rat; 0 / Nerve Tissue Proteins; 0 / Sec7 guanine nucleotide exchange factors; 0 / Sulfur Isotopes; 0 / postsynaptic density proteins; 37589-80-3 / Guanosine 5'-O-(3-Thiotriphosphate); EC 3.6.5.2 / ADP-Ribosylation Factor 1
  •  go-up   go-down


48. Guo JY, Huo HR, Zhao BS, Liu HB, Li LF, Guo SY, Jiang TL: Effect of 3-Phenyl-2-Propene-1-ol on PGE2 release from rat cerebral microvascular endothelial cells stimulated by IL-1beta. Am J Chin Med; 2006;34(4):685-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 3-Phenyl-2-Propene-1-ol on PGE2 release from rat cerebral microvascular endothelial cells stimulated by IL-1beta.
  • In the present study, we examined the influence of interleukin-1beta (IL-1beta) on prostaglandin E(2) (PGE(2)) release, and the effect of 3-phenyl-2-propene-1-ol on IL-1beta-induced PGE(2) release from rat cerebral endothelial cells (rCMEC).
  • In vitro, cells express typical phenotypic markers of brain endothelium.
  • Using a monoclonal antibody against von Willebrand factor, immunocytochemical analysis revealed positive immunoreactivity in the cytoplasm of cultured cells. rCMEC were incubated in M199 medium containing IL-1beta in the presence or absence of 3-phenyl-2-propene-1-ol.
  • [MeSH-major] Dinoprostone / secretion. Endothelial Cells / drug effects. Interleukin-1 / pharmacology. Propanols / pharmacology
  • [MeSH-minor] Animals. Cell Survival / drug effects. Cells, Cultured. Cerebral Cortex / blood supply. Cinnamomum / chemistry. Dose-Response Relationship, Drug. Rats. Time Factors

  • Hazardous Substances Data Bank. 3-PHENYL-2-PROPEN-1-OL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16883638.001).
  • [ISSN] 0192-415X
  • [Journal-full-title] The American journal of Chinese medicine
  • [ISO-abbreviation] Am. J. Chin. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 0 / Interleukin-1; 0 / Propanols; K7Q1JQR04M / Dinoprostone; SS8YOP444F / cinnamyl alcohol
  •  go-up   go-down


49. Huckstepp RT, id Bihi R, Eason R, Spyer KM, Dicke N, Willecke K, Marina N, Gourine AV, Dale N: Connexin hemichannel-mediated CO2-dependent release of ATP in the medulla oblongata contributes to central respiratory chemosensitivity. J Physiol; 2010 Oct 15;588(Pt 20):3901-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Connexin hemichannel-mediated CO2-dependent release of ATP in the medulla oblongata contributes to central respiratory chemosensitivity.
  • As ATP release at the ventral surface of the brainstem has been causally linked to the adaptive changes in ventilation in response to hypercapnia, we have studied the mechanisms of CO(2)-dependent ATP release in slices containing the ventral surface of the medulla oblongata.
  • As agents that act on connexin channels block this release, but compounds selective for pannexin-1 have no effect, we conclude that a connexin hemichannel is involved in CO(2)-dependent ATP release.
  • We have used molecular, genetic and immunocytochemical techniques to demonstrate that in the medulla oblongata connexin 26 (Cx26) is preferentially expressed near the ventral surface.
  • This distribution of CO(2)-dependent dye loading closely mirrors that of Cx26 expression and colocalizes to glial fibrillary acidic protein (GFAP)-positive cells.
  • We therefore propose that Cx26-mediated release of ATP in response to changes in PCO2 is an important mechanism contributing to central respiratory chemosensitivity.
  • [MeSH-minor] Analysis of Variance. Animals. Astrocytes / metabolism. Calcium / metabolism. Connexin 26. Immunohistochemistry. Male. Mice. Mice, Transgenic. Rats. Rats, Sprague-Dawley. Respiration. Reverse Transcriptase Polymerase Chain Reaction

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2005 Sep;289(3):R851-61 [15905224.001]
  • [Cites] Respir Physiol Neurobiol. 2005 Nov 15;149(1-3):165-79 [15876557.001]
  • [Cites] Clin Genet. 2006 May;69(5):371-92 [16650073.001]
  • [Cites] Biochem J. 2006 Jun 1;396(2):e5-7 [16703664.001]
  • [Cites] J Neurosci. 2006 Jul 5;26(27):7230-3 [16822980.001]
  • [Cites] J Neurosci. 2006 Oct 4;26(40):10305-14 [17021186.001]
  • [Cites] Respir Physiol Neurobiol. 2007 Feb 15;155(2):114-20 [16750433.001]
  • [Cites] Nature. 2007 Aug 23;448(7156):901-7 [17713529.001]
  • [Cites] Experientia. 1949 Jun 15;5(6):221-6 [18152121.001]
  • [Cites] Adv Exp Med Biol. 2008;605:343-7 [18085297.001]
  • [Cites] J Neurosci. 2007 Dec 19;27(51):14049-58 [18094244.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1067-72 [18198276.001]
  • [Cites] J Vet Med Sci. 2008 Mar;70(3):265-71 [18388426.001]
  • [Cites] J Appl Physiol (1985). 2008 Aug;105(2):404-16 [18535135.001]
  • [Cites] J Physiol. 2008 Aug 15;586(16):3963-78 [18617567.001]
  • [Cites] J Neurosci. 2008 Aug 27;28(35):8844-50 [18753386.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Sep;295(3):C761-7 [18596212.001]
  • [Cites] N Engl J Med. 2009 Jan 8;360(2):140-9 [19129527.001]
  • [Cites] Lancet Neurol. 2009 Feb;8(2):175-91 [19161909.001]
  • [Cites] J Physiol. 2009 Feb 15;587(Pt 4):713-9 [19218620.001]
  • [Cites] J Appl Physiol (1985). 2009 Apr;106(4):1464-6 [18467549.001]
  • [Cites] Respir Physiol Neurobiol. 2009 Aug 31;168(1-2):49-58 [19394450.001]
  • [Cites] J Neurosci. 2009 Nov 25;29(47):14836-46 [19940179.001]
  • [Cites] Cell Mol Neurobiol. 2010 Apr;30(3):453-60 [19830548.001]
  • [Cites] Science. 2010 Jul 30;329(5991):571-5 [20647426.001]
  • [Cites] J Physiol. 2010 Oct 15;588(Pt 20):3921-31 [20736419.001]
  • [Cites] Respir Physiol. 2001 Dec;129(1-2):101-21 [11738649.001]
  • [Cites] Hum Mutat. 2000 Sep;16(3):190-202 [10980526.001]
  • [Cites] J Comp Neurol. 2000 Nov 27;427(4):485-507 [11056460.001]
  • [Cites] J Comp Neurol. 2001 Feb 26;431(1):88-104 [11169992.001]
  • [Cites] Respir Physiol. 2001 Dec;129(1-2):257-68 [11738659.001]
  • [Cites] J Comp Neurol. 2001 Dec 24;441(4):302-23 [11745652.001]
  • [Cites] Nat Neurosci. 2002 May;5(5):401-2 [11967547.001]
  • [Cites] J Physiol. 2002 Jun 1;541(Pt 2):493-509 [12042354.001]
  • [Cites] EMBO J. 2002 Jul 15;21(14):3598-607 [12110573.001]
  • [Cites] J Neurophysiol. 2002 Aug;88(2):604-12 [12163513.001]
  • [Cites] J Physiol. 2003 Oct 1;552(Pt 1):197-211 [12878756.001]
  • [Cites] Annu Rev Neurosci. 2003;26:239-66 [12598679.001]
  • [Cites] Nat Neurosci. 2003 Nov;6(11):1139-40 [14517544.001]
  • [Cites] Development. 2003 Dec;130(26):6635-42 [14627719.001]
  • [Cites] Eur J Neurosci. 2003 Dec;18(12):3183-92 [14686892.001]
  • [Cites] J Membr Biol. 2004 Feb 1;197(3):179-91 [15042349.001]
  • [Cites] Nat Rev Neurosci. 2004 Jun;5(6):449-61 [15152195.001]
  • [Cites] Paediatr Respir Rev. 2004 Sep;5(3):182-9 [15276129.001]
  • [Cites] Cell Mol Neurobiol. 2004 Oct;24(5):647-65 [15485136.001]
  • [Cites] J Physiol. 1982 Nov;332:1-24 [6818338.001]
  • [Cites] J Appl Physiol (1985). 1985 Feb;58(2):357-64 [3920185.001]
  • [Cites] J Physiol. 1985 Jan;358:285-97 [3920386.001]
  • [Cites] J Physiol. 1991 May;436:107-29 [2061827.001]
  • [Cites] Am J Physiol. 1993 Jun;264(6 Pt 2):F1060-4 [8322892.001]
  • [Cites] J Physiol. 1996 Apr 1;492 ( Pt 1):277-92 [8730602.001]
  • [Cites] J Appl Physiol (1985). 1996 Nov;81(5):1987-95 [8941520.001]
  • [Cites] Br J Pharmacol. 1997 Oct;122(3):423-30 [9351497.001]
  • [Cites] Respir Physiol. 1997 Nov;110(2-3):199-210 [9407612.001]
  • [Cites] J Cell Biol. 1998 Mar 23;140(6):1453-61 [9508777.001]
  • [Cites] Am J Hum Genet. 1998 Apr;62(4):792-9 [9529365.001]
  • [Cites] Am J Physiol. 1998 Oct;275(4 Pt 2):R1152-63 [9756546.001]
  • [Cites] J Physiol. 1999 Jun 15;517 ( Pt 3):899-905 [10358128.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Dec;287(6):C1493-526 [15525685.001]
  • [Cites] Nat Neurosci. 2004 Dec;7(12):1360-9 [15558061.001]
  • [Cites] J Neurosci. 2005 Feb 2;25(5):1211-8 [15689558.001]
  • [Cites] J Neurochem. 2005 Mar;92(5):1033-43 [15715654.001]
  • [Cites] Eur J Neurosci. 2005 Apr;21(7):1859-68 [15869481.001]
  • [Cites] Anal Chem. 2005 May 15;77(10):3267-73 [15889918.001]
  • [Cites] Neuron. 2005 Jun 2;46(5):731-44 [15924860.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):108-11 [16001070.001]
  • [CommentIn] J Physiol. 2010 Nov 15;588(Pt 22):4335-7 [21078598.001]
  • (PMID = 20736421.001).
  • [ISSN] 1469-7793
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / ; United Kingdom / Biotechnology and Biological Sciences Research Council / / ; United Kingdom / Medical Research Council / / G0500198; United Kingdom / Wellcome Trust / / 079040; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Connexins; 0 / Gjb2 protein, mouse; 0 / Gjb2 protein, rat; 127120-53-0 / Connexin 26; 142M471B3J / Carbon Dioxide; 8L70Q75FXE / Adenosine Triphosphate; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC3000581
  •  go-up   go-down


50. Xu M, Lin C, Liang X: [Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82]. Zhonghua Yi Xue Za Zhi; 2000 Sep;80(9):689-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82].
  • OBJECTIVE: To evaluate the therapeutic efficiency of combining p53-expressing adenovirus with chemotherapy agents on GLC-82 human lung adenocarcinoma cells.
  • METHODS: Human lung adenocarcinoma cell line GLC-82 was transfected with adenovirus-mediated p53 gene (Ad-p53) combining with administration of either kind of chemotherapeutic agents-cisplatin (CDDP) and arsenic trioxide (As(2)O(3)).
  • The cell growth, morphological changes, cell cycle, apoptosis and molecular changes were measured using cell counting, reversmicroscope, flow cytometry, TUNEL, RT-PC, immunocytochemical assays, and in vivo therapy experiments to evaluate the therapeutic efficiency of such combined regimen.
  • RESULTS: Ad-p53 transfer and CDDP (or As(2)O(3)) administration to GLC-82 cells could exertubstantially stronger therapeutic effects than the single agent treatment.
  • Especially in in vivo experiments, combined administration of Ad-p53 and CDDP induced almost complete tumor remission (89.0%) compared to the partial tumor remission induced by single agent (43.9% or 57.3%).
  • Moreover, delivery of Ad-p53, or administration of minimal-dose CDDP or As(2)O(3) or combined regimen could induce massive apoptosis of GLC-82 cells.
  • Cell cycle analysis demonstrated that administration of CDDP or As(2)O(3) remarkably arrested GLC-82 cells in G(2)/M prior to apoptotic cell death.
  • When treated with combined regimen, cells were arrested in G(2)/M to a greater extent prior to apoptotic cell death.
  • CONCLUSION: After introduced into GLC-82 cells, Ad-p53 shows enhanced therapeutic efficiency for GLC-82 cells when combined with CDDP or As(2)O(3).
  • [MeSH-minor] Adenoviridae / genetics. Animals. Cell Cycle / drug effects. Combined Modality Therapy. Disease Models, Animal. Genetic Therapy. Mice. Mice, Nude. Neoplasm Transplantation. Transfection / methods. Transplants. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11798837.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Oxides; 0 / Tumor Suppressor Protein p53; Q20Q21Q62J / Cisplatin; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


51. Ryder-Lewis MC, Nelson KM: Reliability of the Sedation-Agitation Scale between nurses and doctors. Intensive Crit Care Nurs; 2008 Aug;24(4):211-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study determined the inter-rater reliability of the Sedation-Agitation Scale (SAS) when used by staff in a tertiary level general intensive care unit (ICU).
  • Intraclass correlations for single measures (r=.921, p<.001) and average measures (r=.959, p<.001) indicated individuals who completed multiple ratings did not introduce bias.
  • It also provides support for the use of the instrument in general ICUs outside the USA.
  • [MeSH-major] Conscious Sedation. Drug Monitoring / methods. Medical Staff, Hospital. Nursing Staff, Hospital. Psychomotor Agitation / diagnosis. Severity of Illness Index

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206372.001).
  • [ISSN] 0964-3397
  • [Journal-full-title] Intensive & critical care nursing
  • [ISO-abbreviation] Intensive Crit Care Nurs
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] Scotland
  •  go-up   go-down


52. Rio RD, Moya EA, Alcayaga J, Iturriaga R: Evidence for histamine as a new modulator of carotid body chemoreception. Adv Exp Med Biol; 2009;648:177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been proposed that histamine is an excitatory transmitter between the glomus cells of the carotid body (CB) and the nerve endings of the petrosal ganglion (PG) neurons.
  • However, there is no evidence that glomus cells contain histamine, or whether its application produces chemosensory excitation.
  • Therefore, we studied its immunocytochemical localization on cat CB and its effects on chemosensory activity.
  • Using perfused and superfused in vitro CB and PG preparations, we assessed the effects of histamine hydrochloride on chemosensory discharges and of histamine H1, H2 and H3 receptor blockers.
  • We found the presence of histamine immunoreactivity in dense-core vesicles in glomus cells.
  • In an in vitro CB preparation we performed pharmacological experiments to characterize histamine effects.
  • [MeSH-major] Carotid Body / drug effects. Carotid Body / metabolism. Histamine / metabolism. Histamine / pharmacology
  • [MeSH-minor] Animals. Cats. Dose-Response Relationship, Drug. Histamine Antagonists / pharmacology. In Vitro Techniques. Male. Pyrilamine / pharmacology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HISTAMINE .
  • Hazardous Substances Data Bank. PYRILAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536479.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histamine Antagonists; 820484N8I3 / Histamine; HPE317O9TL / Pyrilamine
  •  go-up   go-down


53. Shaikh S, Nicholson LF: Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation. J Neurosci Res; 2008 Jul;86(9):2071-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced glycation end products induce in vitro cross-linking of alpha-synuclein and accelerate the process of intracellular inclusion body formation.
  • Cross-linking of alpha-synuclein and Lewy body formation have been implicated in the dopaminergic neuronal cell death observed in Parkinson's disease (PD); the mechanisms responsible, however, are not clear.
  • Reactive oxygen species and advanced glycation end products (AGEs) have been found in the intracellular, alpha-synuclein-positive Lewy bodies in the brains of both PD as well as incidental Lewy body disease patients, suggesting a role for AGEs in alpha-synuclein cross-linking and Lewy body formation.
  • The aims of the present study were to determine 1) whether AGEs can induce cross-linking of alpha-synuclein peptides, 2) the progressive and time-dependent intracellular accumulation of AGEs and inclusion body formation, and 3) the effects of extracellular or exogenous AGEs on intracellular inclusion formation.
  • We first investigated the time-dependent cross-linking of recombinant human alpha-synuclein in the presence of AGEs in vitro, then used a cell culture model based on chronic rotenone treatment of human dopaminergic neuroblastoma cells (SH-SY5Y) over a period of 1-4 weeks, in the presence of different doses of AGEs.
  • Cells (grown on coverslips) and cell lysates, collected at the end of every week, were analyzed for the presence of intracellular reactive oxygen species, AGEs, alpha-synuclein proteins, and intracellular alpha-synuclein- and AGE-positive inclusion bodies by using immunocytochemical, biochemical, and Western blot techniques.
  • Our results show that AGEs promote in vitro cross-linking of alpha-synuclein, that intracellular accumulation of AGEs precedes alpha-synuclein-positive inclusion body formation, and that extracellular AGEs accelerate the process of intracellular alpha-synuclein-positive inclusion body formation.
  • [MeSH-major] Cross-Linking Reagents / pharmacology. Glycosylation End Products, Advanced / pharmacology. Inclusion Bodies / physiology. alpha-Synuclein / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. Neuroblastoma. Reactive Oxygen Species / metabolism. Recombinant Proteins / drug effects. Recombinant Proteins / metabolism. Rotenone / pharmacology

  • Hazardous Substances Data Bank. ROTENONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 Wiley-Liss, Inc.
  • (PMID = 18335520.001).
  • [ISSN] 1097-4547
  • [Journal-full-title] Journal of neuroscience research
  • [ISO-abbreviation] J. Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Glycosylation End Products, Advanced; 0 / Reactive Oxygen Species; 0 / Recombinant Proteins; 0 / alpha-Synuclein; 03L9OT429T / Rotenone
  •  go-up   go-down


54. Chen CR, Young TH: The effect of gallium nitride on long-term culture induced aging of neuritic function in cerebellar granule cells. Biomaterials; 2008 Apr;29(11):1573-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of gallium nitride on long-term culture induced aging of neuritic function in cerebellar granule cells.
  • Gallium nitride (GaN) has been developed for a variety of microelectronic and optical applications due to its unique electric property and chemical stability.
  • In the present study, n-type and p-type GaN were used as substrates to culture cerebellar granule neurons to examine the effect of GaN on cell response for a long-term culture period.
  • It was assumed that the anti-apoptotic effect of Akt phosphorylation could be correlated with cell survival, neurite growth and neuronal function for up to 35 days of incubation.
  • Western blot analysis and immunocytochemical characterization showed that GaN still exhibited the expression of neurite growth and function, such as high levels of GAP-43, synapsin I and synaptophysin even after 35 days of incubation.
  • In addition, survival of cerebellar granule neurons on GaN was improved by the analysis of lactate dehydrogenase (LDH) release from damaged cells.
  • These results indicated that neuronal connections were formed on GaN by a gradual process from Akt activation and cell aggregation to develop neurite growth, fasciculation and function.
  • Therefore, GaN offers a good model system to identify a well-characterized pattern of neuronal behavior for a long-term culture period, consistent with the development of a neurochip requiring the integration of biological system and semiconductor material.
  • [MeSH-major] Cell Aging / drug effects. Cerebellum / cytology. Cerebellum / drug effects. Gallium / pharmacology. Neurites / drug effects. Neurites / physiology
  • [MeSH-minor] Animals. Cells, Cultured. Lactate Dehydrogenases / metabolism. Microscopy, Electron, Scanning. Phosphorylation / drug effects. Proto-Oncogene Proteins c-akt / metabolism. Rats. Rats, Wistar. Time Factors

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GALLIUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18194814.001).
  • [ISSN] 0142-9612
  • [Journal-full-title] Biomaterials
  • [ISO-abbreviation] Biomaterials
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / gallium nitride; CH46OC8YV4 / Gallium; EC 1.1.- / Lactate Dehydrogenases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


55. Maranghi F, Lorenzetti S, Tassinari R, Moracci G, Tassinari V, Marcoccia D, Di Virgilio A, Eusepi A, Romeo A, Magrelli A, Salvatore M, Tosto F, Viganotti M, Antoccia A, Di Masi A, Azzalin G, Tanzarella C, Macino G, Taruscio D, Mantovani A: In utero exposure to di-(2-ethylhexyl) phthalate affects liver morphology and metabolism in post-natal CD-1 mice. Reprod Toxicol; 2010 Jul;29(4):427-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • F1 mice were examined at post-natal days 21 (weaning) and 35 (start of puberty): parameters included liver histopathological, immunocytochemical and alpha-fetoprotein (AFP) gene expression analyses.
  • [MeSH-major] Diethylhexyl Phthalate / toxicity. Drug-Induced Liver Injury / etiology. Environmental Pollutants / toxicity. Fatty Liver / chemically induced. Liver / drug effects. Prenatal Exposure Delayed Effects / chemically induced
  • [MeSH-minor] Animals. Cytoplasm / metabolism. Female. Gene Expression / drug effects. Liver Glycogen / metabolism. Maternal Exposure. Mice. Mice, Inbred Strains. Pregnancy. RNA, Messenger / metabolism. alpha-Fetoproteins / genetics. alpha-Fetoproteins / metabolism. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • Hazardous Substances Data Bank. BIS(2-ETHYLHEXYL) PHTHALATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20307648.001).
  • [ISSN] 1873-1708
  • [Journal-full-title] Reproductive toxicology (Elmsford, N.Y.)
  • [ISO-abbreviation] Reprod. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTNNB1 protein, mouse; 0 / Environmental Pollutants; 0 / Liver Glycogen; 0 / RNA, Messenger; 0 / alpha-Fetoproteins; 0 / beta Catenin; C42K0PH13C / Diethylhexyl Phthalate
  •  go-up   go-down


56. Saitoh N, Hori T, Takahashi T: Activation of the epsilon isoform of protein kinase C in the mammalian nerve terminal. Proc Natl Acad Sci U S A; 2001 Nov 20;98(24):14017-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A variety of PKC isoforms are expressed in the central nervous system, but the isoform involved in the PESP has not been identified.
  • To address this question, we have applied immunocytochemical and electrophysiological techniques to the calyx of Held synapse in the medial nucleus of the trapezoid body (MNTB) of rat auditory brainstem.
  • We conclude that the Ca(2+)-independent epsilon PKC isoform mediates the PESP at this mammalian central nervous system synapse.
  • [MeSH-minor] Animals. Biological Transport. Calcium / metabolism. Cochlear Nucleus. Enzyme Activation. Mammals. Phorbol Esters / pharmacology. Phosphorylation. Presynaptic Terminals / drug effects. Presynaptic Terminals / physiology. Protein Kinase C-epsilon. Rats. Rats, Wistar

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol. 1999 Dec;277(6 Pt 1):C1239-49 [10600776.001]
  • [Cites] Cell Mol Life Sci. 1999 Apr;55(4):534-48 [10357224.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):8054-8 [11416164.001]
  • [Cites] Biochem Biophys Res Commun. 1986 Mar 28;135(3):1144-9 [3516146.001]
  • [Cites] Nature. 1986 May 8-14;321(6066):175-7 [3010137.001]
  • [Cites] Nature. 1987 Jan 1-7;325(6099):58-60 [2432432.001]
  • [Cites] J Biol Chem. 1988 May 15;263(14):6927-32 [2834397.001]
  • [Cites] Cell. 1988 Jun 3;53(5):731-41 [3370672.001]
  • [Cites] Brain Res. 1989 Apr 3;483(2):384-8 [2706529.001]
  • [Cites] J Cell Biol. 1990 Sep;111(3):919-27 [2391368.001]
  • [Cites] J Neurosci. 1991 Jun;11(6):1496-507 [1675264.001]
  • [Cites] J Neurosci Methods. 1991 Apr;37(2):173-82 [1715499.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2576-80 [1557361.001]
  • [Cites] Science. 1992 Oct 23;258(5082):607-14 [1411571.001]
  • [Cites] Brain Res. 1993 Apr 2;607(1-2):241-8 [8481800.001]
  • [Cites] J Biol Chem. 1994 Feb 11;269(6):4653-60 [8308036.001]
  • [Cites] Neuroscience. 1994 Jan;58(2):263-74 [8152538.001]
  • [Cites] Annu Rev Neurosci. 1994;17:551-67 [8210187.001]
  • [Cites] J Physiol. 1994 Sep 15;479 ( Pt 3):381-7 [7837096.001]
  • [Cites] Neuron. 1995 Feb;14(2):353-63 [7857644.001]
  • [Cites] J Cell Biol. 1995 Feb;128(4):589-98 [7860632.001]
  • [Cites] J Neurosci. 1995 Feb;15(2):1249-60 [7869096.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1724-8 [7878048.001]
  • [Cites] Biochim Biophys Acta. 1995 Nov 30;1269(3):307-15 [7495885.001]
  • [Cites] J Cell Biol. 1996 Jan;132(1-2):77-90 [8567732.001]
  • [Cites] J Biol Chem. 1996 May 31;271(22):13008-12 [8662811.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21666-71 [8702956.001]
  • [Cites] J Physiol. 1995 Dec 15;489 ( Pt 3):825-40 [8788946.001]
  • [Cites] Nature. 1996 Oct 3;383(6599):431-4 [8837774.001]
  • [Cites] Science. 1996 Oct 25;274(5287):594-7 [8849448.001]
  • [Cites] J Biol Chem. 1997 Jan 17;272(3):1417-20 [8999804.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):C263-9 [9038832.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):G31-7 [9038873.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16081-4 [9195900.001]
  • [Cites] Learn Mem. 1996 Sep-Oct;3(2-3):182-7 [10456088.001]
  • [Cites] J Neurosci. 1999 Sep 1;19(17):7262-7 [10460232.001]
  • [Cites] FASEB J. 1998 Jan;12(1):35-42 [9438408.001]
  • [Cites] Nature. 1998 Jul 23;394(6691):384-8 [9690475.001]
  • [Cites] Neuron. 1998 Jul;21(1):123-36 [9697857.001]
  • [Cites] J Biol Chem. 1998 Oct 9;273(41):26790-8 [9756923.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):511-21 [9786959.001]
  • [Cites] J Neurosci. 1999 Jan 15;19(2):726-36 [9880593.001]
  • [Cites] Eur J Neurosci. 2000 Nov;12(11):4055-62 [11069602.001]
  • (PMID = 11717460.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Phorbol Esters; EC 2.7.1.- / Prkce protein, rat; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-epsilon; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ PMC61159
  •  go-up   go-down


57. Knight JR, Gross EA, Bradley GH, Bay C, LoVecchio F: Boehler's angle and the critical angle of Gissane are of limited use in diagnosing calcaneus fractures in the ED. Am J Emerg Med; 2006 Jul;24(4):423-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One second-year emergency medicine resident, 1 third-year emergency medicine resident, 2 board-certified emergency medicine attending physicians, and 1 board-certified radiologist prospectively reviewed all films using the Picture Archival and Communication System digital radiology system.
  • BA had an interclass correlation coefficient of 0.84 (95% confidence interval, 0.79-0.87).
  • The CAG interclass correlation was 0.52 (95% confidence interval, 0.43-0.60).
  • Emergency physicians were 97.9% accurate in making the diagnosis by reviewing the plain films without "assistance" of the angle measurements.
  • [MeSH-minor] Area Under Curve. Case-Control Studies. Clinical Competence. Emergency Medicine. Emergency Service, Hospital. Humans. Internship and Residency. Observer Variation. ROC Curve. Radiology. Sensitivity and Specificity. Single-Blind Method. Students, Medical. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Fractures.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16787799.001).
  • [ISSN] 0735-6757
  • [Journal-full-title] The American journal of emergency medicine
  • [ISO-abbreviation] Am J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. Daviet JC, Dudognon P, Preux PM, Rebeyrotte I, Lacroix P, Munoz M, Salle JY: Reliability of transcutaneous oxygen tension measurement on the back of the hand and complex regional pain syndrome after stroke. Arch Phys Med Rehabil; 2004 Jul;85(7):1102-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To verify the reproducibility of measurement of transcutaneous oxygen tension (TcPo(2)) on the back of the hand in control subjects and stroke patients in the assessment of the complex regional pain syndrome type I (CRPS I).
  • SETTING: Physical medicine and rehabilitation department at a university hospital.
  • The reproducibility was evaluated by using the intraclass correlation coefficient (ICC) and the coefficient of variation.
  • RESULTS: In the controls, the values of TcPo(2) were not reproducible, with an ICC of.51 (95% confidence interval [CI],.23-.72).
  • Similarly, in the hemiplegics with and without CRPS I, TcPo(2) was not reproducible, with an ICC of.43 (95% CI, -.15 to.74) and.69 (95% CI,.45-.84), respectively.

  • Genetic Alliance. consumer health - Complex regional pain syndrome.
  • MedlinePlus Health Information. consumer health - Stroke.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15241757.001).
  • [ISSN] 0003-9993
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] S88TT14065 / Oxygen
  •  go-up   go-down


59. Huang MC, Huang CC, Thomas K: Febrile convulsions: development and validation of a questionnaire to measure parental knowledge, attitudes, concerns and practices. J Formos Med Assoc; 2006 Jan;105(1):38-48
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The best medicine for febrile convulsions (FCs) is not prescription medications but effective communication of related information to parents.
  • The item-total correlations in the knowledge and concerns domains ranged from 0.40 to 0.73, but were lower in the attitudes domain (only 4 in 10 items were within 0.40-0.70).
  • The intraclass correlation coefficients (ICC) for the test-retest reliability of the knowledge, attitudes and concerns domains were 0.65, 0.68 and 0.58, respectively.
  • The correlation coefficients between KACP domains were tested and significantly supported the theoretical basis of the questionnaire.
  • Cross-cultural investigation of the questionnaire is needed to facilitate its use in other countries.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16440069.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] Singapore
  •  go-up   go-down


60. Oomizu S, Honda J, Takeuchi S, Kakeya T, Masui T, Takahashi S: Transforming growth factor-alpha stimulates proliferation of mammotrophs and corticotrophs in the mouse pituitary. J Endocrinol; 2000 May;165(2):493-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oestrogen stimulates the proliferation of pituitary cells.
  • The present study was designed to clarify the involvement of transforming growth factor-alpha (TGF-alpha) in the oestrogen-induced growth of mouse pituitary cells in vitro.
  • Anterior pituitary cells obtained from ICR male mice were cultured in a primary serum-free culture system.
  • Proliferation of pituitary cells was detected by monitoring the cellular uptake of bromodeoxyuridine.
  • Secretory cell types were immunocytochemically determined.
  • Treatment with TGF-alpha (0.1 and 1 ng/ml) for 5 days stimulated cell proliferation.
  • Oestradiol-17beta (OE(2), 10(-)(9) M) stimulated mammotrophic and corticotrophic cell proliferation.
  • RG-13022, an EGF receptor inhibitor, inhibited the cell proliferation induced by EGF or OE(2), showing that the EGF receptor was involved in the growth response in mammotrophs and corticotrophs.
  • Treatment with antisense TGF-alpha oligodeoxynucleotide (ODN) inhibited the cell proliferation induced by OE(2), but treatment with antisense EGF ODN did not.
  • These results indicate that TGF-alpha mediates the stimulatory effect of oestrogen on the pituitary cell proliferation in a paracrine or autocrine manner, and that EGF receptor expression is stimulated by oestrogen.
  • [MeSH-minor] Animals. Cell Division / drug effects. Cells, Cultured. Epidermal Growth Factor / genetics. Epidermal Growth Factor / pharmacology. Gene Expression / drug effects. Male. Mice. Mice, Inbred ICR. Oligonucleotides, Antisense / pharmacology. RNA, Messenger / analysis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction. Stimulation, Chemical. Tyrphostins / pharmacology

  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10810313.001).
  • [ISSN] 0022-0795
  • [Journal-full-title] The Journal of endocrinology
  • [ISO-abbreviation] J. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Oligonucleotides, Antisense; 0 / RNA, Messenger; 0 / Transforming Growth Factor alpha; 0 / Tyrphostins; 136831-48-6 / RG 13022; 4TI98Z838E / Estradiol; 62229-50-9 / Epidermal Growth Factor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


61. Shiroshita N, Musashi M, Sakurada K, Kimura K, Tsuda Y, Ota S, Iwasaki H, Miyazaki T, Kato T, Miyazaki H, Shimosaka A, Asaka M: Involvement of protein kinase C-epsilon in signal transduction of thrombopoietin in enhancement of interleukin-3-dependent proliferation of primitive hematopoietic progenitors. J Pharmacol Exp Ther; 2001 Jun;297(3):868-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the effect of thrombopoietin (TPO) on interleukin-3 (IL-3)-dependent bone marrow cell colony formation of mice to clarify the role of protein kinase C (PKC) in the signal transduction of TPO for the proliferation of primitive hematopoietic progenitors.
  • Immunocytochemical studies on PKC isoforms in progenitor cells stimulated with TPO have revealed that the expression pattern of PKC-epsilon is changed, but not that of PKC-alpha, -beta, -gamma, -delta, or -zeta.
  • Selective PKC inhibitors, such as calphostin C and GF 109203X, and PKC-epsilon-specific translocation inhibitor peptide abrogated the enhancing effect of TPO on IL-3-dependent colony formation and the changes in the intracellular expression pattern of PKC-epsilon.
  • [MeSH-major] Hematopoietic Stem Cells / metabolism. Interleukin-3 / metabolism. Isoenzymes / metabolism. Protein Kinase C / metabolism. Signal Transduction / physiology. Thrombopoietin / metabolism
  • [MeSH-minor] Animals. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Cell Count. Cell Division / drug effects. Cells, Cultured. Clone Cells. Colony-Forming Units Assay. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Fluorouracil / pharmacology. Immunohistochemistry. Male. Mice. Protein Kinase C-epsilon

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11356906.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Interleukin-3; 0 / Isoenzymes; 9014-42-0 / Thrombopoietin; EC 2.7.1.- / Prkce protein, mouse; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C-epsilon; U3P01618RT / Fluorouracil
  •  go-up   go-down


62. Hashitani H, Lang RJ, Suzuki H: Role of perinuclear mitochondria in the spatiotemporal dynamics of spontaneous Ca2+ waves in interstitial cells of Cajal-like cells of the rabbit urethra. Br J Pharmacol; 2010 Oct;161(3):680-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of perinuclear mitochondria in the spatiotemporal dynamics of spontaneous Ca2+ waves in interstitial cells of Cajal-like cells of the rabbit urethra.
  • BACKGROUND AND PURPOSE: Although spontaneous Ca(2+) waves in interstitial cells of Cajal (ICC)-like cells (ICC-LCs) primarily arise from endoplasmic reticulum (ER) Ca(2+) release, the interactions among mitochondrial Ca(2+) buffering, cellular energetics and ER Ca(2+) release in determining the spatiotemporal dynamics of intracellular Ca(2+) remain to be elucidated.
  • EXPERIMENTAL APPROACH: Spontaneous Ca(2+) transients in freshly isolated ICC-LCs of the rabbit urethra were visualized using fluo-4 Ca(2+) imaging, while the intracellular distribution of mitochondria was viewed with MitoTracker Red.
  • KEY RESULTS: Spontaneous Ca(2+) waves invariably originated from the perinuclear region where clusters of mitochondria surround the nucleus.
  • Caffeine evoked oscillatory Ca(2+) waves originating from anywhere within ICC-LCs.
  • CONCLUSIONS AND IMPLICATIONS: Perinuclear mitochondria in ICC-LCs play a dominant role in the spatial regulation of Ca(2+) wave generation and may regulate ER Ca(2+) release frequency by buffering Ca(2+) within microdomains between both organelles.
  • [MeSH-major] Calcium Signaling / physiology. Interstitial Cells of Cajal / physiology. Mitochondria / physiology. Urethra / physiology
  • [MeSH-minor] Animals. Caffeine / pharmacology. Calcium / metabolism. Calcium / physiology. Clonazepam / analogs & derivatives. Clonazepam / pharmacology. Deoxyglucose / pharmacology. Endoplasmic Reticulum / metabolism. Glycolysis / drug effects. Glycolysis / physiology. Hydrazones / pharmacology. Indoles / pharmacology. Male. Rabbits. Ruthenium Compounds / pharmacology. Ryanodine / pharmacology. Thiazepines / pharmacology

  • Hazardous Substances Data Bank. 2-DEOXY-D-GLUCOSE .
  • Hazardous Substances Data Bank. CLONAZEPAM .
  • Hazardous Substances Data Bank. CYCLOPIAZONIC ACID .
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13807-12 [10570154.001]
  • [Cites] J Microsc. 2000 Mar;197(Pt 3):239-49 [10692127.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):15305-13 [10809765.001]
  • [Cites] J Physiol. 2000 Jun 1;525 Pt 2:355-61 [10835039.001]
  • [Cites] J Physiol. 2000 Jul 15;526 Pt 2:359-66 [10896724.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 May;280(5):C1349-56 [11287348.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29430-9 [11358971.001]
  • [Cites] J Cell Sci. 2001 Jun;114(Pt 12):2213-22 [11493661.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):2380-5 [11854531.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12909-17 [14699167.001]
  • [Cites] Am J Physiol. 1987 Sep;253(3 Pt 1):C364-8 [2443015.001]
  • [Cites] J Urol. 1993 Jul;150(1):223-8 [7685424.001]
  • [Cites] Br J Pharmacol. 1996 Aug;118(7):1627-32 [8842424.001]
  • [Cites] Science. 1998 Jun 12;280(5370):1763-6 [9624056.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):4987-5000 [9724635.001]
  • [Cites] Biophys J. 1998 Dec;75(6):2801-10 [9826602.001]
  • [Cites] J Physiol. 1999 Jan 15;514 ( Pt 2):459-70 [9852327.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12114-22 [15659398.001]
  • [Cites] J Physiol. 2005 Jun 1;565(Pt 2):449-61 [15760947.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Sep;289(3):C625-32 [16100389.001]
  • [Cites] Annu Rev Physiol. 2006;68:307-43 [16460275.001]
  • [Cites] EMBO Rep. 2006 Apr;7(4):390-6 [16415789.001]
  • [Cites] Cell Calcium. 2006 Sep;40(3):287-98 [16797696.001]
  • [Cites] J Physiol. 2006 Aug 1;574(Pt 3):651-61 [16728449.001]
  • [Cites] BJU Int. 2007 Mar;99(3):687-94 [17212607.001]
  • [Cites] J Physiol. 2007 Sep 1;583(Pt 2):505-19 [17615099.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Feb;294(2):G467-76 [18048480.001]
  • [Cites] J Physiol. 2008 Oct 1;586(Pt 19):4631-42 [18703577.001]
  • [Cites] Cell Calcium. 2009 Aug;46(2):107-13 [19577805.001]
  • [Cites] Br J Pharmacol. 2009 Nov;158 Suppl 1:S1-254 [19883461.001]
  • [Cites] Br J Pharmacol. 2009 Dec;158(8):2030-45 [20050194.001]
  • [ErratumIn] Br J Pharmacol. 2011 Apr;162(8):1894. Hashiatni, Hikaru [corrected to Hashitani, Hikaru]
  • (PMID = 20880405.001).
  • [ISSN] 1476-5381
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hydrazones; 0 / Indoles; 0 / Ru 360; 0 / Ruthenium Compounds; 0 / Thiazepines; 14046-96-9 / carbonyl 3-chlorophenylhydrazone; 15662-33-6 / Ryanodine; 3G6A5W338E / Caffeine; 5PE9FDE8GB / Clonazepam; 75450-34-9 / CGP 37157; 9G2MP84A8W / Deoxyglucose; SY7Q814VUP / Calcium; X9TLY4580Z / cyclopiazonic acid
  • [Other-IDs] NLM/ PMC2990164
  •  go-up   go-down


63. Baldridge WH, Fischer AJ: Nitric oxide donor stimulated increase of cyclic GMP in the goldfish retina. Vis Neurosci; 2001 Nov-Dec;18(6):849-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunocytochemical detection of cGMP following exposure to NO donors has proven an effective method of identifying cells that express sGC.
  • In the presence of the phosphodiesterase (PDE) inhibitor 3-isobutyl-1-methylxanthine (IBMX), incubation of goldfish eyecups in Ringer's solution containing (+/-)-S-nitroso-N-acetylpenicillamine (SNAP) increased cGMP-like immunoreactivity (cG-ir) in bipolar, horizontal, amacrine, and ganglion cells and in ganglion cell axons and optic nerve.
  • Weak labeling was observed in horizontal cells but no change in cG-ir was noted within photoreceptors.
  • The NO donor-stimulated increases of cG-ir in horizontal, bipolar, amacrine, and ganglion cells are consistent with known physiological effects of NO on these neurons.
  • [MeSH-major] Cyclic GMP / metabolism. Nitric Oxide Donors / pharmacology. Penicillamine / analogs & derivatives. Penicillamine / pharmacology. Retina / drug effects
  • [MeSH-minor] 1-Methyl-3-isobutylxanthine / pharmacology. Amacrine Cells / drug effects. Amacrine Cells / metabolism. Animals. Axons / drug effects. Axons / metabolism. Fluorescent Antibody Technique, Indirect. Goldfish. Microscopy, Fluorescence. Optic Nerve / drug effects. Optic Nerve / metabolism. Retinal Ganglion Cells / drug effects. Retinal Ganglion Cells / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (D)-PENICILLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12020075.001).
  • [ISSN] 0952-5238
  • [Journal-full-title] Visual neuroscience
  • [ISO-abbreviation] Vis. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitric Oxide Donors; 0 / S-nitro-N-acetylpenicillamine; GNN1DV99GX / Penicillamine; H2D2X058MU / Cyclic GMP; TBT296U68M / 1-Methyl-3-isobutylxanthine
  •  go-up   go-down


64. Giraudeau B, Ravaud P, Donner A: Sample size calculation for cluster randomized cross-over trials. Stat Med; 2008 Nov 29;27(27):5578-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sample size calculation for cluster randomized cross-over trials.
  • The cluster randomized cross-over design has been proposed in particular because it prevents an imbalance that may bring into question the internal validity of parallel group cluster trials.
  • We derived a sample size formula for continuous outcomes that takes into account both the intraclass correlation coefficient (representing the clustering effect) and the interperiod correlation (induced by the cross-over design).
  • [MeSH-major] Blood Glucose / analysis. Cluster Analysis. Drug Therapy, Computer-Assisted. Hypoglycemic Agents / administration & dosage. Insulin / administration & dosage. Models, Statistical. Randomized Controlled Trials as Topic. Research Design. Sample Size
  • [MeSH-minor] Algorithms. Cross-Over Studies. Data Interpretation, Statistical. Humans. Intensive Care Units. Time Factors

  • MedlinePlus Health Information. consumer health - Blood Sugar.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 John Wiley & Sons, Ltd.
  • [ErratumIn] Stat Med. 2009 Feb 15;28(4):720
  • (PMID = 18646266.001).
  • [ISSN] 0277-6715
  • [Journal-full-title] Statistics in medicine
  • [ISO-abbreviation] Stat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Hypoglycemic Agents; 0 / Insulin
  •  go-up   go-down


65. Nepomnyashchikh LM, Aidagulova SV, Senchukova SR, Voronova NA: Psoriasis associated with opisthorchiasis under conditions of anthelmintic therapy. Bull Exp Biol Med; 2004 Apr;137(4):407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biopsy specimens from patients with psoriasis concomitant with chronic opisthorchiasis were examined.
  • Severe clinical course of combined disease was associated with degenerative changes in epidermocytes, keratinization disorders, and diffuse inflammatory cell infiltration of the derma.
  • Combined therapy including anthelmintic agents produced a positive effect: decreased the degree of acanthosis, increased intracellular regeneration of epidermocytes, and suppressed inflammatory reaction of the derma and hyperplasia of immunocompetent cells.
  • [MeSH-major] Anthelmintics / therapeutic use. Opisthorchiasis / drug therapy. Psoriasis / drug therapy
  • [MeSH-minor] Biopsy. Comorbidity. Drug Therapy, Combination. Humans. Skin / cytology. Skin / metabolism. Skin / pathology

  • Genetic Alliance. consumer health - Opisthorchiasis.
  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15452616.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthelmintics
  •  go-up   go-down


66. Forneris M, Gottardo L, Albertin G, Malendowicz LK, Nussdorfer GG: Expression and function of adrenomedullin and its receptors in Conn's adenoma cells. Int J Mol Med; 2001 Dec;8(6):675-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and function of adrenomedullin and its receptors in Conn's adenoma cells.
  • Adrenomedullin (ADM) is a hypotensive peptide, that derives from the proteolytic cleavage of pro(p)ADM and acts through two subtypes of receptors, called L1-receptor (L1-R) and calcitonin receptor-like receptor (CRLR).
  • CRLR may function as a calcitonin gene-related peptide or a selective ADM receptor depending on the expression of the subtype 1 or the subtypes 2 and 3 of a family of proteins, named receptor-activity modifying proteins (RAMPs).
  • Reverse transcription (RT)-polymerase chain reaction (PCR) allowed the detection of pADM mRNA in dispersed cells of eight Conn's adenomas (aldosteronomas).
  • These cells also expressed peptidyl-glycine alpha-amidating monooxigenase, the enzyme converting immature ADM to the mature form, and contained sizeable amounts of ADM-immunoreactivity as measured by radioimmunoassay.
  • RT-PCR also demonstrated the presence in aldosteronoma cells of the specific mRNAs of L1-R, CRLR and RAMPs 1-3.
  • ADM (10(-8) M) inhibited angiotensin-II (10(-9) M)-simulated aldosterone secretion from cultured aldosteronoma cells, without affecting basal production.
  • ADM (10(-8) M) also enhanced basal proliferation rate of cultured cells, as estimated by the 5-bromo-2'-deoxyuridine immunocytochemical technique.
  • In conclusion, our study provides evidence that aldosteronoma cells express both ADM and ADM22-52-sensitive receptors.
  • These findings, coupled with the demonstration that ADM exerts an aldosterone antisecretagogue action and a proliferogenic effect on cultured aldosteronoma cells, make it likely that endogenous ADM system plays a potentially important role in the paracrine or autocrine functional control of Conn's adenomas.
  • [MeSH-minor] Adrenomedullin. Aldosterone / secretion. Angiotensin II / pharmacology. Gene Expression Regulation, Neoplastic. Humans. RNA, Messenger / genetics. RNA, Messenger / metabolism. Radioimmunoassay. Receptors, Adrenomedullin. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured / drug effects. Tumor Cells, Cultured / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11712085.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Peptides; 0 / RNA, Messenger; 0 / Receptors, Adrenomedullin; 0 / Receptors, Peptide; 11128-99-7 / Angiotensin II; 148498-78-6 / Adrenomedullin; 4964P6T9RB / Aldosterone
  •  go-up   go-down


67. Kohnert KD, Hehmke B, Klöting I, Besch W, Ahrén B: Insulin treatment improves islet function in type 2 diabetic Chinese hamsters. Exp Clin Endocrinol Diabetes; 2001;109(4):196-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin treatment improves islet function in type 2 diabetic Chinese hamsters.
  • To study whether normalization of hyperglycemia improves islet function in long-standing type 2 diabetes, hyperglycemic CHIG/Han subline of the genetic type 2 diabetic Chinese hamster (>15 mmol/l: n=23) were either treated with insulin implants (liberating 1 U/day) or vehicle for two weeks.
  • Specimens were also taken for immunocytochemical analysis of insulin cells.
  • In fact, the linear relation between IBMX-potentiated and glucose-stimulated insulin secretion in controls was absent in islets from diabetic animals.
  • Furthermore, the islet insulin content was significantly increased by the 2 week normalization of glucose and, finally, the severe degranulation and lowering of insulin staining in islet beta cells in diabetic animals were markedly improved by insulin treatment.
  • The results suggest that two-weeks of normalization of glycemia in long-standing type 2 diabetes in non-obese Chinese hamster improves beta cell signaling induced by the cyclic AMP pathway in conjunction with improved islet insulin content and beta cell morphology.
  • [MeSH-major] Diabetes Mellitus, Type 2 / drug therapy. Diabetes Mellitus, Type 2 / physiopathology. Insulin / therapeutic use. Islets of Langerhans / physiopathology
  • [MeSH-minor] 1-Methyl-3-isobutylxanthine / pharmacology. Animals. Blood Glucose / analysis. Cricetinae. Cricetulus. Drug Implants. Drug Synergism. Glucose / pharmacology. Glucose Transporter Type 2. Immunohistochemistry. Monosaccharide Transport Proteins / analysis

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • Hazardous Substances Data Bank. GLUCOSE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11453031.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Drug Implants; 0 / Glucose Transporter Type 2; 0 / Insulin; 0 / Monosaccharide Transport Proteins; IY9XDZ35W2 / Glucose; TBT296U68M / 1-Methyl-3-isobutylxanthine
  •  go-up   go-down


68. Kubota N, Kiuchi Y, Nemoto M, Oyamada H, Ohno M, Funahashi H, Shioda S, Oguchi K: Regulation of serotonin transporter gene expression in human glial cells by growth factors. Eur J Pharmacol; 2001 Apr 6;417(1-2):69-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of serotonin transporter gene expression in human glial cells by growth factors.
  • The aims of this study were to identify monoamine transporters expressed in human glial cells, and to examine the regulation of their expression by stress-related growth factors.
  • Moreover, we also demonstrated SERT expression in glial fibrillary acidic protein-positive cells by immunocytochemical staining in normal human astrocytes.
  • Serotonin transporter gene expression was also detected in glioma-derived cell lines (A172, KG-1-C and KGK).
  • Addition of basic fibroblast growth factor (bFGF) or epidermal growth factor (EGF) for 2 days increased serotonin transporter gene expression in astrocytes and JAR (human choriocarcinoma cell line).
  • These findings suggest that the expression of the serotonin transporter in human glial cells is positively regulated by basic fibroblast growth factor.
  • [MeSH-major] Carrier Proteins / genetics. Growth Substances / pharmacology. Membrane Glycoproteins / genetics. Membrane Transport Proteins. Nerve Tissue Proteins. Neuroglia / drug effects
  • [MeSH-minor] Astrocytes / cytology. Astrocytes / drug effects. Astrocytes / metabolism. Cells, Cultured. Dose-Response Relationship, Drug. Epidermal Growth Factor / pharmacology. Fibroblast Growth Factor 2 / pharmacology. Gene Expression Regulation / drug effects. Glioma / genetics. Glioma / pathology. Humans. RNA, Messenger / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Serotonin / pharmacokinetics. Serotonin Plasma Membrane Transport Proteins. Time Factors. Tumor Cells, Cultured

  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11301061.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Growth Substances; 0 / Membrane Glycoproteins; 0 / Membrane Transport Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 0 / SLC6A4 protein, human; 0 / Serotonin Plasma Membrane Transport Proteins; 103107-01-3 / Fibroblast Growth Factor 2; 333DO1RDJY / Serotonin; 62229-50-9 / Epidermal Growth Factor
  •  go-up   go-down


69. Knoring BE, Titarenko OT, Sakharova IIa, Loginova GP, D'iakova ME, Perova TL, Simbirtsev AS, Pigareva NV: [Cytokine production-adenosine deaminase activity relationship in pulmonary tuberculosis]. Probl Tuberk; 2000;(3):38-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moderate ADA increases reflect the regularly enhanced activity of immunocompetent cells in response to an infectious agent.

  • Genetic Alliance. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10900984.001).
  • [ISSN] 0032-9533
  • [Journal-full-title] Problemy tuberkuleza
  • [ISO-abbreviation] Probl Tuberk
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Interleukin-1; 0 / Interleukin-2; 0 / Tumor Necrosis Factor-alpha; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


70. Hájos N, Ledent C, Freund TF: Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience; 2001;106(1):1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunocytochemical and electrophysiological studies revealed that in the hippocampus CB1 receptors are expressed on axon terminals of GABAergic inhibitory interneurons (Tsou et al., 1999; Katona et al., 1999) and activation of these receptors decreases GABA release (Hájos et al., 2000).
  • Here we examined cannabinoid actions on both glutamatergic and GABAergic synaptic transmission in the hippocampus of wild type (CB1+/+) and CB1 receptor knockout mice (CB1-/-).
  • The synthetic cannabinoid agonist WIN55,212-2 reduced the amplitudes of excitatory postsynaptic currents in both wild type and CB1-/- mice, while inhibitory postsynaptic currents were decreased only in wild type mice, but not in CB1-/- animals.
  • [MeSH-major] Cannabinoids / pharmacology. Glutamic Acid / metabolism. Hippocampus / metabolism. Neural Inhibition / drug effects. Receptors, Drug / deficiency. Synaptic Transmission / physiology. gamma-Aminobutyric Acid / metabolism
  • [MeSH-minor] Analgesics / pharmacology. Animals. Benzoxazines. Electric Stimulation. Excitatory Amino Acid Antagonists / pharmacology. Excitatory Postsynaptic Potentials / drug effects. Excitatory Postsynaptic Potentials / physiology. GABA Antagonists / pharmacology. Interneurons / drug effects. Interneurons / metabolism. Mice. Mice, Knockout. Morpholines / pharmacology. Naphthalenes / pharmacology. Piperidines / pharmacology. Pyramidal Cells / drug effects. Pyramidal Cells / metabolism. Pyrazoles / pharmacology. Receptors, Cannabinoid. Receptors, GABA / drug effects. Receptors, GABA / metabolism. Receptors, Glutamate / drug effects. Receptors, Glutamate / metabolism. Synapses / drug effects. Synapses / metabolism

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11564411.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS 30549
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Benzoxazines; 0 / Cannabinoids; 0 / Excitatory Amino Acid Antagonists; 0 / GABA Antagonists; 0 / Morpholines; 0 / Naphthalenes; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptors, Cannabinoid; 0 / Receptors, Drug; 0 / Receptors, GABA; 0 / Receptors, Glutamate; 134959-51-6 / Win 55212-2; 158681-13-1 / rimonabant; 3KX376GY7L / Glutamic Acid; 56-12-2 / gamma-Aminobutyric Acid
  •  go-up   go-down


71. Wu GS, Zou SQ, Liu ZR, Tang ZH, Wang JH: Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines. World J Gastroenterol; 2003 Jun;9(6):1302-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Celecoxib inhibits proliferation and induces apoptosis via prostaglandin E2 pathway in human cholangiocarcinoma cell lines.
  • AIM: To evaluate the roles and mechanisms of celecoxib in inducing proliferation inhibition and apoptosis of human cholangiocarcinoma cell lines.
  • METHODS: Cyclooxygenase-2-overexpressing human cholangiocarcinoma cell line QBC939 and cyclooxygenase-2-deficient human cholangiocarcinoma cell line SK-CHA-1 were used in the present study.
  • Cell cycle was analyzed by flow cytometry (FCM).
  • The PGE(2) levels in the supernatant of cultured cholangiocarcinoma cells were quantitated by enzyme-linked immunoabsordent assay (ELISA).
  • RESULTS: Celecoxib suppressed the production of PGE(2) and inhibited the growth of QBC939 cells.
  • Celecoxib at 10, 20, and 40 micromol/L inhibited PGE(2) production by 26 %, 58 %, and 74 % in QBC939 cells.
  • The PGE(2) level was much lower constitutively in SK-CHA-1 cells (18.6+/-3.2) compared with that in QBC939 (121.9+/-5.6) cells (P<0.01) and celecoxib had no significant influence on PGE(2) level in the SK-CHA-1 cells.
  • The PGE(2) concentration in SK-CHA-1 cells also reduced but not significantly after treatment with celecoxib.
  • The PGE(2) concentration in SK-CHA-1 cells was (16.5+/-2.9) ng/well, (14.8+/-3.4) ng/well, (13.2+/-2.0) ng/well and (12.6+/-3.1) ng/well respectively, when pre-treated with 1 micromol/L, 10 micromol/L, 20 micromol/L and 40 micromol/L of celecoxib for 48 h (P>0.05, vs control).
  • The anti-proliferation effect of celecoxib (20 micromol/L) on QBC939 cells was time-dependent, it was noticeable on day 2 (OD490=0.23+/-0.04) and became obvious on day 3 (OD490=0.31+/-0.07) to day 4 (OD490= 0.25+/-0.06), and the OD490 in the control group (day 1) was 0.12+/-0.03 (P<0.01, vs control).
  • The proliferation of SK-CHA-1 cells was inhibited slightly by celecoxib, the cell density OD490 in the presence of celecoxib and in control group was 0.31+/-0.04 and 0.42+/-0.03 respectively on day 2 (P>0.05), 0.58+/-0.07 and 0.67+/-0.09 respectively on day 3 (P>0.05), and 0.71+/-0.08 and 0.78+/-0.06 respectively on day 4 (P>0.05).
  • Celecoxib induced proliferation inhibition and apoptosis by G(1)-S cell cycle arrest: the percentage of QBC939 cells in G(0)-G(1) phase after treatment with 40 micromol/L (74.66+/-6.21) and 20 micromol/L (68.63+/-4.36) celecoxib increased significantly compared with control cells (54.41+/-5.12, P<0.01).
  • The percentage of SK-CHA-1 cells in G(0)-G(1) phase after treatment with various concentrations of celecoxib didn't change significantly compared with control cells.
  • The TUNEL index was much higher in QBC939 cells treated with 20 micromol/L celecoxib for 2 d (0.063+/-0.018) and for 4 d (0.102+/-0.037) compared with control cells (0.017+/-0.004, P<0.01).
  • CONCLUSION: The current in vitro study indicates that inhibition of proliferation and induction of apoptosis in human cholangiocarcinoma cells by cyclooxygenase-2 specific inhibitor celecoxib may involve in COX-dependent mechanisms and PGE(2) pathway.
  • Celecoxib as a chemopreventive and chemotherapeutic agent might be effective primarily on COX-2-expressing cholangiocarcinoma.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bile Duct Neoplasms / pathology. Bile Duct Neoplasms / physiopathology. Bile Ducts, Intrahepatic. Cholangiocarcinoma / pathology. Cholangiocarcinoma / physiopathology. Cyclooxygenase Inhibitors / pharmacology. Sulfonamides / pharmacology
  • [MeSH-minor] Apoptosis. Celecoxib. Cell Division / drug effects. Cyclooxygenase 2. Cyclooxygenase 2 Inhibitors. Dinoprostone / metabolism. Humans. Isoenzymes / antagonists & inhibitors. Membrane Proteins. Prostaglandin-Endoperoxide Synthases. Pyrazoles. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827852297 for PMID:12800245 [PharmGKB] .
  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12800245.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cyclooxygenase 2 Inhibitors; 0 / Cyclooxygenase Inhibitors; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Pyrazoles; 0 / Sulfonamides; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases; JCX84Q7J1L / Celecoxib; K7Q1JQR04M / Dinoprostone
  • [Other-IDs] NLM/ PMC4611805
  •  go-up   go-down


72. Kubis AM, Janusz M: [Alzheimer's disease: new prospects in therapy and applied experimental models]. Postepy Hig Med Dosw (Online); 2008 Aug 05;62:372-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An inflammatory process in the central nervous system is believed to play an important role in the pathway leading to neuronal cell death.
  • The inflammatory response is mediated by activated microglia, resident immune cells of the central nervous system.
  • Chronic activation of the microglia and astrocytes may cause damage of the brain-blood barrier and neuronal damage through the release of potentially cytotoxic molecules such as proinflammatory cytokines, reactive oxygen species, NO, and complement proteins.
  • These alterations cause influx of immunocompetent cells from the periphery and their active participation in the local inflammatory reaction.
  • By tracking the sequence of events leading to the Alzheimer's type of dementia, the therapeutic possibilities can be combined with modulation of secretase activation responsible for the formation of amyloidogenic forms Abeta(40-43), inhibition of aggregation or beta amyloid deaggregation,and regulation of the inflammatory response.
  • Several strategies for drug intervention in both the treatment and prevention of AD has been pursued, but so far there is no fully effective cure without side effects.
  • Transplantation of nerve cells and genetic therapy are looked upon as new perspectives.
  • Research is being conducted on the application of proteins deforming beta-sheet structures.
  • Due to the pluricausal and multidirectional type of biological changes characteristic of AD, it seems likely that multidrug therapy or multidirectional medicine would be more efficient.
  • However limited access to fresh brain tissues or primary cell lines, which would be the best experimental models, compel researchers to look for other experimental models allowing investigation of disease occurrence.
  • It seems that transgenic animals fulfill the requirements of relecting the disease process.

  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688208.001).
  • [ISSN] 1732-2693
  • [Journal-full-title] Postepy higieny i medycyny doswiadczalnej (Online)
  • [ISO-abbreviation] Postepy Hig Med Dosw (Online)
  • [Language] POL
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Cytokines; 0 / Reactive Oxygen Species; 0 / tau Proteins
  • [Number-of-references] 174
  •  go-up   go-down


73. Lim HC, Lee ST, Chu K, Joo KM, Kang L, Im WS, Park JE, Kim SU, Kim M, Cha CI: Neuroprotective effect of neural stem cell-conditioned media in in vitro model of Huntington's disease. Neurosci Lett; 2008 Apr 25;435(3):175-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroprotective effect of neural stem cell-conditioned media in in vitro model of Huntington's disease.
  • Although neural stem cell (NSC) transplantation has been investigated as a promising tool for reconstituting damaged brains, recent evidences suggest that NSCs may rescue the brain via paracrine effects rather than by direct cell replacements.
  • Cerebral hybrid neurons (A1) were transfected with either wild-type huntingtin (18 CAG repeats) or mutant huntingtin (100 CAG repeats).
  • At 24h after the transfection, immunocytochemical patterns of the huntingtin aggregations, as well as the level of N-terminal proteolytic cleavages of huntingtin were analyzed.
  • [MeSH-major] Culture Media, Conditioned / pharmacology. Neurons / drug effects. Neuroprotective Agents / pharmacology. Stem Cells / chemistry. Trinucleotide Repeat Expansion / genetics
  • [MeSH-minor] Apoptosis / drug effects. Cells, Cultured. Dose-Response Relationship, Drug. Fetus. Flow Cytometry / methods. Humans. Nerve Tissue Proteins / genetics. Nerve Tissue Proteins / metabolism. Nuclear Proteins / genetics. Telencephalon / cytology. Transfection / methods

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343580.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Culture Media, Conditioned; 0 / HTT protein, human; 0 / Nerve Tissue Proteins; 0 / Neuroprotective Agents; 0 / Nuclear Proteins
  •  go-up   go-down


74. De Nicola AF, Labombarda F, Gonzalez SL, Gonzalez Deniselle MC, Guennoun R, Schumacher M: Steroid effects on glial cells: detrimental or protective for spinal cord function? Ann N Y Acad Sci; 2003 Dec;1007:317-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid effects on glial cells: detrimental or protective for spinal cord function?
  • Repair of damage and recovery of function are fundamental endeavors for recuperation of patients and experimental animals with spinal cord injury.
  • Steroid hormones, such as progesterone (PROG), show regenerative and myelinating properties following injury of the peripheral and central nervous system.
  • In this work, we studied PROG effects on glial cells of the normal and transected (TRX) spinal cord, to complement previous studies in motoneurons.
  • Both neurons and glial cells expressed the classical PROG receptor (PR), suggesting that genomic mechanisms participated in PROG action.
  • PROG also stimulated the immunocytochemical staining for myelin-basic protein (MBP) and the number of oligodendrocyte precursor cells expressing the chondroitin sulfate proteoglycan NG2 in TRX rats.
  • In terms of beneficial or detrimental consequences, these PROG effects may be supportive of neuronal recuperation, as shown for several neuronal functional parameters that were normalized by PROG treatment of spinal cord injured animals.
  • Thus, PROG effects on glial cells go in parallel with morphological and biochemical evidence of survival of damaged motoneurons.
  • [MeSH-major] Neuroglia / drug effects. Neuroprotective Agents / therapeutic use. Progesterone / therapeutic use. Spinal Cord / drug effects. Spinal Cord Injuries / drug therapy
  • [MeSH-minor] Animals. Male. NADPH Dehydrogenase / biosynthesis. Rats. Rats, Sprague-Dawley. Receptors, Progesterone / agonists. Receptors, Progesterone / biosynthesis. Steroids / pharmacology. Steroids / therapeutic use. Up-Regulation / drug effects. Up-Regulation / physiology

  • MedlinePlus Health Information. consumer health - Spinal Cord Injuries.
  • Hazardous Substances Data Bank. PROGESTERONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14993064.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neuroprotective Agents; 0 / Receptors, Progesterone; 0 / Steroids; 4G7DS2Q64Y / Progesterone; EC 1.6.99.1 / NADPH Dehydrogenase
  •  go-up   go-down


75. Zakhary SM, Ayubcha D, Dileo JN, Jose R, Leheste JR, Horowitz JM, Torres G: Distribution analysis of deacetylase SIRT1 in rodent and human nervous systems. Anat Rec (Hoboken); 2010 Jun;293(6):1024-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report the characterization of a panel of SIRT1-specific antibodies within rodent (i.e., rat and mouse) and human central nervous systems.
  • Immunocytochemical and Western blot analyses indicate that the subcellular localization of SIRT1 is predominantly nuclear throughout the rodent brain and spinal cord.
  • A similar subcellular distribution pattern of SIRT1 was detected in human central nervous system material.
  • Finally, we identify the chemical phenotype of SIRT1-containing neurons in a number of brain sites that are strongly compromised by aging.

  • COS Scholar Universe. author profiles.
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Methods. 1999 Nov 15;93(2):149-62 [10634500.001]
  • [Cites] J Biol Chem. 2006 Aug 4;281(31):21745-54 [16751189.001]
  • [Cites] Science. 2002 Jun 14;296(5575):1991-5 [12065827.001]
  • [Cites] Neuron. 2003 Sep 11;39(6):889-909 [12971891.001]
  • [Cites] Synapse. 2003 Dec 15;50(4):353-64 [14556240.001]
  • [Cites] Brain Res Bull. 2004 Jan 15;62(4):315-26 [14709346.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Neurosci Lett. 1992 Oct 26;146(1):96-100 [1475056.001]
  • [Cites] Brain Res Dev Brain Res. 2005 Jan 1;154(1):35-44 [15617753.001]
  • [Cites] Cell. 2005 Feb 25;120(4):473-82 [15734680.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] J Biol Chem. 2005 Apr 22;280(16):16456-60 [15716268.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jun;5(6):493-506 [16732220.001]
  • [Cites] Biochem J. 2007 May 15;404(1):1-13 [17447894.001]
  • [Cites] EMBO J. 2007 Jul 11;26(13):3169-79 [17581637.001]
  • [Cites] Mol Cell. 2007 Oct 12;28(1):91-106 [17936707.001]
  • [Cites] Nat Cell Biol. 2008 Apr;10(4):385-94 [18344989.001]
  • [Cites] Neuron. 2008 Apr 10;58(1):10-4 [18400158.001]
  • [Cites] Biotechniques. 2008 Jun;44(7):Pxii-Pxiv [18540863.001]
  • [Cites] J Neurosci. 2008 Oct 1;28(40):9989-96 [18829956.001]
  • [Cites] J Neurosci. 2009 Apr 1;29(13):4140-54 [19339609.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • (PMID = 20225204.001).
  • [ISSN] 1932-8494
  • [Journal-full-title] Anatomical record (Hoboken, N.J. : 2007)
  • [ISO-abbreviation] Anat Rec (Hoboken)
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / MH064513-02A1; United States / NIMH NIH HHS / MH / R15 MH064513; United States / NIMH NIH HHS / MH / R15 MH064513-02A1; United States / NIMH NIH HHS / MH / R15MH64513-02A1
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirt1 protein, rat; EC 3.5.1.- / Sirtuin 1
  • [Other-IDs] NLM/ NIHMS282053; NLM/ PMC3071026
  •  go-up   go-down


76. Copersino ML, Meade CS, Bigelow GE, Brooner RK: Measurement of self-reported HIV risk behaviors in injection drug users: comparison of standard versus timeline follow-back administration procedures. J Subst Abuse Treat; 2010 Jan;38(1):60-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurement of self-reported HIV risk behaviors in injection drug users: comparison of standard versus timeline follow-back administration procedures.
  • This study compares the frequencies of retrospective self-reported HIV high-risk drug use and sexual behaviors in 127 out-of-treatment injection drug users using the HIV Risk Questionnaire (HRQ) across two administration methods: (a) a brief standard quantity-frequency approach covering the past 30 days and (b) a lengthier timeline follow-back (TLFB) procedure for improving recall.
  • The two procedures produced similar frequencies of risk behavior across most items (80%) and good intra- and interclass correlation coefficients.
  • The TLFB, however, resulted in higher frequencies for two risk behavior questions-sharing of any drug injection equipment and having any type of unprotected sex.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Consult Clin Psychol. 1999 Feb;67(1):37-42 [10028207.001]
  • [Cites] J Stud Alcohol. 1998 Nov;59(6):681-9 [9811089.001]
  • [Cites] Am J Addict. 1998 Fall;7(4):283-7 [9809132.001]
  • [Cites] Ann Behav Med. 1998 Winter;20(1):25-30 [9755348.001]
  • [Cites] Drug Alcohol Depend. 1995 Aug;39(2):91-8 [8529537.001]
  • [Cites] Drug Alcohol Depend. 1994 Jun;35(3):231-8 [7956753.001]
  • [Cites] Am J Psychiatry. 1993 Jan;150(1):53-8 [8417580.001]
  • [Cites] J Subst Abuse Treat. 1992;9(3):199-213 [1334156.001]
  • [Cites] J Stud Alcohol. 2003 Nov;64(6):858-61 [14743950.001]
  • [Cites] Int J STD AIDS. 2001 Jun;12(6):365-75 [11368817.001]
  • [Cites] J Consult Clin Psychol. 2000 Feb;68(1):134-44 [10710848.001]
  • [Cites] J Stud Alcohol Drugs. 2008 May;69(3):468-71 [18432391.001]
  • [Cites] J Subst Abuse Treat. 2007 Dec;33(4):355-61 [17400415.001]
  • (PMID = 19717270.001).
  • [ISSN] 1873-6483
  • [Journal-full-title] Journal of substance abuse treatment
  • [ISO-abbreviation] J Subst Abuse Treat
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / K05 DA000050-15; United States / NIDA NIH HHS / DA / T32 DA007209; United States / NIDA NIH HHS / DA / T32-DA07209; United States / NIDA NIH HHS / DA / R01-DA05127; United States / NIDA NIH HHS / DA / K05-DA00050; United States / NIDA NIH HHS / DA / K05 DA000050; United States / NIDA NIH HHS / DA / DA000050-15; United States / NIDA NIH HHS / DA / T32 DA007209-20
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS132783; NLM/ PMC2789860
  •  go-up   go-down


77. Tammaro P, Smith AL, Hutchings SR, Smirnov SV: Pharmacological evidence for a key role of voltage-gated K+ channels in the function of rat aortic smooth muscle cells. Br J Pharmacol; 2004 Sep;143(2):303-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacological evidence for a key role of voltage-gated K+ channels in the function of rat aortic smooth muscle cells.
  • The whole-cell K(+) currents were recorded in RAMs dialysed with 200 and 444 nm Ca(2+) and in perforated-patch configuration.
  • Correolide (1 microm) (a K(V)1 channel blocker) did not inhibit the I(K(v)), whereas millimolar concentration of TEA (IC(50)=3.1+/-0.6 mm, n=5) and 4-aminopyridine (4-AP, IC(50)=5.9+/-1.9 mm, n=7) suppressed I(K(v)).
  • These results and immunocytochemical analysis suggest the K(V)2.1 channel to be a molecular correlate for I(K(v)).
  • OWs were blocked by diltiazem, ryanodine and cyclopiazonic acid, suggesting the involvement of L-type Ca(2+) channels and ryanodine-sensitive Ca(2+) stores in this process.
  • In conclusion, our findings suggest that the K(V)2.1-mediated I(K(v)), and not BK(Ca), plays an important role in the regulation of the excitability and contractility of rat aorta.
  • [MeSH-minor] Animals. Calcium Signaling / drug effects. Calcium Signaling / physiology. Electrophysiology / methods. Great Britain. Immunochemistry / methods. Indoles / pharmacology. Male. Membrane Potentials / drug effects. Myocytes, Smooth Muscle / drug effects. Myocytes, Smooth Muscle / physiology. Patch-Clamp Techniques / methods. Peptides / pharmacology. Potassium Channels, Calcium-Activated / drug effects. Potassium Channels, Calcium-Activated / physiology. Protein Isoforms. Rats. Rats, Wistar. Tetraethylammonium / pharmacology. Triterpenes / pharmacology. Vasoconstriction / drug effects. Vasoconstriction / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1998 Feb;357(2):92-9 [9521481.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Apr;285(1):293-8 [9536024.001]
  • [Cites] Circ Res. 1998 Apr 6;82(6):729-37 [9546382.001]
  • [Cites] J Pharmacol Exp Ther. 1998 May;285(2):759-66 [9580624.001]
  • [Cites] J Appl Physiol (1985). 1998 Aug;85(2):411-7 [9688713.001]
  • [Cites] Am J Physiol. 1998 Jun;274(6 Pt 1):C1501-10 [9696692.001]
  • [Cites] Pflugers Arch. 1998 Oct;436(5):705-11 [9716703.001]
  • [Cites] Circ Res. 1998 Nov 30;83(11):1104-14 [9831705.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L1-12 [11404238.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jul;281(1):L183-92 [11404261.001]
  • [Cites] J Physiol. 2001 Aug 1;534(Pt 3):691-700 [11483700.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Sep;281(3):H1057-65 [11514271.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Dec;281(6):C1769-75 [11698234.001]
  • [Cites] J Physiol. 2002 Feb 1;538(Pt 3):867-78 [11826170.001]
  • [Cites] J Hypertens. 2002 Mar;20(3):447-54 [11875312.001]
  • [Cites] Lung. 2001;179(3):147-61 [11891605.001]
  • [Cites] J Vasc Res. 2002 Mar-Apr;39(2):122-30 [12011584.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H247-53 [12063297.001]
  • [Cites] Cardiovasc Res. 2002 Apr;54(1):152-61 [12062371.001]
  • [Cites] Life Sci. 2002 Sep 27;71(19):2239-48 [12215371.001]
  • [Cites] Life Sci. 1995;56(6):PL129-34 [7830497.001]
  • [Cites] Acta Physiol Scand. 1998 Dec;164(4):577-87 [9887980.001]
  • [Cites] Pflugers Arch. 1999 Feb;437(3):455-61 [9914403.001]
  • [Cites] Br J Pharmacol. 1999 Jan;126(1):159-68 [10051132.001]
  • [Cites] Biochemistry. 1999 Apr 20;38(16):4922-30 [10213593.001]
  • [Cites] Clin Exp Pharmacol Physiol. 1999 Apr;26(4):275-84 [10225137.001]
  • [Cites] Eur J Pharmacol. 1999 May 7;372(1):103-7 [10374720.001]
  • [Cites] J Biol Chem. 1999 Sep 3;274(36):25237-44 [10464244.001]
  • [Cites] Br J Pharmacol. 1999 Oct;128(3):637-46 [10516643.001]
  • [Cites] J Physiol. 2003 Sep 15;551(Pt 3):751-63 [12815189.001]
  • [Cites] Pflugers Arch. 2003 Nov;447(2):142-9 [14517679.001]
  • [Cites] J Physiol. 1982 Nov;332:363-73 [7153932.001]
  • [Cites] Jpn J Physiol. 1986;36(4):783-94 [3784152.001]
  • [Cites] Jpn Heart J. 1986 Sep;27(5):727-40 [2434672.001]
  • [Cites] Am J Physiol. 1988 May;254(5 Pt 2):H840-54 [3364589.001]
  • [Cites] Am J Physiol. 1988 Sep;255(3 Pt 2):H410-8 [2458046.001]
  • [Cites] FASEB J. 1988 Dec;2(15):3074-82 [2847949.001]
  • [Cites] J Cardiovasc Pharmacol. 1989 Feb;13(2):299-306 [2468961.001]
  • [Cites] J Physiol. 1989 Mar;410:91-106 [2795490.001]
  • [Cites] Am J Physiol. 1990 Jul;259(1 Pt 1):C3-18 [2164782.001]
  • [Cites] Am J Physiol. 1990 Aug;259(2 Pt 2):H409-23 [2167022.001]
  • [Cites] Am J Physiol. 1991 Feb;260(2 Pt 2):H507-15 [1996693.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1798-802 [1705709.001]
  • [Cites] Am J Physiol. 1991 Mar;260(3 Pt 2):H927-34 [1900393.001]
  • [Cites] Circ Res. 1992 May;70(5):968-77 [1533181.001]
  • [Cites] Am J Physiol. 1993 May;264(5 Pt 2):H1337-45 [8498547.001]
  • [Cites] Am J Physiol. 1994 Jan;266(1 Pt 2):H365-70 [8304521.001]
  • [Cites] Acta Physiol Scand Suppl. 1993;614:1-44 [8128886.001]
  • [Cites] Am J Physiol. 1994 May;266(5 Pt 1):C1182-9 [8203481.001]
  • [Cites] Mol Pharmacol. 1994 Jun;45(6):1227-34 [7517498.001]
  • [Cites] J Gen Physiol. 1994 Aug;104(2):241-64 [7807048.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Feb;278(2):L261-7 [10666109.001]
  • [Cites] Br J Pharmacol. 2000 Jan;129(2):381-7 [10694246.001]
  • [Cites] J Vasc Res. 2000 Jan-Feb;37(1):16-25 [10720882.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 Aug;279(2):L242-51 [10926547.001]
  • [Cites] Nature. 2000 Oct 19;407(6806):870-6 [11057658.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2000 Dec;279(6):R2004-14 [11080063.001]
  • [Cites] Circ Res. 2000 Nov 24;87(11):E53-60 [11090555.001]
  • [Cites] Hypertension. 2001 May;37(5):1315-22 [11358947.001]
  • [Cites] Am J Physiol. 1995 Jan;268(1 Pt 2):H74-81 [7840305.001]
  • [Cites] Am J Physiol. 1995 Apr;268(4 Pt 1):C799-822 [7733230.001]
  • [Cites] Circ Res. 1995 Jul;77(1):121-30 [7788870.001]
  • [Cites] Am J Physiol. 1995 Jul;269(1 Pt 2):H348-55 [7631867.001]
  • [Cites] Circ Res. 1996 Oct;79(4):881-6 [8831514.001]
  • [Cites] FEBS Lett. 1996 Dec 9;399(1-2):177-82 [8980147.001]
  • [Cites] Am J Physiol. 1997 May;272(5 Pt 2):H2241-9 [9176292.001]
  • [Cites] J Physiol. 1997 Aug 1;502 ( Pt 3):545-57 [9279807.001]
  • [Cites] Am J Physiol. 1997 Nov;273(5 Pt 1):C1721-31 [9374660.001]
  • [Cites] Am J Physiol. 1997 Dec;273(6 Pt 1):C1849-58 [9435489.001]
  • [Cites] Am J Physiol. 1998 Jan;274(1 Pt 2):H27-34 [9458848.001]
  • [Cites] Am J Physiol. 1998 Feb;274(2 Pt 2):H655-62 [9486271.001]
  • [Cites] J Physiol. 1998 Apr 1;508 ( Pt 1):199-209 [9490839.001]
  • (PMID = 15326038.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Indoles; 0 / Peptides; 0 / Potassium Channels, Calcium-Activated; 0 / Potassium Channels, Voltage-Gated; 0 / Protein Isoforms; 0 / Triterpenes; 0 / correolide; 129203-60-7 / iberiotoxin; 57186-25-1 / paxilline; 66-40-0 / Tetraethylammonium
  • [Other-IDs] NLM/ PMC1575342
  •  go-up   go-down


78. Kravitz RL, Franks P, Feldman MD, Gerrity M, Byrne C, Tierney WM: Editorial peer reviewers' recommendations at a general medical journal: are they reliable and do editors care? PLoS One; 2010;5(4):e10072
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Editorial peer reviewers' recommendations at a general medical journal: are they reliable and do editors care?
  • We examined the relationship between external reviewers' recommendations and the editorial outcome of manuscripts undergoing external peer-review at the Journal of General Internal Medicine (JGIM).
  • Using mixed effects logistic regression models, we estimated intra-class correlation coefficients (ICC) at the reviewer and manuscript level.
  • In mixed effects models adjusting for study year and manuscript type, the reviewer-level ICC was 0.23 (95% confidence interval [CI], 0.19-0.29) and the manuscript-level ICC was 0.17 (95% CI, 0.12-0.22).

  • COS Scholar Universe. author profiles.
  • eScholarship, California Digital Library, University of California. Full text from University of California eScholarship .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Health Sci Educ Theory Pract. 2003;8(1):75-96 [12652170.001]
  • [Cites] BMC Health Serv Res. 2002 Mar 26;2(1):8 [11914164.001]
  • [Cites] West J Med. 1990 Nov;153(5):520-2 [2260288.001]
  • [Cites] Radiology. 1991 Mar;178(3):637-42 [1994394.001]
  • [Cites] Acad Med. 1992 Dec;67(12):856-9 [1457023.001]
  • [Cites] Am J Psychiatry. 1993 Jun;150(6):947-52 [8494074.001]
  • [Cites] J Gen Intern Med. 1993 May;8(5):255-8 [8505684.001]
  • [Cites] Ann Intern Med. 1994 Jul 1;121(1):11-21 [8198342.001]
  • [Cites] Arch Pediatr Adolesc Med. 1996 Apr;150(4):380-3 [8634732.001]
  • [Cites] Croat Med J. 1998 Mar;39(1):3-9 [9475799.001]
  • [Cites] Br J Psychiatry. 1998 Aug;173:110-3; discussion 114-5 [9850221.001]
  • [Cites] Annu Rev Med. 1999;50:99-110 [10073266.001]
  • [Cites] Fam Med. 2005 May;37(5):360-3 [15883903.001]
  • [Cites] JAMA. 2006 Jan 18;295(3):314-7 [16418467.001]
  • [Cites] JAMA. 2006 Apr 19;295(15):1801-8 [16622142.001]
  • [Cites] Indian Pediatr. 2006 Jun;43(6):479-89 [16820657.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):262-5 [17301708.001]
  • [Cites] Am J Ophthalmol. 2007 Apr;143(4):551-60 [17276380.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(2):MR000016 [17443635.001]
  • [Cites] Med Sci Monit. 2009 Feb;15(2):SR1-4 [19179983.001]
  • [Cites] J Gen Intern Med. 2009 Dec;24(12):1349-55 [19936844.001]
  • [Cites] Brain. 2000 Sep;123 ( Pt 9):1964-9 [10960059.001]
  • [Cites] Clin Rehabil. 2004 Mar;18(2):117-24 [15053119.001]
  • [Cites] Ann Intern Med. 1986 Aug;105(2):309-12 [3729227.001]
  • (PMID = 20386704.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2851650
  •  go-up   go-down


79. Grimsey NL, Goodfellow CE, Scotter EL, Dowie MJ, Glass M, Graham ES: Specific detection of CB1 receptors; cannabinoid CB1 receptor antibodies are not all created equal! J Neurosci Methods; 2008 Jun 15;171(1):78-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study of endogenous cannabinoid CB1 receptor proteins in neuronal tissues and cells relies on the availability of highly specific antibodies.
  • We have tested the ability of a series of CB1 antibodies to detect endogenous receptors in brain as well as hemagglutinin (HA)-tagged receptors transfected into HEK-293 cells using a combination of immunological methods.
  • Antibodies were then tested immunocytochemically against HEK cells expressing HA-tagged rat and human CB1 receptors.
  • All antibodies were then screened by Western blotting using lysates from the HEK cells and rodent brain homogenates.
  • Again, none of the commercially available antibodies detected proteins of the correct molecular weight in transfected cell lines or brain homogenates, although all recognized multiple proteins in brain tissues.
  • We conclude that the commercially available antibodies we tested failed to detect CB1 receptors abundantly expressed in HEK cells or native receptors in brain slices or homogenates.
  • [MeSH-minor] Animals. Autoradiography / methods. Brain / drug effects. Brain / metabolism. Cell Line, Transformed. Cyclohexanols / pharmacokinetics. Hemagglutination. Humans. Mice. Protein Structure, Tertiary. Rats. Transfection. Tritium / pharmacokinetics

  • Hazardous Substances Data Bank. TRITIUM, RADIOACTIVE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18406468.001).
  • [ISSN] 0165-0270
  • [Journal-full-title] Journal of neuroscience methods
  • [ISO-abbreviation] J. Neurosci. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies; 0 / Cyclohexanols; 0 / Receptor, Cannabinoid, CB1; 10028-17-8 / Tritium; 83003-12-7 / 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol
  •  go-up   go-down


80. De Godoy MA, Rattan S: Autocrine regulation of internal anal sphincter tone by renin-angiotensin system: comparison with phasic smooth muscle. Am J Physiol Gastrointest Liver Physiol; 2005 Dec;289(6):G1164-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The studies were performed in the freshly isolated smooth muscle cells (SMC) of the IAS.
  • We determined the presence of ANG II precursor angiotensinogen (Angen), and the enzymes that convert it into ANG II, using functional, molecular biology, and immunocytochemical studies in rats.
  • Basal tone in IAS is partially under the autocrine control of cellular RAS evident by the expression of mRNA coding Angen, renin, and ACE and translation to the respective proteins in the SMC.
  • [MeSH-minor] Angiotensinogen / physiology. Animals. Blotting, Western. Captopril / pharmacology. Cell Size / drug effects. Male. Oligopeptides / pharmacology. Rectum / physiology

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPTOPRIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16020656.001).
  • [ISSN] 0193-1857
  • [Journal-full-title] American journal of physiology. Gastrointestinal and liver physiology
  • [ISO-abbreviation] Am. J. Physiol. Gastrointest. Liver Physiol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK-35385
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligopeptides; 11002-13-4 / Angiotensinogen; 11128-99-7 / Angiotensin II; 82131-82-6 / H 77; 9G64RSX1XD / Captopril
  •  go-up   go-down


81. Gironès X, Guimerà A, Cruz-Sánchez CZ, Ortega A, Sasaki N, Makita Z, Lafuente JV, Kalaria R, Cruz-Sánchez FF: N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic Biol Med; 2004 May 15;36(10):1241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • N epsilon-carboxymethyllysine (CML) is an advanced glycation end product (AGE) recently found to be associated with oxidative stress mechanisms.
  • Using immunocytochemical methods we examined the distribution of CML in brain tissue from AD and DM subjects and aging controls.
  • CML reactivity was present in the cytoplasm of neurons, but there were marked differences in the intensity of expression, number of cells, and topographical distribution.
  • [MeSH-major] Aging / drug effects. Alzheimer Disease / metabolism. Brain / drug effects. Diabetes Mellitus / metabolism. Lysine / analogs & derivatives. Lysine / pharmacology. Neurons / drug effects
  • [MeSH-minor] Aged. Aged, 80 and over. Cytoplasm / drug effects. Cytoplasm / metabolism. Female. Glycosylation End Products, Advanced. Humans. Male. Middle Aged. Neurofibrillary Tangles / metabolism. Neurofibrillary Tangles / pathology. Plaque, Amyloid / drug effects. tau Proteins / metabolism

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Alzheimer's Disease.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. L-Lysine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15110389.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycosylation End Products, Advanced; 0 / tau Proteins; 5746-04-3 / N(6)-carboxymethyllysine; K3Z4F929H6 / Lysine
  •  go-up   go-down


82. Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee, Torlakovic EE, Riddell R, Banerjee D, El-Zimaity H, Pilavdzic D, Dawe P, Magliocco A, Barnes P, Berendt R, Cook D, Gilks B, Williams G, Perez-Ordonez B, Wehrli B, Swanson PE, Otis CN, Nielsen S, Vyberg M, Butany J: Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. Am J Clin Pathol; 2010 Mar;133(3):354-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.
  • Immunohistochemical and immunocytochemical assays are highly complex diagnostic analyses used to aid in the accurate identification and biologic characterization of tissue types in neoplastic and nonneoplastic diseases.
  • Immunohistochemical tests are applied mainly to the diagnosis of neoplasms.
  • This document provides recommendations and opinions of the Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry relevant to clinical immunohistochemical terminology, classification of immunohistochemical tests based on risk assessment, and quality control and quality assurance and summarizes matters to be considered for appropriate immunohistochemical/immunocytochemical test development, performance, and interpretation in diagnostic pathology and laboratory medicine.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20154273.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Guideline; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Delhaye D, Remy-Jardin M, Teisseire A, Hossein-Foucher C, Leroy S, Duhamel A, Remy J: MDCT of right ventricular function: comparison of right ventricular ejection fraction estimation and equilibrium radionuclide ventriculography, part 1. AJR Am J Roentgenol; 2006 Dec;187(6):1597-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biphasic administration of a 30% contrast agent was systematically performed (phase 1, 90 mL at 3 mL/s; phase 2, 30 mL at 1.5 mL/s); no patient received additional medication.
  • Agreement between the two techniques was estimated by intraclass correlation coefficient (0.77), the method of Bland and Altman (limits of concordance, -14.9 and 13.7), and percentage of variability between two measurements expressed by mean absolute percentage error (12.1%).

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114556.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Pucovský V, Moss RF, Bolton TB: Non-contractile cells with thin processes resembling interstitial cells of Cajal found in the wall of guinea-pig mesenteric arteries. J Physiol; 2003 Oct 1;552(Pt 1):119-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-contractile cells with thin processes resembling interstitial cells of Cajal found in the wall of guinea-pig mesenteric arteries.
  • Arterial interstitial cells of Cajal (ICC)-like cells (AIL cells) with a multipolar, irregular, elongated shape and with numerous thin (often less than 1 microm), sometimes branching, processes with lengths up to approximately 60 microm were isolated enzymatically from 1st to 7th order branches of guinea-pig mesenteric artery.
  • Some of the processes of AIL cells were growing (average speed approximately 0.15 microm min-1) and their growth was blocked by 10 microM latrunculin B, an inhibitor of actin polymerisation.
  • Staining with BODIPY phalloidin, a fluorescent dye selective for F-actin, showed the presence of F-actin in the processes of AIL cells.
  • Voltage clamp of single AIL cells revealed an inward current that was four times more dense than in myocytes and was abolished by 10 microM nicardipine, and an outward current carried exclusively by potassium ions that was reduced by 1 mM 4-aminopyridine and/or 100 nM iberiotoxin but unaffected by 10 nM dendrotoxin-K.
  • Imaging of intracellular ionised calcium with fluo-4 using a laser scanning confocal microscope showed local or global calcium transients lasting several seconds in approximately 28 % of AIL cells.
  • Unlike myocytes, AIL cells did not contract in response to 1 mM caffeine or 5 microM noradrenaline, although they responded with a [Ca2+]i increase.
  • Single AIL cells stained positive for vimentin, desmin and smooth muscle myosin.
  • The presence of ICC-like cells is demonstrated for the first time in the media of resistance arteries.
  • [MeSH-minor] Animals. Caffeine / pharmacology. Calcium / metabolism. Cell Size. Electric Capacitance. Guinea Pigs. Immunohistochemistry. Male. Membrane Potentials / drug effects. Membrane Potentials / physiology. Microscopy, Electron. Myocytes, Smooth Muscle / chemistry. Myocytes, Smooth Muscle / ultrastructure. Norepinephrine / pharmacology. Patch-Clamp Techniques. Phosphodiesterase Inhibitors / pharmacology. Proto-Oncogene Proteins c-kit / analysis. Smooth Muscle Myosins / analysis. Vasoconstrictor Agents / pharmacology. Vimentin / analysis

  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. CAFFEINE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Submicrosc Cytol. 1985 Apr;17(2):187-97 [3999182.001]
  • [Cites] Acta Anat (Basel). 1984;120(4):185-9 [6516778.001]
  • [Cites] J Pharmacobiodyn. 1987 Aug;10(8):396-403 [3694435.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Sep;86(18):7280-4 [2550938.001]
  • [Cites] J Submicrosc Cytol Pathol. 1989 Jul;21(3):439-60 [2790731.001]
  • [Cites] Am J Physiol. 1989 Oct;257(4 Pt 1):C830-5 [2801932.001]
  • [Cites] J Physiol. 1989 Nov;418:293-309 [2621620.001]
  • [Cites] J Biol Chem. 1990 Jul 5;265(19):11083-90 [1694175.001]
  • [Cites] Nature. 1990 Jul 26;346(6282):374-6 [1695718.001]
  • [Cites] J Neurosci Methods. 1991 Mar;37(1):15-26 [2072734.001]
  • [Cites] Histol Histopathol. 1991 Apr;6(2):269-86 [1802127.001]
  • [Cites] Science. 1993 Oct 29;262(5134):740-4 [8235594.001]
  • [Cites] Lab Invest. 1993 Nov;69(5):589-602 [8246451.001]
  • [Cites] J Physiol. 1994 Oct 1;480 ( Pt 1):91-7 [7853230.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12008-13 [8876253.001]
  • [Cites] Circ Res. 1996 Nov;79(5):1046-53 [8888698.001]
  • [Cites] Cardiovasc Res. 1996 Oct;32(4):687-98 [8915187.001]
  • [Cites] J Auton Nerv Syst. 1996 Nov 6;61(2):169-74 [8946337.001]
  • [Cites] Biochem Cell Biol. 1996;74(4):439-47 [8960350.001]
  • [Cites] Am J Physiol. 1998 May;274(5 Pt 1):G945-54 [9612277.001]
  • [Cites] J Physiol. 1999 Jul 1;518 ( Pt 1):257-69 [10373707.001]
  • [Cites] Circ Res. 1999 Oct 1;85(7):596-605 [10506484.001]
  • [Cites] J Comp Neurol. 1953 Dec;99(3):495-543 [13118000.001]
  • [Cites] Arch Neurol. 1964 Feb;10:158-64 [14088250.001]
  • [Cites] J Microsc. 1999 Dec;196(Pt 3):305-16 [10594771.001]
  • [Cites] J Neurosci. 2000 Feb 15;20(4):1393-403 [10662830.001]
  • [Cites] J Physiol. 2000 Jun 1;525 Pt 2:355-61 [10835039.001]
  • [Cites] J Physiol. 2000 Jul 15;526 Pt 2:359-66 [10896724.001]
  • [Cites] Am J Physiol Cell Physiol. 2000 Aug;279(2):C529-39 [10913020.001]
  • [Cites] J Membr Biol. 2001 Mar 15;180(2):163-75 [11318099.001]
  • [Cites] J Physiol. 2001 Jun 1;533(Pt 2):315-27 [11389194.001]
  • [Cites] J Appl Physiol (1985). 2001 Nov;91(5):2322-33 [11641377.001]
  • [Cites] J Physiol. 2002 Feb 15;539(Pt 1):25-39 [11850499.001]
  • [Cites] J Urol. 2002 Aug;168(2):832-6 [12131376.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Sep;283(3):C885-94 [12176745.001]
  • [Cites] Cell Tissue Res. 2002 Oct;310(1):77-84 [12242486.001]
  • [Cites] Cell Calcium. 2003 Apr;33(4):223-39 [12618143.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Mar;70(3):641-5 [4197624.001]
  • [Cites] J Cell Biol. 1975 Feb;64(2):340-55 [163830.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Apr;72(4):1359-63 [1055411.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Jan;78(1):298-302 [7017714.001]
  • [Cites] Adv Anat Embryol Cell Biol. 1982;71:1-130 [7090872.001]
  • [Cites] Science. 1983 Feb 4;219(4584):493-5 [6681676.001]
  • [Cites] J Physiol. 1986 Feb;371:45-67 [2422353.001]
  • (PMID = 12897177.001).
  • [ISSN] 0022-3751
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Phosphodiesterase Inhibitors; 0 / Vasoconstrictor Agents; 0 / Vimentin; 3G6A5W338E / Caffeine; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit; EC 3.6.1.- / Smooth Muscle Myosins; SY7Q814VUP / Calcium; X4W3ENH1CV / Norepinephrine
  • [Other-IDs] NLM/ PMC2343325
  •  go-up   go-down


85. Leelawat K, Udomchaiprasertkul W, Narong S, Leelawat S: Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells. J Cancer Res Clin Oncol; 2010 Oct;136(10):1537-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of MKP-1 prevents the cytotoxic effects of PI3K inhibition in hilar cholangiocarcinoma cells.
  • PURPOSE: Hilar cholangiocarcinoma (Klatskin tumor) is one of the most difficult cancers to treat.
  • We demonstrate activation of phosphoinositide-3-kinase (PI3K)/Akt signaling, which is a critical pathway for cell survival, in hilar cholangiocarcinoma cells.
  • However, inhibition of PI3K has little effect on hilar cholangiocarcinoma cell survival.
  • In this study, we investigated the mechanism by which hilar cholangiocarcinoma cells resist PI3K inhibitors.
  • METHODS: Human hilar cholangiocarcinoma cells KKU-100 were treated with PI3K inhibitors, and cell viability and apoptosis assays were performed.
  • The expression of a MAPK phosphatase (MKP-1) that contributes to cancer cell survival in response to multiple stress stimuli was assayed by quantitative real-time RT-PCR and western blotting.
  • In addition, the effects of the MKP-1 inhibitor were studied in KKU-100 cells treated with PI3K inhibitors.
  • RESULTS: Incubation of KKU-100 cells with PI3K inhibitors resulted in increased expression of MKP-1.
  • Furthermore, we found that inhibition of MKP-1 using siRNA silencing sensitized KKU-100 cells to PI3K inhibitor-induced apoptosis via increased phosphorylation of p38 MAPK.
  • CONCLUSIONS: These results indicate that concurrent inhibition of PI3K and MKP-1 induces apoptosis in KKU-100 cells.
  • Simultaneous targeting of the PI3K pathway and MKP-1 may be a useful approach to improve therapies directed against hilar cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / drug therapy. Bile Ducts, Intrahepatic. Cholangiocarcinoma / drug therapy. Dual Specificity Phosphatase 1 / physiology. Phosphatidylinositol 3-Kinases / antagonists & inhibitors
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Chromones / pharmacology. Cycloheximide / pharmacology. Humans. Morpholines / pharmacology. Phosphorylation. p38 Mitogen-Activated Protein Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • Hazardous Substances Data Bank. CYCLOHEXIMIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2008 Jun;27(2):253-61 [18330678.001]
  • [Cites] Crit Care Med. 2000 Apr;28(4 Suppl):N67-77 [10807318.001]
  • [Cites] Mol Endocrinol. 2005 Jun;19(6):1569-83 [15817653.001]
  • [Cites] Oncogene. 2006 Jun 1;25(23):3335-45 [16462770.001]
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):660-7 [19147772.001]
  • [Cites] Future Oncol. 2006 Aug;2(4):509-14 [16922617.001]
  • [Cites] Gastroenterology. 2000 May;118(5):929-36 [10784592.001]
  • [Cites] Mol Pharmacol. 2004 Dec;66(6):1478-90 [15448190.001]
  • [Cites] Cancer Chemother Pharmacol. 2010 May;65(6):1101-7 [19707761.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4459-66 [17483361.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 30;338(4):1732-8 [16289033.001]
  • [Cites] J Biol Chem. 2009 Oct 30;284(44):30372-82 [19748889.001]
  • [Cites] Cancer Lett. 2009 Dec 28;286(2):206-16 [19553005.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):27864-71 [12023956.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 17;95(6):3014-9 [9501207.001]
  • [Cites] Surg Clin North Am. 2008 Dec;88(6):1409-28, x-xi [18992602.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Apr;97(4):465-70 [15088030.001]
  • [Cites] Hepatology. 2004 Mar;39(3):732-8 [14999691.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21534-41 [12676937.001]
  • [Cites] FEBS J. 2009 Mar;276(5):1255-65 [19175673.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3639-49 [15173070.001]
  • [Cites] Cancer Cell Int. 2009 Jan 08;9:3 [19128511.001]
  • [Cites] World J Gastroenterol. 2007 Mar 14;13(10 ):1561-8 [17461449.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):590-9 [18057991.001]
  • [Cites] Cell Cycle. 2009 Oct 1;8(19):3191-8 [19755862.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):631-5 [18086631.001]
  • [Cites] Pharmacol Rev. 2008 Sep;60(3):261-310 [18922965.001]
  • [Cites] World J Gastroenterol. 2005 Jun 14;11(22):3392-7 [15948244.001]
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):579-85 [17717636.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):517-23 [15099972.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3530-9 [19417026.001]
  • [Cites] Breast Cancer Res Treat. 2006 Nov;100(1):33-47 [16807678.001]
  • [Cites] Br J Pharmacol. 2001 Nov;134(5):1084-92 [11682457.001]
  • (PMID = 20145951.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chromones; 0 / Morpholines; 31M2U1DVID / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; 98600C0908 / Cycloheximide; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases; EC 3.1.3.48 / DUSP1 protein, human; EC 3.1.3.48 / Dual Specificity Phosphatase 1
  •  go-up   go-down


86. Poupon R, Chazouillères O, Poupon RE: Chronic cholestatic diseases. J Hepatol; 2000;32(1 Suppl):129-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chronic cholestatic diseases.
  • Chronic cholestatic diseases, whether occurring in infancy, childhood or adulthood, are characterized by defective bile acid transport from the liver to the intestine, which is caused by primary damage to the biliary epithelium in most cases.
  • In this article, approaches to diagnosis and management of the main specific disorders are provided and some of the recent developments in this field are discussed.
  • Major advances in the understanding of the cellular and molecular physiology of bile secretion have led to identification of genetic defects responsible for the different types of progressive familial intrahepatic cholestasis (PFIC).
  • The majority of adult patients with chronic cholestasis have primary biliary cirrhosis (PBC) or primary sclerosing cholangitis (PSC).
  • The term autoimmune cholangitis is used to describe patients having chronic non-suppurative cholangitis with negative antimitochondrial antibodies (AMA) but positive antinuclear and/or antismooth muscle antibodies.
  • Among the putative mechanisms of the beneficial effects of UDCA, description of anti-apoptotic properties and effect on endotoxin disposal in biliary cells have provided new insights.
  • In patients with incomplete response to UDCA, combination of UDCA with antiinflammatory or immunosuppressive drugs is under evaluation.
  • Variant forms of PSC have also been described, including PSC-AIH overlap syndrome, especially in children or young adults, and small-duct PSC, which is characterized by normal cholangiogram in patients having chronic cholestasis, histologic features compatible with PSC and inflammatory bowel disease.
  • Development of cholangiocarcinoma (CC) is a major feature of PSC, occurring in 10-15% of patients.
  • Early diagnosis of CC is a difficult challenge, although positron emission tomography seems a promising tool.
  • [MeSH-major] Cholestasis / diagnosis. Cholestasis / therapy
  • [MeSH-minor] Adult. Anti-Inflammatory Agents / therapeutic use. Child, Preschool. Cholagogues and Choleretics / therapeutic use. Chronic Disease. Humans. Immunosuppressive Agents / therapeutic use. Liver Transplantation. Ursodeoxycholic Acid / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10728800.001).
  • [ISSN] 0168-8278
  • [Journal-full-title] Journal of hepatology
  • [ISO-abbreviation] J. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] DENMARK
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Cholagogues and Choleretics; 0 / Immunosuppressive Agents; 724L30Y2QR / Ursodeoxycholic Acid
  • [Number-of-references] 120
  •  go-up   go-down


87. Nilsson P, Baigi A, Marklund B, Månsson J: Cross-cultural adaptation and determination of the reliability and validity of PRTEE-S (Patientskattad Utvärdering av Tennisarmbåge), a questionnaire for patients with lateral epicondylalgia, in a Swedish population. BMC Musculoskelet Disord; 2008;9:79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-cultural adaptation and determination of the reliability and validity of PRTEE-S (Patientskattad Utvärdering av Tennisarmbåge), a questionnaire for patients with lateral epicondylalgia, in a Swedish population.
  • Therefore, the aim of this study was to translate and cross-culturally adapt the questionnaire "Patient-rated Tennis Elbow Evaluation" into Swedish (PRTEE-S; "Patientskattad Utvärdering av Tennisarmbåge"), and to evaluate the reliability and validity of the test.
  • METHODS: The Patient-rated Tennis Elbow Evaluation was cross-culturally adapted for the Swedish language according to well-established guidelines.
  • Reliability was determined via calculation of the intra-class correlation coefficient (ICC) the internal consistency was assessed by Cronbach's alpha, and validity was calculated using Spearman's correlation coefficient.
  • RESULTS: The test-retest reliability, using the PRTEE-S (Patientskattad Utvärdering av Tennisarmbåge) intraclass correlation coefficient, was 0.95 and the internal consistency was 0.94.

  • MedlinePlus Health Information. consumer health - Elbow Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Musculoskelet Disord. 2005;6:12 [15748297.001]
  • [Cites] J Hand Ther. 1999 Jan-Mar;12(1):31-7 [10192633.001]
  • [Cites] J Hand Ther. 2005 Oct-Dec;18(4):400-6 [16271686.001]
  • [Cites] J Hand Ther. 2005 Oct-Dec;18(4):407-10 [16271687.001]
  • [Cites] Am J Epidemiol. 2006 Dec 1;164(11):1065-74 [16968862.001]
  • [Cites] J Hand Ther. 2007 Jan-Mar;20(1):3-10; quiz 11 [17254903.001]
  • [Cites] Musculoskeletal Care. 2007 Mar;5(1):36-50 [17183512.001]
  • [Cites] Clin Exp Rheumatol. 2007 Mar-Apr;25(2):195-205 [17543142.001]
  • [Cites] BMJ. 1997 Feb 22;314(7080):572 [9055718.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91 [11124735.001]
  • [Cites] Acta Orthop Scand. 2000 Dec;71(6):613-8 [11145390.001]
  • [Cites] J Hand Ther. 2001 Apr-Jun;14(2):105-14 [11382250.001]
  • [Cites] J Hand Ther. 2001 Apr-Jun;14(2):128-46 [11382253.001]
  • [Cites] Clin J Sport Med. 2001 Oct;11(4):214-22 [11753057.001]
  • [Cites] Curr Drug Targets. 2002 Feb;3(1):43-54 [11899264.001]
  • [Cites] Occup Environ Med. 2003 May;60(5):322-9 [12709516.001]
  • [Cites] Hong Kong Med J. 2004 Jun;10(3):172-7 [15181221.001]
  • [Cites] Rheumatology (Oxford). 2004 Nov;43(11):1434-40 [15304676.001]
  • [Cites] J Bone Joint Surg Br. 1972 Aug;54(3):499-508 [4340924.001]
  • [Cites] Scand J Rehabil Med. 1988;20(3):99-101 [3187466.001]
  • [Cites] Phys Ther. 1989 Apr;69(4):276-81 [2928394.001]
  • [Cites] Clin J Pain. 1990 Sep;6(3):221-6 [2135016.001]
  • [Cites] J Clin Epidemiol. 1993 Dec;46(12):1417-32 [8263569.001]
  • [Cites] Am J Ind Med. 1996 Jun;29(6):602-8 [8773720.001]
  • [Cites] J Hand Ther. 1996 Apr-Jun;9(2):178-83 [8784681.001]
  • [Cites] Arch Phys Med Rehabil. 1998 Jul;79(7):832-7 [9685101.001]
  • [Cites] J Orthop Sports Phys Ther. 2005 Apr;35(4):200-2 [15901120.001]
  • (PMID = 18534009.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2435532
  •  go-up   go-down


88. Silkov AN, Gavrilenko VA, Denisova VV, Grishina LV, Kozlov VA, Sennikov SV: Effects of recombinant IL-4delta2 on human peripheral blood mononuclears. Bull Exp Biol Med; 2007 Jan;143(1):72-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In human cells, expression of IL-4 gene involves alternative mRNA splicing.
  • IL-4delta2 splice variant is an antagonist of full-length IL-4 protein and blocks its effect on the functional activity of immunocompetent cells.
  • The effect of recombinant IL-4delta2 on cytokine-producing activity of human peripheral blood mononuclear cells is shown for the first time.
  • [MeSH-major] Interleukin-4 / pharmacology. Leukocytes, Mononuclear / drug effects
  • [MeSH-minor] Alternative Splicing. Cell Proliferation / drug effects. Humans. Immunoglobulin E / biosynthesis. Immunoglobulin E / blood. In Vitro Techniques. Interleukin-6 / biosynthesis. Interleukin-6 / blood. Interleukin-6 / genetics. Recombinant Proteins / pharmacology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019017.001).
  • [ISSN] 0007-4888
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / IL4 protein, human; 0 / Interleukin-6; 0 / Recombinant Proteins; 207137-56-2 / Interleukin-4; 37341-29-0 / Immunoglobulin E
  •  go-up   go-down


89. Flechtner KM, Steinacher B, Sauer R, Mackert A: Smooth pursuit eye movements of patients with schizophrenia and affective disorder during clinical treatment. Eur Arch Psychiatry Clin Neurosci; 2002 Apr;252(2):49-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth pursuit eye movements of patients with schizophrenia and affective disorder during clinical treatment.
  • BACKGROUND: Smooth pursuit eye movement dysfunctions are considered a biological indicator for vulnerability to schizophrenia.
  • RESULTS: Intraclass correlation coefficients as a measure for retest-stability were highly significant in each group for all time-points, except for anticipatory saccades in schizophrenics.
  • No significant correlations were found between psychopathological status, neuroleptic medication and eye movement variables.
  • CONCLUSIONS: Our results indicate that the most important measures of eye tracking performance in psychiatric patients are not significantly influenced by neuroleptic medication or clinical state and are stable across time.
  • [MeSH-major] Antipsychotic Agents / pharmacology. Antipsychotic Agents / therapeutic use. Depressive Disorder, Major / drug therapy. Depressive Disorder, Major / physiopathology. Saccades / drug effects. Saccades / physiology. Schizophrenia / drug therapy. Schizophrenia / physiopathology

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12111336.001).
  • [ISSN] 0940-1334
  • [Journal-full-title] European archives of psychiatry and clinical neuroscience
  • [ISO-abbreviation] Eur Arch Psychiatry Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


90. Nishimura M: A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer. World J Hepatol; 2010 May 27;2(5):192-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A successful treatment by hepatic arterial infusion therapy for advanced, unresectable biliary tract cancer.
  • There has been no standard chemotherapy for advanced BTC.
  • However, recently, gemcitabine (GEM) have been used against BTC as the most active agent, and promising response rates and overall survival times with tolerable drug toxicities have been observed.
  • In this article, two cases of advanced intrahepatic cholangiocarcinoma and unresectable metastatic gallbladder (GB) cancer are reported.
  • They were treated with hepatic arterial infusion (HAI) chemotherapy using a combination of GEM and cisplatin, along with the systemic administration of GEM.
  • As a consequence, multiple liver tumors, the GB cancer and metastatic lymph nodes regressed without severe drug toxicities, and favorable results (the overall survival times were 16 and 14 mo, respectively) were achieved.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160995.001).
  • [ISSN] 1948-5182
  • [Journal-full-title] World journal of hepatology
  • [ISO-abbreviation] World J Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999280
  • [Keywords] NOTNLM ; Cisplatin / Gallbladder cancer / Gemcitabine / Hepatic arterial infusion / Intrahepatic cholangiocarcinoma
  •  go-up   go-down


91. Pang R, Zhang SL, Zhao L, Liu SL, Dong JH, Tao JY: [Effect of petroleum ether extract from Melilotus suaveolens Ledeb on the expression of NF-kappaB and Heme oxygenase 1]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Sep;24(9):861-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Inflammatory cell model was constructed by LPS acting on the RAW264.7 cell line.
  • The expression and distribution of NF-kappaB were detected using immunocytochemical method.
  • RESULTS: The immunocytochemical analysis showed that the cytoplasm stained to brown presented NF-kappaB inactivation after the intervention of petroleum ether extract while the cell nucleus stained to brown presented NF-kappaB activation after the only intervention of LPS.
  • [MeSH-major] Anti-Inflammatory Agents / pharmacology. Gene Expression / drug effects. Heme Oxygenase-1 / genetics. Melilotus / chemistry. NF-kappa B / genetics. Plant Extracts / pharmacology
  • [MeSH-minor] Animals. Cell Line, Tumor. Ether / chemistry. Inflammation / drug therapy. Inflammation / genetics. Inflammation / immunology. Mice

  • Hazardous Substances Data Bank. DIETHYL ETHER .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782516.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / NF-kappa B; 0 / Plant Extracts; 0F5N573A2Y / Ether; EC 1.14.99.3 / Heme Oxygenase-1
  •  go-up   go-down


92. Dechakhamphu S, Yongvanit P, Nair J, Pinlaor S, Sitthithaworn P, Bartsch H: High excretion of etheno adducts in liver fluke-infected patients: protection by praziquantel against DNA damage. Cancer Epidemiol Biomarkers Prev; 2008 Jul;17(7):1658-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic infection by Opisthorchis viverrini (OV) is a strong risk factor for developing cholangiocarcinoma (CCA).
  • To clarify the involvement of oxidative stress and lipid peroxidation (LPO)-derived DNA damage, the excretion of LPO-derived etheno DNA adducts was measured in urine samples collected from healthy volunteers and OV-infected Thai subjects.
  • Mean epsilondA and epsilondC levels were 3 to 4 times higher in urine of OV-infected patients; MDA, nitrate/nitrite, and ALP were also increased up to 2-fold.
  • Two months after a single dose of the antiparasitic drug Praziquantel, epsilondA and epsilondC concentrations in urine of OV-infected subjects were decreased; MDA, nitrate/nitrite, and ALP were concomitantly lowered.
  • We conclude that chronic OV infection through oxidative/nitrative stress leads to increased urinary excretion of the etheno-bridged deoxyribonucleosides, reflecting high LPO-derived DNA damage in vivo.
  • These promutagenic DNA etheno adducts in bile duct epithelial cells may increase the risk of OV-infected patients to later develop CCA.
  • [MeSH-major] Anthelmintics / pharmacology. DNA Adducts / urine. DNA Damage / drug effects. Deoxyadenosines / urine. Deoxycytidine / analogs & derivatives. Opisthorchiasis / urine. Praziquantel / pharmacology
  • [MeSH-minor] Adult. Animals. Bile Duct Neoplasms / epidemiology. Bile Duct Neoplasms / etiology. Bile Duct Neoplasms / prevention & control. Bile Ducts, Intrahepatic. Cholangiocarcinoma / epidemiology. Cholangiocarcinoma / etiology. Cholangiocarcinoma / prevention & control. Chromatography, High Pressure Liquid. Feces / parasitology. Female. Humans. Immunoprecipitation. Incidence. Male. Middle Aged. Opisthorchis / isolation & purification. Oxidative Stress. Risk Factors. Thailand / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628417.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthelmintics; 0 / DNA Adducts; 0 / Deoxyadenosines; 0W860991D6 / Deoxycytidine; 6490C9U457 / Praziquantel; 68498-25-9 / 1,N(6)-ethenodeoxyadenosine; 68498-26-0 / 3,N(4)-ethenodeoxycytidine
  •  go-up   go-down


93. Cauza K, Grassauer A, Hinterhuber G, Horvat R, Rappersberger K, Wolff K, Foedinger D: FcgammaRIII expression on cultured human keratinocytes and upregulation by interferon-gamma. J Invest Dermatol; 2002 Nov;119(5):1074-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keratinocytes of human epidermis are actively involved in inflammatory and autoimmune reactions of the skin and interact with resident or infiltrating immunocompetent cells via cytokines, chemokines, and intercellular adhesion mechanisms.
  • Most immunocompetent cells have been reported to express Fcgamma receptors (FcgammaR), which are important for immunoregulatory functions.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Interferon-gamma / pharmacology. Keratinocytes / physiology. Receptors, IgG / genetics
  • [MeSH-minor] Adult. Antibodies. Antigens, CD / analysis. Antigens, CD / genetics. Cells, Cultured. Fluorescent Antibody Technique, Indirect. GPI-Linked Proteins. Gene Expression / drug effects. Humans. RNA, Messenger / analysis. Up-Regulation / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12445195.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / FCGR3B protein, human; 0 / GPI-Linked Proteins; 0 / RNA, Messenger; 0 / Receptors, IgG; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


94. Nurmi E, Bergman J, Eskola O, Solin O, Hinkka SM, Sonninen P, Rinne JO: Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. J Cereb Blood Flow Metab; 2000 Nov;20(11):1604-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven de novo patients with Parkinson's disease (PD) were studied twice, before and after three months of levodopa medication.
  • The regions of interest (anterior and posterior putamen, caudate nucleus, and cerebellum) were drawn on individual magnetic resonance imaging (MRI) images, matched with the PET images, and copied onto the PET images.
  • In PD patients, the percent change from baseline was 4.1% in the anterior putamen, 1.9% in the posterior putamen, and 4.0% in the caudate nucleus.
  • The intraclass correlation, indicating the reproducibility of the PET scan within subjects, was 0.94 for the anterior putamen, 0.86 for the posterior putamen, and 0.91 for the caudate nucleus.
  • The percent change from baseline was 4.0% in the anterior putamen, 1.1% in the posterior putamen, and 2.8% in the caudate nucleus.
  • [MeSH-major] Antiparkinson Agents / administration & dosage. Carrier Proteins / metabolism. Cocaine / analogs & derivatives. Levodopa / administration & dosage. Membrane Glycoproteins. Membrane Transport Proteins. Nerve Tissue Proteins. Parkinson Disease / drug therapy. Parkinson Disease / radionuclide imaging. Tomography, Emission-Computed / standards
  • [MeSH-minor] Adult. Aged. Biological Transport / drug effects. Dopamine Plasma Membrane Transport Proteins. Dopamine Uptake Inhibitors / pharmacokinetics. Female. Fluorine Radioisotopes. Humans. Male. Middle Aged. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Parkinson's Disease.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. COCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11083235.001).
  • [ISSN] 0271-678X
  • [Journal-full-title] Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • [ISO-abbreviation] J. Cereb. Blood Flow Metab.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antiparkinson Agents; 0 / Carrier Proteins; 0 / Dopamine Plasma Membrane Transport Proteins; 0 / Dopamine Uptake Inhibitors; 0 / Fluorine Radioisotopes; 0 / Membrane Glycoproteins; 0 / Membrane Transport Proteins; 0 / Nerve Tissue Proteins; 46627O600J / Levodopa; 50370-56-4 / (1R-(exo,exo))-3-(4-fluorophenyl)-8-methyl-8- azabicyclo(3.2.1)octane-2-carboxylic acid, methyl ester; I5Y540LHVR / Cocaine
  •  go-up   go-down


95. Lorigados-Pedre L, Morales-Chacón L, Pavón-Fuentes N, Serrano-Sánchez T, Robinson-Agramonte MA, García-Navarro ME, Bender-del Busto JE: [Immunological disorders in epileptic patients are associated to the epileptogenic focus localization]. Rev Neurol; 2004 Jul 16-31;39(2):101-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Alteraciones inmunológicas en pacientes epilépticos asociadas a la localización del foco epileptogénico.
  • The purpose of this work was to study the immunological aspects in 30 epileptic patients with complex partial crisis resistant to antiepileptic drugs.
  • The following immunological evaluations has been carried out: levels of serum immunoglobulins (IgG, IgM e IgA) by radial immunodiffusion test and lymphocytic subpopulations using immunocytochemical methods.
  • RESULTS: The results show a significant increase of CD8+ lymphocytes (p < 0.05) and in the activation markers (CD25+ and HLA-DR+ cells).
  • CONCLUSIONS: Taking into account that patients diagnosed as psychogenic received an antiepileptic drug treatment identical to that of the other group, the observed immunological changes might be related with the patogeny of certain epilepsy variants associated with the focus localization and not with the medication.

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Immune System and Disorders.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Rev Neurol. 2005 Oct 16-31;41(8):510-1; author reply 511 [16224743.001]
  • [CommentIn] Rev Neurol. 2005 Mar 1-15;40(5):319; author reply 319-20 [15782368.001]
  • (PMID = 15264156.001).
  • [ISSN] 0210-0010
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Immunoglobulins
  •  go-up   go-down


96. Danzer M, Samberger C, Schicho R, Lippe IT, Holzer P: Immunocytochemical characterization of rat brainstem neurons with vagal afferent input from the stomach challenged by acid or ammonia. Eur J Neurosci; 2004 Jan;19(1):85-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical characterization of rat brainstem neurons with vagal afferent input from the stomach challenged by acid or ammonia.
  • This study examined whether exposure of the Sprague-Dawley rat stomach to hydrochloric acid (HCl) or ammonium hydroxide (NH4OH), a noxious chemical produced by Helicobacter pylori, activates different vagal afferent pathways as reflected by different circuitries in the medullary brainstem.
  • Two hours after intragastric treatment with HCl or NH4OH the activation of neurons in the nucleus tractus solitarii at the rostrocaudal extension of the area postrema (NTSAP) was visualized by c-Fos immunohistochemistry and their chemical coding characterized by double-labelling immunohistochemistry.
  • Glutamate receptors of the N-methyl-D-aspartate type were found on approximately 50% of the c-Fos-positive cells in the NTSAP, whereas tachykinin NK1, NK2 and NK3 receptors were present on 5-10% of the activated neurons.
  • The similar number and distribution of c-Fos-expressing neurons within the NTSAP and their identical chemical coding indicate that exposure of the rat stomach to backdiffusing concentrations of HCl and NH4OH activates the same vagal afferent-NTSAP pathway.
  • [MeSH-major] Chemoreceptor Cells / physiology. Gastric Mucosa / innervation. Solitary Nucleus / metabolism. Vagus Nerve / physiology. Visceral Afferents / physiology
  • [MeSH-minor] Amino Acid Transport System X-AG / drug effects. Amino Acid Transport System X-AG / metabolism. Ammonia / pharmacology. Animals. Area Postrema / cytology. Area Postrema / drug effects. Area Postrema / metabolism. Calbindins. Excitatory Amino Acid Transporter 3. Female. Glutamate Plasma Membrane Transport Proteins. Glutamic Acid / metabolism. Hydrochloric Acid / pharmacology. Hydrogen-Ion Concentration. Immunohistochemistry. Neuropeptide Y / metabolism. Proto-Oncogene Proteins c-fos / metabolism. Rats. Rats, Sprague-Dawley. Receptors, N-Methyl-D-Aspartate / metabolism. Receptors, Tachykinin / drug effects. Receptors, Tachykinin / metabolism. S100 Calcium Binding Protein G / metabolism. Symporters / drug effects. Symporters / metabolism. Synaptic Transmission / physiology

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. HYDROGEN CHLORIDE .
  • Hazardous Substances Data Bank. Ammonia .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14750966.001).
  • [ISSN] 0953-816X
  • [Journal-full-title] The European journal of neuroscience
  • [ISO-abbreviation] Eur. J. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Amino Acid Transport System X-AG; 0 / Calbindins; 0 / Excitatory Amino Acid Transporter 3; 0 / Glutamate Plasma Membrane Transport Proteins; 0 / Neuropeptide Y; 0 / Proto-Oncogene Proteins c-fos; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Receptors, Tachykinin; 0 / S100 Calcium Binding Protein G; 0 / Slc1a1 protein, rat; 0 / Symporters; 3KX376GY7L / Glutamic Acid; 7664-41-7 / Ammonia; QTT17582CB / Hydrochloric Acid
  •  go-up   go-down


97. Orlić P, Dvornik S, Husnjak SC, Aralica M, Orlić L, Zivcić-Cosić S, Sladoje-Martinović B, Fućak M: [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation]. Acta Med Croatica; 2003;57(1):49-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Cytomegalovirus (CMV) infection is the most common infectious complication after organ transplantation.
  • Dissatisfied with serologic follow-up after kidney transplantation, three years ago we introduced detection of CMV antigenemia by an immunocytochemical method using a monoclonal antibody specific for the pp65 CMV matrix protein.
  • These 76 patients were divided into three groups according to the number of positive cells per 200,000 leukocytes: < 5 (group I), 6-20 (group II) and > 20 (group III).
  • DISCUSSION: Various centers differ according to the approach to treatment of CMV infection, ranging from prophylaxis to deferred treatment for CMV disease.
  • A promising novel drug valganciclovir will allow for good prophylaxis owing to its better absorption from the gut.
  • Based on our three-year experience, optimal cut-off for antigenemia has been set at 20 positive cells per 200,000 leukocytes.
  • The existence of symptoms or changes in the level of leukocytes, platelets or transaminases goes in favor of treatment decision.
  • Patients with primary CMV infection, those with rejection episode and threshold of 20 positive cells require preemptive treatment with ganciclovir.
  • Intensive monitoring for CMV infection allows for quick and specific detection of active CMV infection.
  • [MeSH-major] Antigens, Viral / blood. Cytomegalovirus Infections / diagnosis. Kidney Transplantation / adverse effects. Phosphoproteins / blood. Viral Matrix Proteins / blood

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cytomegalovirus Infections.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12876863.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Phosphoproteins; 0 / Viral Matrix Proteins; 0 / cytomegalovirus matrix protein 65kDa
  •  go-up   go-down


98. Comporti M, Arezzini B, Signorini C, Vecchio D, Gardi C: Oxidative stress, isoprostanes and hepatic fibrosis. Histol Histopathol; 2009 07;24(7):893-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Isoprostanes are also agonists of important biological effects.
  • Since a relationship between oxidative stress and collagen hyperproduction has been previously suggested, and since lipid peroxidation products (aldehydes) have been proposed as possible mediators of liver fibrosis, we investigated whether collagen synthesis is induced by F2-isoprostanes, which can posses